Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
6-16-2017 12:00 AM

Cognitive and Non-Cognitive Dysfunction in a Mouse Model of
Alzheimer's Disease
Wai-Jane V. Lee, The University of Western Ontario
Supervisor: Dr. Marco Prado, The University of Western Ontario
Joint Supervisor: Dr. Vania Prado, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Neuroscience
© Wai-Jane V. Lee 2017

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Cognitive Neuroscience Commons

Recommended Citation
Lee, Wai-Jane V., "Cognitive and Non-Cognitive Dysfunction in a Mouse Model of Alzheimer's Disease"
(2017). Electronic Thesis and Dissertation Repository. 4592.
https://ir.lib.uwo.ca/etd/4592

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
Sensitive and translational tasks that efficiently and accurately assess cognitive function
during pre-clinical trials would be useful in developing novel treatments for Alzheimer's
disease (AD) patients. The Bussey-Saksida touchscreens employ various tasks similar
to those used in humans to effectively evaluate high-level cognitive and executive
functions in mice. This face validity provides the best chance of successful cognitive
translation across species.
In our study, donepezil had minor effects on the performance of 5xFAD mice in the 5CSRTT, a touchscreen task evaluating attention. Additionally, 5xFAD mice do not
demonstrate impairments in the PVD task, which assesses visual discrimination/
cognitive flexibility. However, the parameters recorded by the touchscreen apparatus
found latency differences in task response and reward collection – which led us to
uncover severe gait impairments in old 5xFAD mice. In summary, our findings suggest
that the 5xFAD mouse model can be used as an animal model of non-cognitive function
in AD.
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1 Introduction
1.1 Alzheimer’s Disease
Alzheimer’s disease (AD) is a disabling and fatal chronic disorder characterised by
progressive

cognitive

impairment

– often

beginning with

memory loss

and

neuropsychiatric symptoms such as depression, apathy and aggression (Li et al.,
2014b). The disease may progress gradually for several years before other cognitive
domains, such as language, executive function, visuospatial function, and attention are
affected (Perry and Hodges, 1999). Although the rate of decline can be extremely
variable, AD is usually fatal within 7-10 years of diagnosis (Dudgeon, 2010). The most
common cause of death among AD patients is pneumonia, which is hastened by the
marked inability of the patient to cough and move about normally (Dudgeon, 2010).
AD currently affects over 35.6 million individuals worldwide, accounting for
approximately half of the new cases of dementia diagnosed annually (Brookmeyer et
al., 2007; Prince et al., 2013). This number is predicted to double within the next 20
years (Prince et al., 2013). The majority of new cases of AD are sporadic, and tend to
occur in older age groups (Dudgeon, 2010). However, 5-7% of cases are early onset,
and can result from mutations in one of the many genes involved in amyloid processing
(Dudgeon, 2010). These cases of AD are referred to as familial Alzheimer’s disease.
The clinical diagnosis of AD is currently based on clinical history, neurological
examination and neurological tests. A criterion often used to diagnose AD (as stated by
the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition [DSM-IV]))

1

requires these patients to demonstrate a loss of two or more of the following: memory,
language, calculation, orientation or judgment in the absence of other probable
diseases (Kawas, 2003). A more recent criterion suggested by McKhann et al. requires
patients that meet the criteria for dementia to also demonstrate a deterioration in
cognition along with one of the following: amnesia, impairments in language,
visuospatial function or executive function (McKhann et al., 2011). Again, this probable
diagnosis must be made in the absence of evidence pointing to other disease
(McKhann et al., 2011). These cognitive domains can be tested using the Mini-Mental
State Examination (MMSE), the Abbreviated Mental Test Score (AMTS) and objective
computerized Cambridge Neuropsychological Test Automated Battery (CANTAB).
Although expert clinicians correctly diagnose AD 70-90% of the time (Beach et al.,
2012; Kaye, 1998), a definitive diagnosis of AD requires a post-mortem confirmation,
with the presence of two histopathological features: amyloid plaques and neurofibrillary
tangles (Braak and Braak, 1991).

1.1.1 The neuropathology of AD
Alzheimer’s disease is characterized by the presence of amyloid plaques and
neurofibrillary tangles in the brain (Braak and Braak, 1991). Although these pathological
features are often seen in cognitively normal age-matched controls, the density and
distribution of these features differ (Bekris et al., 2010).
Amyloid plaques are composed of small A peptides that are processed from the
amyloid precursor protein (APP). APP is a type-I transmembrane protein that is
expressed at high levels in the brain and has been suggested to be involved in a variety
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of physiological functions, including neurite outgrowth, synaptogenesis, protein
trafficking along the axon, transmembrane signal transduction, cell adhesion and
calcium metabolism (Zhang et al., 2011; Zheng and Koo, 2006). However, APP can
also have neurotoxic properties and other aversive effects (Zhang et al., 2011).
APP is processed by a series of sequential proteases into various fragments. A is
produced following the cleavage of APP by -secretase (also known as -APP cleaving
enzyme or BACE), forming soluble APP and a  C-terminal fragment (CTF). Soluble
APP is thought to be involved in neuronal pruning and axonal cell death (Nikolaev et
al., 2009). Cleavage of APP by -secretase prevents A generation, as its cleavage site
is within the A domain – between lys16 and leu17 (Zhang et al., 2011). This forms
soluble APP and an  C-terminal fragment (CTF). Soluble APP plays an important
role in neuronal plasticity/survival and in central nervous system development, where it
regulates neural stem cell proliferation (Zhang et al., 2011). The CTF and CTF are
further processed by -secretase to p83 and A40/42, respectively. P83 has no known
function and is rapidly degraded (Zhang et al., 2011). The CTF can be cleaved into
A40 or A42, where the number indicates the number of amino acids in the fragment.
At low levels, A has positive, modulatory roles on neurotransmission and memory,
while excessive levels of A leads to synaptic dysfunction and synapse loss (Zhang et
al., 2011). A42 is more hydrophobic and thus, more prone to fibril formation and
aggregation than A40 (Zhang et al., 2011). Under normal conditions, only 10% of the
A produced is A42 (Burdick et al., 1992). Alterations in this ratio has been suggested
to be critical for AD pathogenesis (Burdick et al., 1992).
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Neurofibrillary tangles are composed of hyperphosphorylated filaments of the
microtubule-associated phosphoprotein tau. Tau projects from the surface of
microtubules, allowing them to interact with other cytoskeletal elements, cytoplasmic
organelles and proteins (Buée et al., 2000). Tau is regulated via phosphorylation, which
modulates the affinity between tau and the microtubules to allow for microtubule
assembly, affecting axonal morphology, growth and polarity (Buée et al., 2000). In AD,
the hyperphosphorylation of tau leads to the formation of fibrils which can then
aggregate within cells to form insoluble paired helical filaments, leading to
neurodegeneration (Buée et al., 2000).

1.1.2 Genetic risk factors and Familial Alzheimer’s Disease
A fraction of familial AD cases can be traced to mutations in proteins that affect amyloid
processing. Mutations in the gene encoding APP on chromosome 21 leads to the
abnormal formation of APP, affecting how it is processed (Goate et al., 1991; Mullan,
1992). To date, over 32 APP missense mutations have been identified, and the majority
of these mutations are located at the secretase cleavage sites (Goate et al., 1991;
Mullan, 1992). Examples include the Swedish (K670N, and M671L) and London (V717I)
mutations, which lead to an increase in the production of A and the development of AD
(Goate et al., 1991; Mullan, 1992). These mutations have been introduced in mice and
used to generate animal models of AD.
Mutations on chromosome 14 and chromosome 1 result in the partial loss of function of
presenilin 1 and 2, respectively (Bekris et al., 2010). Presenilins are major components
of the -secretase complex, and are responsible for cleaving the C-terminal fragments of
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APP (De Strooper et al., 1998). Thus, mutations in these proteins affect APP
processing. Defects in presenilin 1 lead to the most severe forms of AD – with complete
penetrance, leading to early onset AD (Bekris et al., 2010). Meanwhile, mutations in
presenilin 2 are rarer, and are of lower penetrance than mutations in presenilin 1 (Bekris
et al., 2010).
The human apolipoprotein E (ApoE) gene on chromosome 19 exists as one of three
isoforms: 2, 3 and 4 (Wu and Zhao, 2016). In the brain, lipidated ApoE is responsible
for binding and removing aggregated A in an isoform dependent manner (Wu and
Zhao, 2016). The ApoE 2 polymorphism is very rare, and is considered to protect
against AD, as it enhances the ability of ApoE to clear A through a variety of
mechanisms (Conejero-Goldberg et al., 2014; Wu and Zhao, 2016). ApoE 3 has
recently been found to have neuroprotective effects as well (de-Almada et al., 2011).
However, the ApoE 4 polymorphism has been associated with both familial and
sporadic cases of late-onset AD (Bekris et al., 2010). ApoE 4 lipoproteins bind A with
a lower affinity than the other polymorphisms, thus possibly impairing A clearance (Liu
et al., 2013a).

1.1.3 The amyloid cascade hypothesis of AD
The amyloid cascade hypothesis of AD suggests that the accumulation and deposition
of A in the brain is a crucial step that ultimately leads to the development of AD
(Karran et al., 2011). This had been observed many years prior to other AD-related
manifestations (Selkoe and Hardy, 2016) and is likely a result of an unbalance between
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the production and clearance of A peptides. This hypothesis is supported by genetic
mutations in the presenilins and APP leading to early-onset or AD in humans (Bekris et
al., 2010). Meanwhile, the ApoE 4 polymorphism, which affects the clearance of A,
can predispose an individual to AD (Liu et al., 2013a). In addition, soluble oligomers of
A42 taken from AD patients can cause neurodegeneration, inhibit long-term
potentiation and enhance long-term synaptic depression in the hippocampus of healthy
rats (Selkoe and Hardy, 2016). These oligomers are also capable of inducing tau
hyperphosphorylation and enhancing the toxicity of tau (Selkoe and Hardy, 2016).
However, treatments aimed at A in humans have failed – and in some cases,
treatment accelerated deterioration in cognition and reduced quality of life compared to
placebo controls (Karran et al., 2011). Furthermore, the amyloid cascade hypothesis
fails to consider the effect of tau on the development of the disease. Tau pathology itself
can cause neuronal loss as well (Karran et al., 2011). The temporal and mechanistic
relationships between A and tau pathology remain to be resolved (Karran et al., 2011).

1.1.4 The cholinergic hypothesis of AD
The cholinergic hypothesis of AD suggests that the disease is a result of the
degeneration of cholinergic neurons in the basal forebrain and the associated loss of
cholinergic transmission (Bartus et al., 1982). This degeneration is accompanied by a
decrease in choline acetyltransferase (ChAT; responsible for synthesizing acetylcholine)
and a reduction of acetylcholine release and reuptake in cortex and hippocampus
(Francis et al., 1999). Similar observations have also been made in mouse models of
AD (Boncristiano et al., 2002; Devi and Ohno, 2010; German et al., 2003). The fact that
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cholinergic transmission has been implicated in a variety of cognitive functions, and that
anti-cholinergic drugs have amnestic effects and can reproduce memory deficits in nondemented elderly patients add merit to this theory (Contestabile, 2011; Francis et al.,
1999). In addition, cholinergic mimetics proved to be particularly useful in treating the
symptoms and cognitive decline associated with AD in humans and mouse models
(Contestabile, 2011; Dong et al., 2009; Romberg et al., 2011). Thus, a majority of the
drugs used to treat patients with AD target the cholinergic system.

1.1.5 Treating AD
There is currently no cure for AD, and all pharmacological interventions are palliative.
Two classes of drugs are currently available for the treatment of patients with AD in
Canada: three cholinesterase inhibitors (donepezil, rivastigmine and galantamine) and
an NMDA (N-methyl-D-aspartate) receptor blocker (memantine). Cholinesterase
inhibitors block acetylcholinesterase, preventing the degradation of acetylcholine in the
synaptic cleft and enhancing cholinergic transmission (Birks, 2006). These drugs are
usually used to treat patients with mild to moderate AD, while memantine is often
prescribed to patients with severe AD or to patients that cannot tolerate the side effects
of cholinesterase inhibitors (Bishara et al., 2015). Memantine blocks excess NMDA
receptor activity – which is thought to result in neuronal injury and death – without
disturbing

its

normal

neuroprotective

attributes

(Bishara

et

al.,

2015).

The

pharmacological treatments for AD are not always well tolerated, as they commonly
lead to side effects including: dizziness, nausea, vomiting, diarrhea and anorexia
(Bishara et al., 2015). These drugs also interact with a variety of other pharmaceuticals,
including those used to treat high-blood pressure and epilepsy, making treatment for
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patients with other comorbidities even more difficult (Bishara et al., 2015). Thus, there is
a great need for the development of new pharmacological agents to treat patients with
AD. If interventions could delay the onset and progression of the disease for only 1
year, there would be nearly 9.2 million fewer cases of the disease in 2050 (Brookmeyer
et al., 2007)

1.1.5.1 Donepezil
Donepezil (Aricept) is a selective and reversible acetylcholinesterase inhibitor that binds
to the active site of acetylcholinesterase with high affinity – thus avoiding unintended
interactions with butyrylcholinesterase and other receptors (Kryger et al., 1999).
Donepezil preserves the levels of acetylcholine at the synaptic cleft, which has been
shown to protect against ischemic damage, glutamate excitotoxicity and A toxicity,
while also attenuating hippocampal and cortical neurodegeneration (Akasofu et al.,
2008; Cutuli et al., 2013).
Donepezil is usually prescribed to patients with mild to moderate AD (Bishara et al.,
2015). However, recent studies suggest that donepezil can also be used for moderate
to severe cases of AD in combination with memantine (Bishara et al., 2015; Howard et
al., 2012). Donepezil must be administered to a patient daily, and administration should
not be interrupted, as its effects are quickly lost and may not be fully regained when
treatment is re-initiated (Bishara et al., 2015).
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1.1.6 Visuospatial function and attention in AD
Visuospatial function and attention are among the first cognitive domains to be affected
early in AD, and continue to decline as the disease progresses (Albert, 1996; Pal et al.,
2016; Perry and Hodges, 1999; Quental et al., 2013). Although there are clear
neuropathological

correlations,

the

direct

neurobiological

correlates

of

these

impairments have yet to be determined (Li et al., 2014a; Perry and Hodges, 1999).
Visuospatial function involves the identification of a stimulus and its location, and can be
assessed in humans using the Visual Object and Space Perception (VOSP) battery,
which effectively evaluates visuospatial function while minimizing interference from
other cognitive domains (Quental et al., 2013). Studies have shown that patients with
AD score poorly on the VOSP battery when compared to controls, and that their scores
continue to drop as the disease progresses (Pal et al., 2016; Quental et al., 2013).
Visuospatial ability has also been found to be an important contributor to functional
status in AD patients (Fukui and Lee, 2009), and requires connectivity between the
prefrontal cortex and the striatum to remain intact (Brigman et al., 2013). Visual
discrimination has been shown to depend on the perirhinal cortex in rodent models –
the volume of which is significantly reduced in AD as well (Bussey et al., 2003;
Juottonen et al., 1998).
Attention has been suggested to be the first non-memory domain to be affected after
the initial amnesic stage of AD (Perry and Hodges, 1999). Cholinergic activity plays an
important role in attention (Sarter et al., 2005). The cholinergic neurons that project to
the cortex from the basal forebrain release acetylcholine in response to attentionally
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demanding tasks (Arnold et al., 2002), while lesions to this system impair attentional
function (Muir et al., 1996). These neurons also degenerate in patients with AD,
resulting in the loss of cholinergic transmission (Bartus et al., 1982).
Attention consists of three subtypes: selective, sustained and divided, and these are
differentially affected in AD. Selective attention refers to the ability to filter out random
stimuli, while sustained attention or vigilance refers to the ability to focus attention on a
task for unbroken periods of time (Perry and Hodges, 1999). Divided attention is where
an individual has to either focus their attention on a stimulus or multiple stimuli, or on
two separate tasks. Divided attention and some aspects of selective attention are
particularly vulnerable, while sustained attention usually remains intact for the early
stages of the disease (Perry and Hodges, 1999). The various domains of attention can
be tested by various tasks, including tasks in the CANTAB (Perry and Hodges, 1999).

1.1.7 Gait impairments in patients with AD
Patients with AD also experience gait disturbances, with cautious gait dominating in
patients with mild AD, and frontal gait disorders dominating in those with severe AD
(O’keeffe et al., 1996; Sala et al., 2004). These extensive gait impairments contribute to
the increase in fall risk and immobility in AD patients compared to age matched controls
(Amboni et al., 2013; Muir et al., 2012; Nutt, 2013). Immobility is associated with
changes in social behaviour, personality and deteriorations in mental health, along with
poorer outcomes and the development of more co-morbidities (McCarron et al., 2005).
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Cautious gait is a slow gait, with shortened steps and en bloc turns – which are defined
as turns where the individual keeps their head and trunk rigid, taking multiple steps
rather than twisting the body and pivoting the toes to turn (Nutt, 2013). These
individuals may also widen their base to increase stability (Nutt, 2013). Cautious gait is
an appropriate adaptation to real or perceived imbalance and is also commonly
observed in patients with Parkinson’s Disease (Nutt, 2013; O’keeffe et al., 1996).
Frontal gait disorders, or gait apraxia includes disturbances in trunk movements,
standing and walking that are not caused by any orthopedic abnormalities, muscle
wasting, arteriosclerosis in the lower limbs, neuromuscular deficits, ataxia, dystonias,
dyskinesias, psychiatric disease, side effects of drugs or cautious gait (Sala et al.,
2004). Several forms of gait apraxia have been reported in patients with AD, including
small steps, freezing of gait and disequilibrium (Nutt, 2013).

1.1.7.1 The association between gait and attention
Gait is increasingly considered to be more than just an automated motor activity.
Rather, gait requires a combination of executive function, attention and a judgement of
internal and external cues, which requires intact visuospatial function as well (Amboni et
al., 2013). There is a direct relationship between cognitive impairment and gait
abnormalities. When individuals are subject to a dual task paradigm, gait is
detrimentally affected. In this paradigm, individuals are asked to walk while performing a
concurrent cognitive or motor task, thus increasing competition for attentional resources
and forcing the brain to prioritize between the tasks (Amboni et al., 2013). In healthy
subjects, dual task paradigms exert an adverse effect on gait variables, with stronger
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effects being observed in older adults (Lindenberger et al., 2000). However, in patients
with AD, the effect of dual task paradigms are much more pronounced, and an increase
in the complexity of the second task and/or the severity of cognitive impairment further
worsens gait measures (Amboni et al., 2013; Muir et al., 2012).

1.1.8 Mouse models of AD
Our knowledge of the autosomal dominant mutations leading to early onset AD have
allowed for the development of many animal models of the disease. These models have
been invaluable tools for identifying and characterizing molecular, cellular and
pathological changes that lead to the onset of AD (Newman et al., 2007). There are
over 20 strains of AD mouse models with mutations in APP, and many others with
mutations in tau and presenilins, causing these mice to develop the characteristic
plaques and tangles of AD (Newman et al., 2007). In addition, many of these mice
recapitulate various cellular and behavioural aspects of the disease.

1.1.8.1 The 5xFAD mouse model of AD
The 5xFAD mouse model of AD, developed by Oakley et al. (2006), co-expresses five
familial AD mutations: the Swedish (K670N/M671L), Florida (I716V) and London (V717l)
mutations of the amyloid precursor protein, and two mutations in presenilin 1 (M146L
and L286V). These mice are B6/SJL F1 hybrids and the genes were introduced by sitedirected mutagenesis and then subcloned into the mouse neuron-specific Thy1 (or
cluster of differentiation 90 – CD90) transgene cassette (Oakley et al., 2006). These
mutations collectively cause 5xFAD mice to accumulate high levels of intraneuronal
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A42 in the brain and develop amyloid plaques and gliosis as early as 2 months of age
(Oakley et al., 2006), while the majority of AD mouse models take at least 6-12 months
to develop amyloid plaques (Spires and Hyman, 2005). The levels of A42 continue to
increase linearly and plaques begin to appear in the deep layers of the cortex and the
subiculum, moving throughout most of the cortex and hippocampus as the mice age
(Oakley et al., 2006). Plaques also eventually appear in the thalamus, brainstem and
olfactory bulb, although they are fewer in number (Oakley et al., 2006). Interestingly, the
cerebellum is often spared. These amyloid plaques are surrounded by activated
astrocytes and microglia (indicative of neuroinflammation), another hallmark of the AD
brain (Akiyama et al., 2000; Oakley et al., 2006). Gliosis increases with age in these
mice and closely follows the distribution of amyloid deposits (Oakley et al., 2006). This
leads to neurodegeneration and neuronal loss in specific regions of the brain – such as
cortical layer 1 and 5 – as the mouse ages, correlating with the deposition of amyloid
plaques and intraneuronal A (Oakley et al., 2006). Although 5xFAD mice recapitulate
amyloid pathology in AD relatively quickly, they do not develop neurofibrillary tangles or
appear to display hyperphosphorylated tau epitopes like some other APP transgenic
mice (Maarouf et al., 2013; Oakley et al., 2006).
Like AD patients, 5xFAD mice also demonstrate a significant reduction of ChAT, a
marker of cholinergic neurons (Devi and Ohno, 2010; Francis et al., 1999). Moreover,
the transplantation of ChAT+ basal forebrain cholinergic neurons derived from human
embryonic stem cells to the basal forebrain of 4-month-old 5xFAD mice was capable of
improving learning and memory in the Morris Water Maze (Yue et al., 2015). Also, Devi
and Ohno were able to reduce cholinergic neuron degeneration and improve memory in
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the Y-maze with the partial knockdown of BACE1 (-APP cleaving enzyme 1) at 6
months but not at 15-18 months of age (Devi and Ohno, 2010).
With age, 5xFAD mice develop deficits in spatial memory on the Y-maze at
approximately 4-5 months, disturbances in learning in the Morris Water Maze beginning
at 9 months and severe motor impairments in the rota-rod at approximately 12 months
of age (Macdonald et al., 2013; Oakley et al., 2006; Schneider et al., 2014). In addition,
5xFAD mice also demonstrate changes in brain glucose metabolism, anxiety and
electroencephalogram (EEG) disturbances at 6 months of age (Macdonald et al., 2013;
Schneider et al., 2014). EEG recordings revealed that 5xFAD mice spend less time in
rapid-eye-movement sleep in relation to the total amount of sleep when compared to
wild-type controls (Schneider et al., 2014). In summary, 5xFAD mice develop amyloid
pathology, functional disturbances and behavioural deficits that make them a good
model for studying many aspects of AD.

1.1.8.1.1 Retinal degeneration in the 5xFAD mouse model
5xFAD mice have a mixed background: C57Bl6 and Swiss Jim Lambert (SJL). SJL mice
are homozygous for the recessive Pdebrd1 allele, which codes for the β-subunit of cGMP
phosphodiesterase on mouse chromosome 5 (Clapcote et al., 2005; Giménez and
Montoliu, 2001). Thus, F1 5xFAD mice should be heterozygous for the mutation. The
mutated allele is a nonsense mutation that decreases the transcription of the
phosphodiesterase, leading to retinal degeneration and blindness by wean age at
approximately 3 weeks and rendering mice homozygous for the Pdebrd1 allele
unsuitable for use in some experiments (Giménez and Montoliu, 2001). This same
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mutation is seen in FVB/NJ (Friend Virus B/ National Health Institute Jackson) mice as
well (Giménez and Montoliu, 2001).

1.2 The Bussey-Saksida Touchscreen System
High-level cognitive and executive functions in mouse models can be effectively
assessed using the Bussey-Saksida touchscreen system. This touchscreen system can
be used to study both impairments and enhancements in visual discrimination,
extinction, attention, impulsivity, compulsivity and a variety of other cognitive domains
(Bussey et al., 2012). The tasks can be identical to those used in humans – like those in
the CANTAB (Brigman et al., 2005; Bussey et al., 2001; Downes et al., 1989; Robbins
et al., 1994; Sahakian and Coull, 1993). This face validity provides the best chance of
successful cognitive translation across species. These tasks can be used to evaluate
various cognitive perturbations in mouse and rat models of disease, including those of
Alzheimer’s Disease, Parkinson’s disease, Schizophrenia, Attention Deficit Hyperactive
Disorder (ADHD), Obsessive Compulsive Disorder and addiction (Bussey et al., 2012).
This touchscreen system is automated, reducing variability and scope for error (Bussey
et al., 2001). The entire task – from stimulus presentation to reward provision – is
completely controlled by a computer program, minimizing experimenter interference,
inconsistencies and any other confounds. To switch between tasks, the experimenter
only needs to switch to the correct mask (which has task-specific windows allowing for
the mouse to see and respond to the task while reducing unintended responses) and
schedule. Automation also allows for the “in parallel” testing of many animals
simultaneously, thus increasing statistical power and throughput.
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Several parameters, such as accuracy (responding to the correct location), omissions
(failing to respond), perseverative responses (responding repeatedly to a previously
correct location; a measure of compulsivity), premature responses (responding before
the stimulus appears; also a measure of impulsivity), time to make a correct response
(correct response latency) and time to collect reward (reward collection latency) are
automatically recorded by the equipment during each task. The results can then be
exported to common data formats allowing for the creation of expandable databases to
facilitate increased data access and reproducibility.
Lastly, the tasks employed by these touchscreens are non-aversive and low stress,
providing a food reward for a correct response rather than punishing the animal for an
incorrect response (Bussey et al., 2012). The touchscreen chambers are also isolated
from the experimenter and its surroundings, minimizing distractions and other stressinducing stimuli as well.

1.2.1 The Pairwise Visual Discrimination Task
Visual discrimination and cognitive flexibility can be assessed using the pairwise visual
discrimination (PVD) touchscreen task (Brigman et al., 2008; Bussey et al., 2008).
Impairments in both visual discrimination and cognitive flexibility have been reported in
the early stages of AD and have been suggested to serve as specific and accurate
prognostic markers of the disease (Albert, 1996; Pal et al., 2016; Quental et al., 2013).
In the PVD task, the mouse is presented with two stimuli and has to learn that one of
the stimuli (S+) leads to a reward while the other (S-) does not. The spatial location of
the stimuli is irrelevant to the completion of the task. Once the task is learned, the
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stimulus-reward association is reversed. The mouse then has to inhibit the response
acquired and associate the previously unrewarded stimulus with the reward (reversal
learning) and learn a new rule, providing an assessment of cognitive flexibility.
Performance of this task has been shown to be dependent on the prefrontal cortex in
rats and mice (Brigman and Rothblat, 2008; Bussey et al., 1997; Chudasama and
Robbins, 2003). Inactivation of the perirhinal cortex with either muscimol (a gammaAminobutyric acid-A receptor blocker), AP5 ((2R)-amino-5-phosphonopentanoate, a
NMDA receptor antagonist) or scopolamine (a muscarinic receptor antagonist) impairs
performance in this task as well (Winters et al., 2010). Deficits in visual discrimination
learning and reversal in the PVD task have also been observed in NMDA receptor 2A
knockout mice (Brigman et al., 2008). AD patients also demonstrate a selective and
differential reduction of NMDA receptor levels in the brain (including receptor 2A), and
the levels of these receptors correlate with cognitive performance (Maragos et al., 1987;
Sze et al., 2001). In addition, the reduction of forebrain cholinergic tone in VAChTSix3-Creflox/flox

(vesicular acetylcholine transporter (VAChT) deficient) mice impairs cognitive

flexibility in the PVD task (Kolisnyk et al., 2013a). The expression of VAChT is
significantly reduced in AD patients, correlating with the severity of dementia (Efange et
al., 1997; Gilmor et al., 1999). Visual discrimination acquisition is impaired in 11-month
old rTg4510 mice as well (Harper et al., 2013). These mice express a human tau
mutation (Harper et al., 2013).
The PVD task can be administered multiple times, each with a different set of S+ and Sstimuli. This allows for the longitudinal testing of animal models, allowing determination
of when deficits in the task (if any) begin to appear.
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1.2.2 The 5-Choice Serial Reaction Time Task
The 5-choice serial reaction time task (5-CSRTT), is mainly used to study attention,
which is impaired in AD patients (Bussey et al., 2012; Carli et al., 1983; Leonard, 1959;
Perry and Hodges, 1999). The task also gives information about impulsivity (premature
responses) and compulsivity (preservative responses). In the 5-CSRTT, mice are
required to scan a horizontal array of five screens for the presence of a brief,
randomized light stimulus and respond appropriately with a nose poke. The shorter the
duration of the stimulus, the higher the attentional demand required to successfully
perform the task (Bari et al., 2008).
Performance in the 5-CSRTT is impaired in mouse models of cholinergic dysfunction,
including M1 muscarinic receptor deficient mice (Bartko, 2011), ChAT-ChR2-EYFP mice
who express channel rhodopsin 2 (ChR2) under control of the choline acetyltransferase
(ChAT) (Kolisnyk et al., 2013b) and VAChTSix3-Cre-flox/flox mice (Kolisnyk et al., 2013a).
The accuracy of mice in the 5-CSRTT task is also significantly reduced by damage to
the prefrontal cortex and/or striatum (Muir et al., 2012; Passetti et al., 2003; Rogers et
al., 2001). However, performance in the task can be improved with drug treatment. For
example, the attentional impairments observed in triple transgenic (3xTG) mouse model
of AD, which is likely a result of pathological changes in the prefrontal cortex, was
reduced following treatment with the cholinesterase inhibitor donepezil (Romberg et al.,
2011). Galantamine has also been shown to improve performance of WT mice in this
task (Kolisnyk et al., 2013a). Other mouse models of AD demonstrate deficits in this
task as well. Response accuracy is significantly reduced in TgCRND8 mice at 4-4.5
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months of age (Romberg et al., 2013). These mice have the Swedish K670N/M671L
and the Indiana V717F APP mutations, leading to plaque formation by 3 months of age
(Chishti et al., 2001). Deficits in the 5-CSRT task have also been observed in male
5xFAD mice at 10 months of age (Masood, 2015). Masood (2015) observed a
significant decrease in percentage accuracy and the number of preservative responses,
along with delays in reward collection and task response.

1.2.3 Using touchscreen tasks to identify cognitive deficits in
mouse models of AD
Given the high prevalence and poor prognosis of AD, the development of novel
treatments for patients with AD is imperative. The drugs currently given to these
patients do not cure or prevent the progression of the disease, interact with drugs
commonly used to treat other comorbidities and are often extremely difficult to tolerate
(Bishara et al., 2015). Up to 85% of patients experience the adverse side effects of
these treatments and some even opt to discontinue treatment for this reason (Burns et
al., 2007). Unfortunately, the drug development process is tedious and costly; clinical
trials take many years and require several million dollars to complete. Between 2002
and 2012, 24 phase 1, 206 phase 2 trials and 83 phase 3 clinical trials were attempted,
with an overall success rate of 0.4% (Cummings et al., 2014). Most of these registered
trials aimed to improve cognition in AD patients, but failed to do so (Cummings et al.,
2014). Thus, the ability to predict whether a novel treatment can improve cognitive
function in humans during pre-clinical development would be greatly beneficial. This
requires a sensitive and translational task that can efficiently and accurately assess
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cognitive function. Therefore, touchscreens have the potential to become a powerful
new platform for the pre-clinical evaluation of new pharmacological treatments directed
at cognitive function in AD patients.
Attention, visual discrimination and cognitive flexibility are commonly affected in patients
with AD (Albert, 1996; Pal et al., 2016; Perry and Hodges, 1999; Quental et al., 2013),
and all these parameters can be assessed in mice using touchscreen tasks.
Impairments in visual discrimination and attention have been observed in various
mouse models of cholinergic and glutamatergic dysfunction (Bartko, 2011; Brigman et
al., 2008; Kolisnyk et al., 2013a; Romberg et al., 2013; Winters et al., 2010), and a few
mouse models of AD (Harper et al., 2013; Romberg et al., 2011, 2013). However, little
remains known about the onset and presence of deficits in executive function on the
different mouse models of AD.
Romberg and colleagues were able to rescue attentional deficits in 3xTG mice following
treatment with donepezil (Romberg et al., 2011). Since our lab has also observed
attentional deficits in male and female 5xFAD mice at 10 months of age (Masood,
2015), the question remains whether donepezil can rescue the attentional impairments
in these mice as well.
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1.3 Rationale and Hypothesis
We hypothesize that male 5xFAD mice develop reproducible age-dependent
deficits in the PVD and that deficits in the 5-CSRTT that can be ameliorated by
treatment with donepezil.
The overall objective of this thesis is to perform a longitudinal evaluation of visual
discrimination and cognitive flexibility in male 5xFAD mice, as the presence of cognitive
dysfunction is an important proof of the face validity of the 5xFAD mouse model. We
also want to determine if specific cognitive deficits can be rescued by donepezil as a
proof of principle. To address these objectives, the specific aims of this thesis are:

1) To perform a longitudinal evaluation of visual discrimination and reversal learning
in male 5xFAD mice at 4, 7, and 10 months of age.
2) To assess the effects of donepezil on cognition in male 5xFAD mice at 10 and 13
months of age using the 5-CSRTT.
3) To genotype the 5xFAD mice that have been subject to touchscreen evaluation
for the recessive PDEBrd1 allele to ensure that task performance is not affected.
4) To determine whether the mild food-restriction used to motivate mice to perform
touchscreen tasks affected amyloid pathology in male and female 5xFAD mice.
5) To evaluate gait, locomotion and grip force in male 5xFAD mice.
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2 Materials and Methods

2.1 5x Familial Alzheimer’s Disease Mouse Model
The 5xFAD mice (B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax, Jax
stock #006554) and age-matched wild-type controls (B6SJLF1/J, Jax stock #100012)
used in the PVD experiments were purchased from the Jackson Laboratory (Bar
Harbor, Maine) and delivered to the university. The 5xFAD mice used in the 5-CSRTT
experiments were bred at Western University. All mice used for the experiments were
tattooed in their tails at least a week prior to testing for identification purposes. Male
5xFAD mice and their age-matched wild-type controls (wild-type littermates were only
used for the 5-CSRTT) were used for all behavioral tasks, whereas male and female
5xFAD mice and their age-matched wild-type controls were used for pathological
analyses. All procedures were performed in accordance with the Canadian Council of
Animal Care guidelines at the University of Western Ontario with an approved animal
protocol (2008-127).

2.2 Housing and Diet
Mice that underwent behavioural tasks were singly housed without environmental
enrichment in a temperature and pressure controlled room with a 12-hour light/dark
cycle. Lights would turn on at 7:00am and shut off at 7:00pm daily. All behavioural tests
were conducted during the light phase of this cycle. Cages were changed biweekly.
Mice that were to be tested on the touchscreens were mildly food restricted to 85%
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percent of their original baseline adult weight (according to the Adult Mouse Food
Restriction Standard Operating Procedure – Appendix 1) to ensure that they would be
motivated to complete the task. The mice were put on food restriction prior to the start of
behavioural testing and the body weights were gradually lowered to 85% of their original
weight. All mice were weighed daily. Water was provided ad libitum.
For the pathology experiments, male and female 5xFAD mice were either foodrestricted to 85% percent of their original baseline adult weight (according to the Adult
Mouse Food Restriction Standard Operating Procedure – Appendix 1) or provided food
ad libitum for 2-3 months – until they were euthanized at 6 months of age. Water was
provided ad libitum in both cases. All mice were fed with Teklad Laboratory Animal
Chow (Envigo).

2.3 Genotyping Pdebrd1
DNA was extracted from mouse ear tissue and amplified using the REDExtract-N-Amp
Tissue PCR Kit Protocol (Sigma-Aldrich, Oakville, Ontario). Polymerase chain reaction
(PCR) was done using the Bio-Rad T100 Thermal Cycler (Bio-Rad Laboratories,
Hercules, California) with a 500bp x 40 cycle schedule (94C x 3 minutes followed by 40
x [94C x 30 seconds] + 60C x 30 seconds + 72C x 30 seconds then 72C x 2
minutes). The tubes were held at 10C until use. The following reagents were used for
each sample: 5l of 2x premix, 0.5l of retinal degeneration (RD) 3 oligonucleotide
primer (concentration: 0.5 M; 28-mer, 5’-TGACAATTACTCCTTTTCCCTCAGTCTG-3’,
accession number L02109, nucleotides 84 to 111), 0.1l of RD4 oligonucleotide primer
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(concentration: 0.02 M; 28-mer, 5’-GTAAACAGCAAGAGGCTTTATTGGGAAC-3’,
accession number L02109, nucleotides 644 to 617) and 2.9l of RD6 oligonucleotide
primer (concentration: 14.5 M; 28-mer, 5’-TACCCACCCTTCCTAATTTTTCTCAGC-3’,
accession number L02110, nucleotides 2539 to 2512). RD3 and RD4 amplifies a 0.55kb
PCR product from the Pdebrd1 mutant allele, while RD3 and RD6 amplifies a 0.40kb
PCR product from the WT allele (Giménez and Montoliu, 2001). The PCR products are
then run on an agarose gel along with a 100bp ladder (Gene DireX, Frogga Bio,
Toronto, Ontario) and imaged with FluorChem Q (Alpha Innotec Corp., San Leandro,
California).
The positive control for Pdebrd1 was ear tissue from a Friend Virus B NIH Jackson
mouse (FVB/NJ; Jax stock #001800), an inbred strain of mouse known to be
homozygous for the Pdebrd1 mutation. This mouse was purchased from the Jackson
Laboratory (Bar Harbor, Maine). The control for the WT allele of Pdeb for this gel was
ear tissue obtained from a B6SJLF1/J mouse.

2.4 Administration of Donepezil
Donepezil hydrochloride (C6821-50mg) monohydrate was obtained from Sigma-Aldrich
(Oakville, Ontario) and rehydrated using saline and 10% dimethyl sulfoxide (DMSO) to a
dose of 2.5 mg/kg (for the osmotic pumps) or 1.0mg/kg for the intraperitoneal injections.

2.4.1 Subcutaneous Osmotic Pumps
The implantation of subcutaneous osmotic mini-pumps allows for the continuous,
systemic infusion of a soluble substance over an intermediate duration of time (up to 6
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weeks). Relative to bolus dosing (injection), the infusion of a modulating agent has the
potential to widen the therapeutic index of the agent, increase its efficacy and/or reduce
any side effects (Fara and Urquhart, 1984). This is especially true for substances with
short-half lives. The infusion of an agent also reduces the possibility of injuring or
subjecting laboratory animals to the additional stress of daily injections, possibly
confounding the results of subsequent behavioral analyses. Thus, osmotic mini-pumps
can be an effective alternative to daily injections when executing a moderately long-term
study.
Osmotic mini-pumps purchased from Alzet (Durect Cooperation, Cupertino, California)
are composed of 3 concentric layers: a semipermeable, rate controlling membrane, an
osmotic layer that contains a high concentration of sodium chloride and an impermeable
but flexible drug reservoir (http://www.alzet.com/products/guide_to_use/implantation_
and_explantation.html). Water enters the pump across the semipermeable membrane
due to the high concentration of sodium chloride in the osmotic layer. The entry of water
causes the osmotic chamber to expand, compressing the flexible reservoir and
delivering

the

drug

solution

through

the

flow

moderator

(http://www.alzet.com/products/guide_to_use/implantation_and_explantation.html).
These pumps have been used in the evaluation of a variety of different modulating
agents in laboratory animals, including the effect donepezil in AD mouse models (Dam
et al., 2008; Spilman et al., 2014).
Twenty male 5xFAD mice were implanted with subcutaneous osmotic pumps (model
1004, Alzet, Durect Cooperation, Cupertino, California) designed to deliver the drug at a
fixed rate of 0.11µL/hr for 28 days. Ten 5xFAD mice were randomly chosen to receive
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pumps loaded with saline + 10% DMSO or donepezil. Donepezil was diluted and
prepared based on calculations done using the drug concentration calculator on the
Alzet website (http://www.alzet.com/products/guide_to_use/formulating.html). This was
based on the pump model, flow rate, weight of the mouse and the desired dose. The
pumps were loaded with a 1mL syringe (the appropriate needle was provided with the
pumps), capped with a pin, and then soaked in saline until they were implanted within
one hour. Mice were first anesthetized with 4% isoflurane at 1L/minute until
unconscious. Maintenance was done with 1.5% isoflurane. The dorsal side of the
mouse was sprayed with ethanol and then small incision was made on the right side
(near the shoulder of the mouse). The pump was inserted and the incision was sealed
with a wound clip. Mice were allowed to recover in their home cage under a heat lamp.
The mice were given two days to recover from pump insertion before beginning a 5CSRTT probe trial. Any mice that pulled out their own pump were euthanized. One
mouse was dropped from the experiment for this reason. All surviving mice had their
pumps removed after 28 days.

2.4.2 Intraperitoneal Injection
At approximately 14 months of age, 5xFAD mice were randomly chosen to receive
either donepezil or saline + 10% DMSO for 5 consecutive days. After a two-day
washout, the cohort that received saline received donepezil and vice-versa. Donepezil
was administered via intraperitoneal injection at the lower right or left quadrant of the
abdomen to avoid damage to the urinary bladder and other abdominal organs. Mice
were then placed back in their home cage for 30 minutes before beginning any
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behavioural tests.

2.5 Touchscreens
The pairwise visual discrimination (PVD) and 5-choice serial reaction time tasks (5CSRTT) were conducted using the automated Bussey-Saksida Touchscreen System for
mice (Model 81426, Campden Instruments, Lafayette, Indiana), which consists of a
testing chamber housed within a ventilated sound and light-attenuating box. The
chamber has a house light, a tone generator, and stimuli are displayed on a LCD
monitor that is equipped with infrared sensors. The mouse views the stimuli through a
black mask that contains windows through which each stimulus can be seen. This also
prevents unintended responses by other body parts of the mouse. The mask used
depends on task being administered. The entire apparatus is controlled by the Abet II
Touch Software Version 2.20 (Lafayette Instrument Company, Lafayette, Indiana). The
schedules were designed and the data was collected using this software as well. Each
mouse was only run on one schedule at approximately the same time each day.

2.5.1 Touchscreen Pre-training
Prior to the commencement of either the PVD or the 5-CSRT task, mice are subject to a
basic training schedule (Figure 1A). Mice are habituated to the touchscreen chambers
for the first four days. Habituation 1 (day 1) lasts 10 minutes – all lights are tuned off
and no stimulus or reward is presented. Habituation 2a (day 2 and 3) lasts 20 minutes.
The food tray light will be on at the beginning of each trial and the mouse can complete
an unlimited number of trials within the 20-minute session. When the mouse enters the
food tray, a tone is played and a strawberry milkshake reward (Saputo Inc., Montreal,
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Quebec) is dispensed. When the mouse leaves the food tray, the tray light turns off. The
tray light will turn back on after 10 seconds and another trial begins. Habituation 2b (day
4) is the exact same as habituation 2a, but it lasts 40 minutes. The mouse must be
removed from the cabinet once a habituation schedule is complete.
Following habituation, mice are subject to initial touch, where a white square (for 5CSRTT) or image (for PVD; can be any image not designated for use in
discrimination/reversal) is displayed in one window pseudo-randomly (such that the
stimulus is not shown in the same position more than three times in a row) while the
other window(s) are left blank. The stimulus disappears after 30 seconds and reward is
delivered. If the mouse touches the screen where the white square is displayed while it
is still being displayed (within 30 seconds), a tone will be played and 3x the reward will
be delivered immediately (this is accompanied by a tone and the illumination of the tray
light). The mouse then has to collect the reward, turning the tray light off, and initiating
the inter-trial interval (20 seconds for PD, 5 seconds for 5-CSRTT) – after which another
trial begins. Collection of the reward starts the next inter-trial interval. The mouse must
complete 30 of these trials within 60 minutes and this usually only takes one session.
Otherwise, this schedule is repeated until criterion is achieved.
Initial touch is followed by must touch. In PVD, the stimulus is an image selected
pseudo-randomly (no image shown more than three times in a row) from a list of images
that do not include any of the images that will be used in the discrimination and reversal
trials. In 5-CSRTT, the stimulus remains as a white square. The position of the stimulus
is also chosen pseudo-randomly. The mouse must touch the stimulus to receive a
reward. This is accompanied by a tone and the illumination of the tray light. There is no
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response if the mouse touches the blank screen(s). Collection of the reward starts the
next trial after the inter-trial period (20 seconds for PD, 5 seconds for 5-CSRTT). The
mouse must complete 30 of these trials within 60 minutes to reach criterion. If the
mouse does not reach criterion after 7 sessions for PVD or 5 sessions for the 5-CSRTT,
the mouse is retrained on initial touch until it reaches criterion. If the mouse does not
reach criterion after 7 sessions (PVD) or 5 sessions (5-CSRTT) of the second attempt of
must touch, it is removed from the study.
Must touch is followed by must initiate. For each trial, a free delivery of food is made,
and the tray light is illuminated. The mouse must nose poke and exit the reward tray
before a stimulus (same stimuli with the same criterion as those used in must touch;
task dependent) appears. The other window(s) remain blank and there is no response if
the mouse touches it. The mouse must touch the stimulus to receive a reward. This is
accompanied by a tone and the illumination of the tray light. After the mouse collects the
reward, the inter-trial interval (20 seconds for PD, 5 seconds for 5-CSRTT) begins. The
mouse must nose-poke and exit the reward tray before the next stimulus is displayed.
Thirty of these trials must be completed within 60 minutes to reach criterion. If the
mouse does not reach criterion after 5 sessions, the mouse is retrained on must touch
until it reaches criterion. For the second attempt, if the mouse does not reach the
criterion for must initiate within 5 sessions, it is removed from the study.
The last pre-training phase is punish incorrect, which is similar to must initiate – except
when the mouse touches a blank window, the house light will be turned on for 5
seconds and no reward will be given. After the light turns off, the mouse will not be able
to initiate another trial until the inter-trial interval ends. To reach criterion, mice have to
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complete ≥ 24/30 trials correctly within 60 minutes two days in a row. If the mouse
cannot reach criterion after 30 days, it is removed from the study.
A

C

B
Habituation 1
(10 minutes)

Acquistion
( ≥ 24/30 trials in 60
min 2 days in a row)

Habituation 2a
(20 minutes)

Baseline
(30 trials or 60 min 2
days in a row)

Habituation 2a
(20 minutes)

Habituation 2b
(40 minutes)

Initial Touch
(30 trials in 60 min)

Must Touch
(30 trials in 60 min)

Must Initiate
(30 trials in 60 min)
Punish Incorrect
( ≥ 24/30 trials in 60
min 2 days in a row)

Reversal
(30 trials or 60 min
10 days in a row)

Two Week
Break

Retention Reversal
(30 trials or 60 min 2
days in a row)

Maintenance
(30 trials or 60 min
once per week until
next time-point)

4 Second Stimulus
(50 trials or 60 min with
≥ 80% acuracy and ≤
20% ommisions 3 days
in a row; must
complete at least 30
trials)

2 Second Stimulus
(50 trials or 60 min with
≥ 80% acuracy and ≤
20% ommisions 3 days
in a row; must
complete at least 30
trials)

Probe Trials at 1.5,
1.0, 0.8, 0.6 and 0.4
Second Stimulus
Lengths
(50 trials or 60 min;
2 days each)

Maintenance at the 2
Second Stimulus
Length
(50 trials or 60 min once
per week until the next
time-point)

Figure 1. Summary of touchscreen pre-training, PVD and 5-CSRTT schedules.
A) Flow chart of the touchscreen pre-training schedules, their duration and criterion. B)
Flow chart of pairwise visual discrimination acquisition, baseline, reversal and retention
reversal (7 and 10-month time-point only) which is repeated with a different pair of
images at each time point. C) Flow chart of the 5-CSRTT training and probe trials at 1.5,
1.0, 0.8, 0.6 second stimulus lengths.
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2.5.2 Pairwise Visual Discrimination
Pairwise visual discrimination involves two general phases: visual discrimination
(acquisition and baseline; Figure 1B and Figure 2A) and reversal (Figure 1B and Figure
2B). A black mask with two squares is placed in front of the screen. The PVD task
begins with acquisition, where the reward tray is first primed with the reward. As the
mouse exits the food tray, the first trial begins and a S+ and S- image is displayed. The
location (i.e., left or right side of the mask) of the stimulus is pseudo-random. If the
mouse touches the location where the S+ image is displayed, a reward will be delivered,
along with illumination of the tray light and a tone. The inter-trial period of 20 seconds
begins after the mouse exits the food tray, after which the tray light will turn on, and the
mouse must enter and exit the tray to initiate the next trial. If the mouse touches the
location where the S- stimulus is displayed, the house light will turn on for 5 seconds
and the inter-trial period will follow. Afterwards, the tray light will come on and the
mouse must enter and exit the food tray to begin a correction trial, where the left/right
locations of the stimuli remain the same as the previous trial and is repeated with each
subsequent correction trial until the correct choice is made. The results of the correction
trials do not count toward the criteria for completion of the session (≥24/30 trials within
60 minutes, two days in a row).
Baseline runs for two sessions immediately after reaching the criteria for acquisition,
and is the same as acquisition, except that there is no score required to pass. The
purpose of baseline is to take a baseline measurement of performance. The session
ends after 30 trials or 60 minutes. After completing baseline, reversal is run for the next
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10 sessions. For reversal, trials are initiated and correction trials are run the same way.
The only difference is that the stimulus reward association is reversed (i.e., the previous
S+ image will now be the S- image and vice versa). There is no score required to pass,
and the session ends after 30 trials or 60 minutes.
Beginning at the 7-month time-point, we added the retention reversal schedule, which
was run after a two week (maintenance-free) break from the task. Retention reversal
was the same as reversal, and the purpose of this schedule was to evaluate how well
the mice remembered what they learned in reversal.
Different images were used as S+ and S- stimuli for each time-point (Figure 2C). This
was necessary for each time-point to include a visual discrimination phase and a
subsequent reversal phase.
There are a total of three time-points: a 4-month, 7-month and 10-month time-point.
Each time-point usually takes approximately 2-2.5 months to complete, although some
mice can take up to 3.5 months to complete the last time-point. Thus, during the 4month time-point, the mice are usually between 4-6.5 months of age. During the 7month time-point, the mice usually between 7-9.5 months of age, and during the 10month time-point, they are usually between 10-13.5 months of age. Between each timepoint, the maintenance schedule was run once a week until the next time-point begins.
This schedule was identical to punish incorrect, except there was no criterion that
needed to be met. A summary of the PVD schedules can be found in Figure 1B. For the
detailed PVD standard operating procedure see Appendix B.
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The data collected was submitted to a quality control filtering program (Baycrest,
Toronto, Ontario) before analysis. This program removes any duplicate sessions and
sessions that were ended prematurely (the mouse neither completed 30 trials and the
session was not 60 minutes long). This data will also be added to a new branch of the
Extensible Neuroimaging Archive Toolkit (XNAT), with the ultimate goal of providing an
open-sourced database of mouse touchscreen data.

A

1) Discrimination Stage
S-

C

4-Month Time-point

B

S+

2) Reversal Stage
S+

7-Month Time-point

S-

10-Month Time-point

Figure 2. S+ and S- stimulus presentation and stimuli used in pairwise visual
discrimination.
A) Illustration of stimuli presentation during discrimination (acquisition schedule), where
the yin-yang is S+ and the array of shapes is S-. B) Illustration of stimuli presentation
during reversal, where the yin-yang is now S- and the array of shapes becomes S+. C)
Images used as stimuli in PVD across time-points.
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2.5.3 5-Choice Serial Reaction Time Task
For the 5-CSRTT, a mask with a grid of 5 small squares arranged horizontally (Figure
3A) is placed in front of the screen. The 5-CSRTT begins with a 4 second (s) stimulus
length. Each session begins when the mouse enters and exits the primed reward tray.
Five seconds (delay interval) after the mouse exits the food tray, a stimulus (a small
white square) is presented in one of the 5 grid spaces in a pseudorandom fashion,
where there are 4 presentations at each spatial location within each block of 20 trials.
The mouse must respond by touching the location where the stimulus was presented
within 5 seconds after the stimulus disappears to receive a reward. The delivery of the
reward is accompanied by a tone and illumination of the tray light. If the mouse touches
the incorrect location, this is considered an incorrect response. However, if the mouse
makes no response this is considered an omission. If the mouse responds during the 5
second delay interval, this is categorized as a premature response. Both incorrect
responses, premature responses and omissions will cause the house light to turn on for
5 seconds. Regardless of the response (Figure 3), after the 5 second inter-interval trial,
the tray light is lit once again and the mouse must enter and exit the tray to begin the
next trial. Each session lasts 50 trials or 60 minutes. To reach criterion, mice must
complete at least 30 trials and perform with an accuracy of ≥ 80% with ≤ 20% omissions
3 days in a row. Accuracy and omissions were calculated as follows:

𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =

𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑡𝑟𝑖𝑎𝑙𝑠
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑖𝑎𝑙𝑠 𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑒𝑑 𝑡𝑜 (𝑏𝑜𝑡ℎ 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑎𝑛𝑑 𝑖𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡)
𝑂𝑚𝑖𝑠𝑠𝑖𝑜𝑛𝑠 =

𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑖𝑎𝑙𝑠 𝑚𝑖𝑠𝑠𝑒𝑑
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑖𝑎𝑙𝑠
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The 4s stimulus length is followed by a 2s stimulus length. Other than the length of the
stimulus, the rest of the schedule remains the same. To reach criterion the mice must
once again complete at least 30 trials and perform with an accuracy of ≥ 80% with ≤
20% omissions 3 days in a row. After the mice meet the 2s stimulus performance
criteria, the probe trial evaluations begin. There is no minimum performance criterion
required to advance through the probe trials. Probe trial schedules are also the same as
the 4s and 2s schedules, except that the stimulus length is different. Probe trials
consists of two days of 1.5, 1.0, 0.8 and 0.6s stimulus lengths with two days of 2s
stimulus length sessions run in between each stimulus duration. Mice are randomly
assigned to one of four subgroups and the order with which each subgroup of mice are
subject to in probe trial is counterbalanced as indicated in Table 1. For the detailed 5CSRTT standard operating procedure see Appendix C and Figure 1C.
Subcutaneous osmotic pumps were implanted into 5xFAD mice and their WT littermates
at approximately 10 months of age as described in section 2.4.1. Two days after pump
implantation, mice began a probe trial, starting with five days of 2s sessions to rebaseline. Each mouse is assigned to a subgroup (Table 1). After completion of this
probe trial, mice were subject to one session of the 2s stimulus length once a week until
the next time-point began.
At approximately 14-months of age, the 5xFAD mice were subjected to a probe trial
consisting of only the 0.6s stimulus length following five 2s sessions of re-baseline. Mice
repeated 8 sessions of 5-CSRTT at the 0.6s stimulus length. Thirty minutes prior to the
task, mice were injected with either donepezil or saline 10% DMSO for four consecutive
sessions. After a two-day washout, the cohort of mice that received donepezil received
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saline + 10% DMSO and vice versa. The timeline of this experiment is outlined in Figure
4.
Correct Response

Incorrect Response

Omission

Premature Response

Figure 3. Illustration of the possible responses to the stimulus in 5-CSRTT.
Illustration of a correct response, an incorrect response, an omission and a premature
response in the 5-CSRTT.

Begin 5-CSRTT
training.
5xFAD mice should be
on the first round of
probe trials.

7 Mon

10 Mon
Mon

Finished first round of probe
trials. Implant pumps
(donepezil or saline +10%
DMSO) into 5xFAD mice.
5xFAD mice finish probe trials.
Evaluate locomotion, gait,
then remove pumps.

13 Mon
Mon

Inject donepezil or saline + 10%
DMSO (4 days each with 2-day
washout in between) 30min
prior to 0.6s stimulus length
only probe trial.
Evaluate locomotion
and gait.

14 Mon
Mon

Figure 4. 5-CSRTT experiment timeline.
Illustration of the procedures and behavioural experiments performed in the cohort of
mice used for the 5-CSRTT experiments.
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Table 1. Order of probe trial sessions at 0.6s, 0.8s, 1.0s and 1.5s for individual
subgroups in the 5-CSRTT.
Order of Probe Trial Stimulus Duration
# of Consecutive
Sessions

Sub-group
A

Sub-group
B

Sub-group
C

Sub-group
D

2

0.6s

0.8s

1.0s

1.5s

2

2.0s

2.0s

2.0s

2.0s

2

1.5s

0.6s

0.8s

1.0s

2

2.0s

2.0s

2.0s

2.0s

2

1.0s

1.5s

0.6s

0.8s

2

2.0s

2.0s

2.0s

2.0s

2

0.8s

1.0s

1.5s

0.6s

2.6 Open-Field Locomotion
5xFAD mice and their WT controls that underwent touchscreen evaluation were all
subject to locomotor assessments using open-field locomotor boxes (Omnitech
Electronics Inc., Columbus, Ohio) while still on food-restriction. One group of mice was
then taken off food-restriction for a month and assessed again.
Mice were first habituated to the room where the locomotor assessments were held for
at least 30 minutes prior to the assessment. The mice were habituated in their home
cages. The mice were placed in the open-field locomotor boxes for 2 hours, and
measurements were taken every 5 minutes.
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2.7 Gait Analysis
5xFAD mice and their WT controls were subject to gait analyses after completing
locomotor assessments. Gait analyses were conducted using the CatWalk 7.1
automated gait analysis system (Noldus Information Technology, Wageningen, The
Netherlands). The system uses a video camera to capture the reflection of light as a
mouse moves across an illuminated glass plate. Mice were habituated to the room and
the darkness prior to the experiment. For the first 5 minutes, the lights were dimmed
and the door remained open. The lights were then turned off for another 5 minutes. The
door was then closed for another 5 minutes before the first run. The mouse is placed on
one side of the CatWalk and was allowed to walk across and explore for 25 seconds.
The mouse was then removed, and the video file saved. The glass walkway was
cleaned with Windex and/or 70% ethanol between each run. Three videos were taken
for each mouse, and the two best walks across the glass were chosen. A good walk
was defined as one where the mouse walks at a regular pace across the glass without
pausing. The runs were subsequently analyzed using the CatWalk 7.1 program. The
pixel threshold was set at 65, and each of the paws in a run were labelled by hand. The
data was then exported into an excel file. This included static parameters that were not
affected by the movement of the mouse, and dynamic parameters – parameters that
change as the mouse moved across the glass plate. The types of limb support and step
patterns used by the mice – in addition to the regularity of those step patterns (regularity
index) were also recorded.
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2.8 Forelimb Grip Strength
Forelimb grip strength was assessed using a grip strength meter (Columbus
Instruments, Columbus, Ohio). Each mouse grasped the pull bar of the apparatus with
their forelimbs and the tail of the mouse was gently pulled back horizontally, such that
the body of the mouse was parallel to the bar. The peak force in Newton’s (N) applied to
the bar was recorded. Each mouse underwent 5 separate trials, and the average of
these trials were taken.

2.9 Transcardial Mouse Perfusion, Tissue Preservation and
Slicing
Mice were anesthetized using a 10% ketamine and 5% xylazine mixture diluted in 0.9%
sodium chloride and subsequently euthanized by transcardiac perfusion with 1x
phosphate buffered saline (PBS, pH 7.4). For each mouse, one hemibrain was stored at
-80C for biochemical analyses, while the other hemibrain was post-fixed in 4%
paraformeldahyde overnight at 4C and then stored in 1x PBS and 0.02% azide at 4C
until use. Two pieces of ear tissue were collected from each mouse as well.
Male 5xFAD hemibrains were cryopreserved using increasing concentrations of sucrose
(15%, 20%, 30%), embedded in optimal cutting temperature (OCT) compound and
frozen at -80C. Sagittal sections (10m) were cut using a cryostat (Leica Biosystems,
Weltzar, Germany), directly mounted and frozen. All slides were immersed in 70%
ethanol for 1 minute followed by distilled water for another minute before they were
stained as described below.
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Female 5xFAD hemibrains were sliced (30m) using a vibratome (Leica Biosystems,
Weltzar Germany) and free-floating sections were placed into cold 1x PBS in a 24-well
plate.

2.10 Thioflavin-S Stain
Slices were washed twice with distilled water, stained with a filtered 1.25% Thioflavin-S
solution in 50% ethanol for 8 minutes at room temperature (Sun et al., 2002). Slices
were then washed twice with 80% ethanol, once with 95% ethanol, and then three times
with distilled water (Sun et al., 2002). Slices were then stained with To-Pro-3 (Life
Technologies, Bibco, Carlsbad, CA)

2.11 Amyloid-Beta Immunohistochemistry
Slices were washed in 1x Tris buffered saline (TBS), and then permeabilized with 1%
Triton X-100 (Tx) in 1x TBS for 15 minutes. Non-specific binding was blocked using 2%
horse serum (HS), 2% bovine serum albumin (BSA) and 0.3% Tx in TBS1x. Slices were
then incubated overnight at 4C with 6E10 primary antibody (Biolegend, San Diego, CA)
diluted in TBS 1x (1:300). The next day, following two TBS 1x washes, slices were
incubated at 4C in 488 goat-anti-mouse secondary antibody (Life Technologies, Bibco,
Carlsbad, CA) diluted in TBS 1x (1:1000), 1% HS and 1% BSA. Slices were then rinsed
three times with TBS 1x before being stained with To-Pro (Life Technologies, Bibco,
Carlsbad, CA).
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2.12 To-Pro-3 Iodide Nuclear Stain
Slices were washed three times in PBS 1x, and then incubated with To-Pro-3-Iodide
(Life Technologies, Bibco, Carlsbad, CA) diluted in PBS 1x (1:1000) for 15 minutes at
room temperature. Slices were then washed three more times in PBS 1x before being
mounted onto slides and/or cover-slipped.

2.13 Microscopy and Quantification
Mounted slices were imaged using the Leica-TSC SP8 or SP5 (Leica Biosystems,
Weltzar, Germany) using the 20x/0.75 objective and quantified using ImageJ (National
Institutes of Health). For each mouse, the cortex and hippocampus (dentate gyrus, CA3,
CA1b and CA1a) of 3-4 slices were imaged and quantified in terms of percentage area.
The experimenter was blind to genotype during image acquisition and quantification.

2.14 Statistical Analysis
All data are expressed as mean  SEM. Analyses were done using GraphPad Prism
7.0a. Comparisons between two experimental groups were done with the Student’s ttest. When several experimental groups or treatments were analyzed, a two-way
analysis of variance (ANOVA) or a repeated measures (RM) two-way ANOVA was
used. When ANOVA results were significant, a Sidak’s multiple comparisons post-hoc
analysis test was used. Outliers were removed using the regression outlier removal
(ROUT) method (Motulsky and Brown, 2006) with a maximum false discovery rate (Q)
of 1%. Mice that did not complete 10 sessions of reversal in PVD were also excluded.

41

3 Results

3.1 Visual Discrimination and Reversal Learning in 5xFAD Mice
Patients with AD begin to demonstrate deficits in visual discrimination and cognitive
flexibility in the early stages of the disease (Albert, 1996; Pal et al., 2016; Quental et al.,
2013). Visuospatial function is an important contributor to functional status in AD
patients, accurately predicting the prognosis of the patient (Fukui and Lee, 2009).
Visuospatial function involves the prefrontal and perirhinal corticies (Brigman and
Rothblat, 2008; Bussey et al., 1997; Chudasama and Robbins, 2003; Winters et al.,
2010) and the striatum (Brigman et al., 2013). It is important to determine whether
5xFAD mice also replicate these aspects of the disease, as it would add to the validity
and versatility of this AD mouse model.
In order to evaluate visual discrimination and cognitive flexibility in 5xFAD mice, we
subjected the mice to the PVD touchscreen task beginning at 4, 7 and 10 months of age
– each with a different set of S+ and S- stimuli. Analysis of male 5xFAD mice on the
learning phase of the visual discrimination task showed that the number of sessions
taken by 5xFAD and control mice to achieve initial touch, must initiate and must touch
criteria at the 4-month time-point did not differ (all mice took 1 session to reach each
criterion; Figure 5A). In addition, the number of sessions taken by 5xFAD mice to
achieve acquisition criteria did not differ from WT mice at the 4-month (t(18) = 0.8865, p =
0.3781; Figure 5B), 7-month (t(18) = 0.587, p = 0.5645; Figure 5C), or the 10-month timepoint (t(24) = 1.565, p = 0.1312; Figure 5D). Likewise, the total number of trials (out of 30)
completed by 5xFAD and WT for each session in baseline and reversal were not
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significantly different at the 4-month time-point (F(1,18) = 1.968, p=0.1777; Figure 6E).
The total number of trials completed by 5xFAD and WT for each session in baseline,
reversal and retention reversal were not significantly different at the 7-month: F(1, 18) =
0.3517, p=0.5605; Figure 7E) and 10-month time-point (F(1,

23)

= 1.354, p=0.1386,

Figure 8E) as well. The number of sessions completed by the mice increased as
reversal progressed at the 4-month (F(11,198) = 18.93, p<0.0001, no significant interaction
with genotype: F(11,198) = 1.234, p=0.2662; Figure 6E), 7-month (F(13,

324)

= 19.78,

p<0.0001, no significant interaction with genotype: F(13,324) = 0.8073, p=0.6521; Figure
7E) and 10-month time-point (F(13, 299) = 11.99, p<0.0001, no significant interaction with
genotype: F(13, 299) = 1.475, p=0.1255; Figure 8E).
During reversal learning, the accuracy of male 5xFAD mice and WT controls improved
over 10 sessions at the 4-month (F(11, 198) = 54.17, p<0.0001, no significant interaction
with genotype: F(11,

198)

= 1.032, p=0.4195; Figure 6A), 7-month (F(13,

324)

= 58.83,

p<0.0001, significant interaction with genotype: F(13,324) = 2.192, p=0.0106; Figure 7A)
and 10-month time-point (F(13,
genotype: F(13,

299)

299)

= 41.18, p<0.000, no significant interaction with

= 1.523, p=0.1079; Figure 8A). Accuracy did not differ between

5xFAD mice and WT controls during baseline or reversal learning at the 4-month timepoint (F(1,18) = 0.06227, p=0.8058; Figure 6A), or during baseline, reversal learning and
retention reversal at the 7-month (F(1, 18) = 0.6589, p=0.4275; Figure 7A) and 10-month
time-point (F(1, 23) = 1.077, p=0.3102; Figure 8A).
The number of correction trials done by male 5xFAD mice and the WT controls
decreased over the 10 sessions of reversal at the 4-month (F(11, 198) = 51.33, p<0.0001,
significant interaction with genotype: F(11,

198)

= 1.032, p=0.4195; Figure 6B), 7-month
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(F(13,

324)

= 58.3, p<0.0001, no significant interaction with genotype: F(13,324) = 0.5936,

p=0.8662; Figure 7B) and 10-month time-point (F(13,

299)

= 77.15, p<0.0001, no

significant interaction with genotype: F(13,299) = 1.066, p=0.3886; Figure 8B). The
number of correction trials also did not differ between 5xFAD mice and WT controls
during baseline or reversal at the 4-month time-point (F(1,18) = 3.571, p=0.0750, Figure
6B), or during baseline, reversal and retention reversal at the 7-month (F(1,
0.01309, p=0.9102, Figure 7B) and 10-month time-point (F(1,

23)

=

18)

= 0.07534, p=0.7862;

Figure 8B).
The time taken by male 5xFAD mice and the WT controls to correctly respond to the
task decreased as they progressed through baseline and reversal at the 4-month (F(11,
198)

= 7.941, p<0.0001, no significant interaction with genotype: F(11,

p=0.9511; Figure 6C), 7-month (F(13,

324)

198)

= 0.4088,

= 20.05, p<0.0001, no significant interaction

with genotype: F(13,324) = 1.147, p=0.3205; Figure 7C) and 10-month time-point (F(13, 299)
= 11.59, p<0.0001, no significant interaction with genotype: F(13, 299) = 1.244, p=0.2470;
Figure 8C). The correct response latency did not differ between 5xFAD mice and WT
controls during baseline or reversal at the 4-month time-point (F(1,18) = 4.012, p=0.0605;
Figure 6C), or during baseline, reversal and retention reversal at the 7-month time-point
(F(1,

18)

= 0.703, p=0.4128; Figure 7C). However, at the 10-month time-point, 5xFAD

mice take significantly longer than their WT controls to correctly respond to the task
during baseline, reversal and retention reversal (F(1, 23) = 16.89, p=0.0004; Figure 8C).
The time taken by male 5xFAD mice and the WT controls to collect the reward
decreased as the mice progressed through baseline and reversal at the 4-month (F(11,
198)

= 3.095, p=0.0007, no significant interaction with genotype: F(11,

198)

= 0.7969,
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p=0.6431; Figure 6D), but not at the 7-month (F(13, 324) = 1.023, p=0.4296, no significant
interaction with genotype: F(13,324) = 0.8913, p=0.5630; Figure 7D) and 10-month timepoint (F(13,

299)

= 1.3, p=0.2116, no significant interaction with genotype: F(13,

299)

=

0.3533, p=0.9823; Figure 8D). The reward collection latency did not differ between
5xFAD mice and WT controls during baseline or reversal at the 4-month time-point
(F(1,18) = 4.094, p=0.0581; Figure 6D), or during baseline, reversal and retention reversal
at the 7-month time-point (F(1,

18)

= 3.496, p=0.0779; Figure 7D). However at the 10-

month time-point, 5xFAD mice take significantly longer than their WT controls to
correctly respond to the task during baseline, reversal and retention reversal (F(1, 23) =
57.12, p<0.0001; Figure 8D).
There were two WT outliers (as calculated using the ROUT method and a G of 1%) at
the 4-month time-point.
In summary, male 5xFAD mice did not demonstrate significant differences in task
acquisition or performance during reversal when compared to their WT controls at all
time-points. However, at the 10-month time-point, 5xFAD mice take significantly longer
than their WT controls to correctly respond to the the task and collect the reward during
baseline, reversal and retention reversal.
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5xFAD

1.0

50

No. of Sessions to Criteria

Sessions to Criteria

WT

0.5

0.0

Initial Touch
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Must Initiate

D
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WT

20
10

5xFAD
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5xFAD
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5xFAD

50

No. of Sessions to Criteria

No. of Sessions to Criteria

50

0

30

0

Training Session

C

40

40
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20
10
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Figure 5. Learning phase of the PVD task.
Number of sessions taken to achieve A) initial touch, must initiate and must touch
criterion at 4-months of age (5xFAD: n=11, WT: n=10) (Mean  SEM of the number of
sessions taken by 5xFAD mice and their WT controls to reach aquisiton criterion at B) 4
month (5xFAD: n=11, WT: n=10), C) 7 month (5xFAD: n=12, WT: n=9) and D) 10 month
time-point (5xFAD: n=15, WT: n=10). Repeated measures two-way ANOVA (A) or
unpaired two-tailed t-test (B-D).
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Figure 6. Reversal learning phase of the PVD task at the 4-month time-point.
A) Mean  SEM accuracy (%), B) number of correction trials, C) correct response
latency (s), D) reward collection latency (s), E) number of trials completed by 5xFAD
mice (n=11) and their WT (n=10) controls and F) the stimuli used at the 4-month timepoint. Parameters were measured across baseline (B) days 1 and 2 (B1, B2) and
reversal (R) days 1 to 10 (R1-R10). Repeated-measures two-way ANOVA.
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Figure 7. Reversal learning phase of the PVD task at the 7-month time-point.
A) Mean  SEM accuracy (%), B) number of correction trials, C) correct response
latency (s), D) reward collection latency (s), E) number of trials completed by 5xFAD
mice (n=12) and their WT (n=9) controls and F) stimuli used at the 7-month time-point.
Parameters were measured across baseline days 1 and 2 (B1, B2), reversal days 1 to
10 (R1-R10) and retention reversal (RR) days 1 and 2 (RR1, RR2). Repeated measures
two-way ANOVA.
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1 to 10 (R1-R10) and retention reversal days 1 and 2 (RR1, RR2). Repeated measures
two-way ANOVA (***p<0.0005, ****p<0.0001).
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3.2 Genotyping Pdebrd1
Fifteen 5xFAD mice and twelve of their WT controls were genotyped for the recessive
retinal denegation 1 mutation of the β-subunit of cGMP phosphodiesterase (Figure 9). It
is important to ensure that none of the mice are affected by this mutation as
performance on the touchscreen tasks require the mouse to see the images/stimuli. Out
of the 15 5xFAD mice that were genotyped, 10 of the mice (67%) were homozygous for
the WT Pdeb allele, while 5 (33%) were heterozygous for the Pdebrd1 allele. Out of the
12 WT mice, 2 mice (17%) were homozygous for the WT Pdeb allele, while 10 (83%) of
the WT mice were heterozygous for the Pdebrd1 allele. None of the mice genotyped
were homozygous for the Pdebrd1 allele. Thus, vision in these 5xFAD mice should not
be affected by this mutation.

Wild-Type Mice
+ WT 1

2

3

4 5

6

L

7 8

5xFAD Mice
9 10 1

2

3

4

5

6

7

8

9 10 11 L
1500
1000

500
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Figure 9. Representative PDEBrd1 genotyping results.
5xFAD mice (red) and WT controls (black) were genotyped as described. In the first
lane, there is a positive control (+) for the 550bp Pdebrd1 mutant allele obtained from
FVB/NJ mice, followed by a WT control for the 400bp wild-type PDEB allele (WT).
Ladder (L).
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3.2.1 The effect of carrying the Pdebrd1 allele on performance in
PVD at the 10-month time-point
The 5xFAD mice that were genotyped for Pdebrd1 were used to evaluate whether
carrying one Pdebrd1 allele affected performance in the touchscreens. Although none of
the mice were homozygous for this allele, it is important to evaluate whether the
presence of the allele played any role in task performance.
At the 10-month time-point, the accuracy of male 5xFAD mice that carried the Pdebrd1
allele did not differ significantly from those who did not (F(1, 13) = 0.862, p=0.3701; Figure
10A), although accuracy significantly increased across the sessions (F(13,
p<0.0001, no interaction with group: F(13,

169)

169)

= 21.48,

= 0.9362, p=0.5171; Figure 10A). The

number of correction trials done by both groups decreased over the sessions of reversal
and retention reversal (F(13, 169) = 31.07, p<0.0001, no interaction with group: F(13, 169) =
0.5835, p=0.8651; Figure 10B) and did not differ between groups (F(1,

13)

= 2.109,

p=0.1701; Figure 10B). The amount of time taken to correctly respond to the task did
not significantly differ between groups (F(1,
significantly decreased with session (F(13,

13)

169)

= 3.031, p=0.1053; Figure 10C), but

= 6.252, p<0.0001, no interaction with

group: F(13, 169) = 1.203, p=0.2805; Figure 10C). The time taken to collect the reward did
not differ between groups (F(1, 13) = 1.189, p=0.2952; Figure 10D) and was not affected
by session (F(13,

169)

= 0.6317, p=0.8251, no interaction with group: F(13,

169)

= 1.106,

p=0.3573; Figure 10D). Both groups completed the same number of trials (F(1,

13)

=

0.7796, p=0.3933; Figure 10E), which increased across the sessions of reversal (F(13,
169)

= 7.119, p>0.0001, no interaction with group: F(13,

169)

= 1.237, p=0.2568; Figure
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10E).
In summary, carrying the Pdebrd1 allele did not affect the performance of male 5xFAD
mice in the PVD task.
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Figure 10. Reversal learning phase of the PVD task at the 10-month time-point
separated by Pdebrd1 genotype.
A) Mean  SEM accuracy (%), B) number of correction trials, C) correct response
latency (s), D) reward collection latency (s), E) number of trials completed by 5xFAD
mice that did (n=5) and did not (n=10) carry the Pdebrd1 allele and F) stimuli used at the
10-month time-point. Parameters were measured across baseline days 1 and 2 (B1, B2)
reversal days 1 to 10 (R1-R10) and retention reversalndays 1 and 2 (RR1, RR2).
Repeated measures two-way ANOVA.
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3.3 The Effect of Donepezil on Attention in 5xFAD mice
Deficits in attention have been observed in the 3xTG mouse model of AD (Romberg et
al., 2011) and linked to cholinergic dysfunction (Klinkenberg et al., 2011; Proulx et al.,
2015; Sahakian et al., 1993). Romberg and colleagues were also able to rescue deficits
in these mice following treatment with intraperitoneal injections of donepezil. Our lab
has also observed attentional deficits in male and female 5xFAD mice between 7-10
months of age. The question remains whether donepezil can rescue these impairments
in 5xFAD mice as well.

3.3.1 Infusion of donepezil affects vigilance in the 5-CSRTT
In addition to reducing stress and chances of injury, the infusion of donepezil has the
potential to increase its therapeutic index, efficacy and/or reduce any side effects. Thus
we choose initially to infuse donepezil into the male 5xFAD mice rather than performing
daily injections for the duration of the task. At approximately 10 months of age, male
5xFAD mice were implanted with subcutaneous osmotic pumps that would release
donepezil or saline + 10% DMSO for 28 days. The 5xFAD mice treated with donepezil
completed as many trials as those treated with saline + 10% DMSO (F(1,

14)

= 1.138,

p=0.3402; Figure 11). Stimulus length had no effect on the number of trials completed
by 5xFAD mice (F(3, 42) = 0.922, p=0.4059, no significant interaction with treatment: F(3,
42)

= 0.8001, p=0.5008; Figure 11) after treatment with donepezil.

Donepezil had no significant effect on the percentage accuracy (F(1,

14)

= 0.7788,

p=0.3895; Figure 12A) or omission (F(1, 14) = 0.5874, p=0.4595; Figure 12B) of 5xFAD
mice in the 5-CSRTT. As previously observed, accuracy decreased (F(3,

42)

= 21.83,
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p<0.0001, no significant interaction with treatment: F(3,

42)

12A) and the percentage of omissions increased (F(3,
significant interaction with treatment: F(3,

42)

= 0.9016, p=0.4484; Figure
42)

= 34.62, p<0.0001, no

= 0.1138, p=0.9515; Figure 12B) as

stimulus length decreased.
The accuracy of 5xFAD mice generally increased across bins at the 1.5s (F(4,
5.484, p=0.0007, no significant interaction with treatment: F(4,
Figure 13A), 1.0s (F(4,

67)

68)

68)

=

= 0.2494, p=0.9091;

= 6.372, p=0.0002, no significant interaction with treatment:

F(4, 67) = 0.2116, p=0.9311; Figure 13C), 0.8s (F(4, 66) = 3.868, p=0.0070, no significant
interaction with treatment: F(4,

66)

= 0.02601, p=0.9987; Figure 13E), or 0.6s (F(4,

67)

=

2.787, p=0.0333, no significant interaction with treatment: F(4, 67) = 0.02416, p=0.9988;
Figure 13G) stimulus length. Meanwhile the percentage of omissions was significantly
affected across the bins at the 1.5s stimulus length (F(4,

68)

= 3.455, p=0.0125, no

significant interaction with treatment: F(4, 68) = 0.1124, p=0.9778; Figure 13B), but not at
the 1.0s (F(4, 67) = 0.1299, p=0.9710, no significant interaction with treatment: F(4,
0.2629, p=0.9007; Figure 13D), 0.8s (F(4,
interaction with treatment: F(4,

66)

66)

67)

=

= 0.1031, p=0.9810, no significant

= 0.2421, p=0.9134; Figure 13F), or 0.6s (F(4,

67)

=

0.1367, p=0.9682, no significant interaction with treatment: F(4, 67) = 0.8046, p=0.5266;
Figure 13H) stimulus length. Treatment with donepezil did not affect the accuracy or
omissions of 5xFAD mice across bins at the 1.5s (accuracy: F(1, 68) = 0.2879, p=0.5933;
Figure 13A, omissions: F(1, 68) = 3.746, p=0.0571; Figure 13B), 0.8s (accuracy: F(1, 66) =
0.3762, p=0.5418; Figure 13E, omissions: F(1, 66) = 0.689, p=0.4095; Figure 13F) or at
the 0.6s stimulus length (accuracy: F(1, 67) = 0.3393, p=0.5622; Figure 13G, omissions:
F(1, 67) = 2.133, p=0.1489; Figure 13H). However, at the 1.0s stimulus length, donepezil
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treatment led to a significant increase in the percentage of omissions (F(1,

67)

= 7.488,

p=0.0079; Figure 13D). Accuracy was not affected at this stimulus length (F(1,

67)

=

0.4167, p=0.5208; Figure 13C).
Correct response latency decreased as stimulus length decreased (F(3,

42)

= 5.07,

p=0.0044, no significant interaction with treatment: F(3,

42)

= 0.6235, p=0.6038; Figure

12C) and was not affected by donepezil treatment (F(1,

14)

= 0.2169, p=0.6486; Figure

12C). Reward collection latency remained unaffected by stimulus length (F(3,
0.008512, p=0.9678, no significant interaction with treatment: (F(3,

42)

=

42)

= 0.6874,

p=0.5664; Figure 12D), and was also not affected by donepezil treatment (F(1,

14)

=

0.2302, p=0.6388; Figure 12D).
The number of premature responses did not differ in 5xFAD mice treated with donepezil
(F(1,

14)

= 3.197, p=0.0954; Figure 12E). This was not affected by the stimulus length

(F(3, 42) = 0.04979, p=0.9851, no significant interaction with treatment: F (3, 42) = 0.1322,
p=0.9403; Figure 12E). The number of preservative responses did not differ between
5xFAD mice that were treated with donepezil and 5xFAD mice that were treated with
saline + 10% DMSO (F(1,

14)

= 1.08, p=0.3163; Figure 12F), although for both groups,

the number of preservative responses increased as stimulus length decreased (F(3, 42) =
3.074, p=0.0379, no significant interaction with treatment: F(3,

42)

= 0.9088 p=0.4449;

Figure 12F).
In summary, other than leading to a significant increase in the percentage of omissions
at the 1.0s stimulus length, administration of donepezil using the ALZET pump has no
significant effect on the performance of 5xFAD mice in the 5-CSRTT.
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Figure 11. Number of trials completed by 5xFAD mice in the 5-CSRTT.
Mean  SEM of the number of trials (maximum 50) completed by 5xFAD mice infused
with saline + 10% DMSO (n=9) and donepezil (n=7) at each stimulus length. Repeated
measures two-way ANOVA.

56

A

5xFAD Control

B

90

80

Omission (%)

100

80
70
60

60
40
20
0

1.2
1.0

6
0.

1.

Stimulus Length (s)

Stimulus Length (s)

E

F
10

10

4
2

0

8

6

1.

0.

0.

1.

5

0

Stimulus Length (s)

6
4
2
0
0.
6

6

8

0.
8

8

1.
5

Preservative Responses

Premature Responses

8

0.8

0.
6

0.
8

1.
0

0.8

1.4

0.

1.0

6
0.

0

1.2

8
0.

1.6

5

Reward Collection Latency (s)

1.4

0
1.

Stimulus Length (s)

D

1.6

1.
5

5

1.

Stimulus Length (s)

C

1.

0.
6

0.
8

1.
0

1.
5

50

Correct Response Latency (s)

5xFAD Donepezil

1.
0

Accuracy (%)

100

Stimulus Length (s)

Figure 12. Performance and response measures of 5xFAD mice during the 5CSRTT probe trial.
A) Mean  SEM accuracy (%), B) omission (%), C) correct response latency (s), D)
reward collection latency (s), E) number of premature responses and F) number of
preservative responses in 5xFAD mice that were implanted with osmotic pumps infusing
donepezil (n=7) or saline + 10% DMSO (n=9). Repeated measures two-way ANOVA.
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Figure 13. The vigilance of 5xFAD mice during the 5-CSRTT probe trial.
Mean  SEM accuracy (%) and omission (%) of 5xFAD mice that were implanted with
osmotic pumps infusing donepezil (n=7) or saline + 10% DMSO (n=9) at 1.5s (A, B),
1.0s (C, D), 0.8s (E, F), and 0.6s (G, H) stimulus lengths. Trials are divided into bins of
10 trials each. Two-way ANOVA (**p<0.005).

3.3.2 Performance of 5xFAD mice at the 0.6s stimulus length in
the 5-CSRTT following Donepezil injection
As the infusion of donepezil in 5xFAD mice did not have any effect on the performance
of these mice in the 5-CSRTT, we chose to do daily injections of donepezil in order to
replicate the method of administration used by Romberg et. al (2011). Male 5xFAD mice
were tested in the most difficult stimulus length (0.6s) of the 5-CSRTT at approximately
13 months of age. 5xFAD mice were injected with 1mg/kg of donepezil 30 minutes prior
to beginning the task. Injection of donepezil does not affect percentage accuracy (t(7) =
1.373, p=0.2112; Figure 15A), omission (t(7) = 1.296, p=0.2361; Figure 15B), correct
response latency (t(7) = 1.094, p=0.3100; Figure 15C), reward collection latency (t(7) =
0.08446, p=0.9531; Figure 15D), the number of preservative responses (t(7) = 0.4729,
p=0.6507; Figure 15E) or the number of premature responses (t(7) = 0.092, p=0.9293;
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Figure 15F) in male 5xFAD mice. Donepezil had no significant effect on the number of
trials completed (t(7) = 1.366, p=0.2141; Figure 15G). However, the injection of
donepezil reduced the percentage of omissions in 5xFAD mice across bins of 10 trials
each (F(1, 66) = 5.396, p=0.0233; Figure 14B). Percentage omission was not significantly
affected across the bins (F(4,
treatment: F(4,

66)

66)

= 2.431, p=0.0561, no significant interaction with

= 0.1748, p=0.9506; Figure 14B). Percentage accuracy was not

affected by treatment (F(1, 66) = 1.744, p=0.1913; Figure 14A), but increased across bins
(F(4,

66)

= 5.988, p=0.0004, no significant interaction with treatment: F(4,

66)

= 0.175,

p=0.9505; Figure 14A).
In summary, injection of donepezil reduces the omission percentage in male 5xFAD
mice across bins of ten trials each in the 0.6s second stimulus length of the 5-CSRTT at
13-months of age.
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Figure 14. The vigilance of 5xFAD mice during the 0.6s stimulus length of the 5CSRTT.
A) Mean  SEM accuracy (%) and B) omission (%) of 5xFAD mice that were implanted
with osmotic pumps infusing donepezil (n=7) or saline + 10% DMSO (n=9) at 1.5s Trials
are divided into bins of 10 trials each. Two-way ANOVA (*p<0.05).
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Figure 15. Performance and response measures of 5xFAD mice in the 0.6s
stimulus length of the 5-CSRTT.
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3.4 Spontaneous Locomotor Activity in Male 5xFAD Mice
Activity in open-field locomotor boxes allows us to evaluate a group of non-cognitive
domains that could be important to touchscreen performance. With open-field, we can
evaluate locomotion, exploratory, rearing and anxiety-like activity – some of which have
been shown to be affected in 5xFAD mice (O’Leary, 2013; O’Leary et al., 2013;
Schneider et al., 2014). To assess whether any of these non-cognitive parameters
were affected in male 5xFAD mice at 10-months of age, 5xFAD mice and their WT
controls were evaluated in open field-locomotor boxes. There was no significant
difference in distance travelled between WT and 5xFAD mice every 5 minutes (F(23,391) =
0.000501, p=0.9824; Figure 16A) or the total distance travelled across the 2 hour testing
period (t(17)= 0.3648, p=0.7204; Figure 16B). The distance travelled by the mice
decreased as the test progressed (F(23, 391) = 13.05, p<0.0001, no significant interaction
with treatment F(23, 391) = 1.08 p=0.3648; Figure 16A). Genotype had no effect on rearing
time (t(17) = 1.105 p=0.2844; Figure 16D) or center time (t(17) = 0.3427, p=0.7360; Figure
16C). One WT mouse and one 5xFAD mouse as they were calculated to be outliers
according to the ROUT method.
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Figure 16. Spontaneous locomotor activity of 10-month old 5xFAD mice.
A) Mean  SEM distance (cm) travelled by 10-month old male 5xFAD mice (n=9) and
their WT controls (n=9) every 5 minutes for a total of 2 hours (repeated measures twoway ANOVA). B) Mean  SEM of the total distance (cm) travelled, C) time spent in the
centre (s) and D) time spent rearing (s). Unpaired two-tailed t-test.
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3.4.1 Effect of Donepezil on spontaneous locomotor activity in
male 5xFAD mice
To investigate the effect of donepezil on locomotion, anxiety and rearing activity in
5xFAD mice, following the completion of the 5-CSRTT, the locomotor activity of these
mice was assessed using open-field locomotor boxes. The pumps were still implanted
and releasing donepezil or saline + 10% DMSO at this time. Donepezil has previously
been shown to have effects on locomotion in mice (Kim et al., 2014), and improvements
in motor ability could augment touchscreen performance – specifically in terms of
latencies. Infusion with donepezil had no effect on the distance travelled by 5xFAD mice
every 5 minutes (F(1, 15) = 0.1331, p=0.7204; Figure 17A) or the total distance travelled
across the 2 hour testing period (t(15)= 0.3648, p=0.7204; Figure 17B). The distance
travelled by the mice decreased as the test progressed (F(23, 345) = 8.706, p<0.0001, no
significant interaction with treatment F(23, 345) = 0.9339 p=0.5528; Figure 17A). Donepezil
also had no effect on rearing time (t(15) = 0.6816, p=05059; Figure 17D). However,
5xFAD mice that were implanted with an donepezil infusing osmotic pump spent more
time in the center of the locomotor box than mice that were given saline + 10% DMSO
osmotic pumps (t(15) = 3.403, p=0.0039; Figure 17C). Three 5xFAD mice were removed
(1 control and 2 donepezil), as they were calculated to be outliers according to the
ROUT method.
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Figure 17. Spontaneous locomotor activity of 5xFAD mice treated with donepezil.
A) Mean  SEM distance (cm) travelled by 10-month old male touchscreen 5xFAD mice
every 5 minutes for a total of 2 hours (repeated measures two-way ANOVA). B) Mean 
SEM of the total distance (cm) travelled, C) time spent in the centre (s) and D) time
spent rearing (s) by male 5xFAD mice treated with donepezil (n=8) or saline + 10%
DMSO (n=9). Unpaired two-tailed t-test; **p<0.005.
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3.4.2 Locomotor activity in old 5xFAD male mice
Age-related changes in motor ability and locomotion have been observed in old 5xFAD
mice (O’Leary, 2013; O’Leary et al., 2013; Schneider et al., 2014). Schneider et al.
observed a significant reduction in locomotion and rearing activity at 9 months of age in
male 5xFAD mice compared to WT littermates (Schneider et al., 2014). This was
accompanied by a reduction in anxiety, where the 5xFAD mice spent significantly more
time in the center of the open-field (Schneider et al., 2014). Meanwhile, O'Leary found
that male 5xFAD mice only travel significantly less than their WT controls at 12 and 15
months of age and reared significantly less at 9, 12 and 15 months (O’Leary, 2013).
However, anxiety did not appear to be affected (O’Leary, 2013). Another study found
5xFAD mice to be hyperactive at both 9 and 12 months of age (Yang et al., 2014). To
determine whether 5xFAD mice used in our experiments undergoing food-restriction
present any locomotor deficits when aged, we tested them in locomotor boxes at 14
months. Male 5xFAD mice do not demonstrate differences in locomotion when
compared to their WT controls at 14 months of age – both in terms of distance travelled
in 2 hours measured in intervals of 5 min (F(1, 35) = 1.793, p=0.1892; Figure 18A) or total
distance travelled in 2 hours (t(35) = 1.339, p=0.1892; Figure 18B). The distance
travelled by the mice decreased with time (F(23,

828)

= 20.16, p<0.0001, no significant

interaction with genotype: F(23, 828) = 0.4807, p=0.9819; Figure 18A).
On average, the 5xFAD mice spend approximately the same amount of time as their
WT controls in the center of the locomotor box (t(35) = 0.1126, p=0.9110; Figure 18C).
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However, 5xFAD mice spend significantly less time rearing at 14-months of age (t(35) =
4.633, p<0.0001; Figure 18D).
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Figure 18. Spontaneous locomotor activity of 14-month old 5xFAD mice.
A) Mean  SEM distance (cm) travelled by 14-month old 5xFAD male mice (n=17) and
their WT controls (n=20) every 5 minutes for a total of 2 hours (repeated measures twoway ANOVA). B) Mean  SEM of the total distance (cm) travelled, C) time spent in the
centre (s) and D) time spent rearing (s) by 5xFAD male mice (n=17) and their WT
controls (n=20). Unpaired two-tailed t-test; ****p<0.0001.
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3.4.3 Locomotor activity in 15-month old 5xFAD mice
The same mice used for the experiments in Figure 18 were taken off food-restriction
and given food ad libitum to evaluate whether food-restriction had an effect on
locomotion in these mice, as caloric-restriction has been observed to have a significant
effect on spontaneous locomotor activity in mice (Kuhla et al., 2013). After one month of
free-food, 5xFAD mice and their WT controls do not travel significantly different
distances every 5 minutes (F(1,

20)

= 0.8303, p=0.3730; Figure 19A) or total distances

(t(20) = 0.9112, p=0.3730; Figure 19B). The distance travelled by the mice decreased
with time (F(23, 460) = 6.929, p<0.0001, no significant interaction with treatment: F(23, 460) =
1.428, p=0.0914; Figure 19A).
5xFAD mice and their WT controls did not spend significantly different amounts of time
in the center of the locomotor box (t(20) = 0.8951, p=0.3814; Figure 19C). Interestingly,
5xFAD mice still spent less time rearing (t(20) = 4.83, p=0.0001; Figure 19D). Two
5xFAD mice were calculated to be outliers and were removed according to the ROUT
method.
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Figure 19. Spontaneous locomotor activity of 15-month old 5xFAD mice.
A) Mean  SEM distance (cm) travelled by 15-month old 5xFAD male mice (n=8) and
their WT controls (n=14). Measurements were taken every 5 minutes for a total of 2
hours (repeated measures two-way ANOVA). B) Mean  SEM of the total distance (cm)
travelled, C) time spent in the centre (s) and D) time spent rearing (s) by male 5xFAD
mice (n=8) and their WT controls (n=14). Unpaired two-tailed t-test; ***p<0.0005.

3.5 Gait Analyses in Male 5xFAD Mice
Gait and the ability of mice to walk is vital to their performance in many behavioural
assessments. Given touchscreen results indicating that 5xFAD mice take more time to
touch the screen and collect their reward, it is important to determine if perturbations in
gait are also present in the 5xFAD mouse model. The presence of gait impairments
would also add to the validity of the 5xFAD mouse model as an animal model of AD. AD
patients begin to develop perturbations in gait early in the disease and these
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impairments continue to evolve as the disease progresses (O’keeffe et al., 1996; Sala et
al., 2004).

3.5.1 Gait is not impaired in 10-month-old 5xFAD mice
We subjected male 5xFAD mice to gait analyses at 10-months of age to probe for any
gait impairments. At 10-months of age, the print width (forelimb: t(16) = 0.6151,
p=0.5741, hindlimb: t(16) = 1.647, p=0.1190) and print length (forelimb: t(16) = 0.07134,
p=0.9440, hindlimb: t(16) = 0.4885, p=0.6318) of 5xFAD mice was not significantly
altered when compared to WT mice. Thus, there were also no significant differences in
print area (forelimb: t(16) = 0.7174, p=0.4835, hindlimb: t(16) = 1.826, p=0.0866). There
were no significant differences in paw intensity as well (forelimb: t(16) = 1.841, p=0.0843,
hindlimb: t(16) = 1.539, p=0.1435). 5xFAD mice also do not demonstrate significant
changes in forelimb (t(16) = 0.052, p=0.9592) or hindlimb paw angle (t(16) = 1.156,
p=0.2646). The values of these static gait parameters (parameters that are not affected
by the mouse as its walks) are listed in Table 2.
Stride length (forelimb: t(16) = 0.8291, p=0.4192, hindlimb: t(16) = 1.074, p=0.2986) and
swing speed (forelimb: t(16) = 0.8155, p=0.4267, hindlimb: t(16) = 0.3184, p=0.7543) did
not differ significantly between groups. The duration of the swing phase (forelimb: t (16) =
0.7965, p=0.4374, hindlimb: t(16) = 0.6361, p=0.5337), stand/stance phase (forelimb: t(16)
= 0.4176, p=0.6818, hindlimb: t(16) = 0.05118, p=0.9598), and duty cycle (forelimb: t(16) =
0.03817, p=0.9700, hindlimb: t(16) = 0.3945, p=0.6984), was not altered. The forelimb
(t(16) = 0.1806, p=0.8589) and hindlimb (t(16) = 1.46, p=0.1637) stand index of 5xFAD
mice also did not differ from WT mice. The values of these dynamic gait parameters
(parameters that are affected by the mouse as it walks) are listed in Table 3.
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5xFAD mice do not have significantly different step pattern frequencies when compared
to their WT controls. (F(1,

96)

= 1.296 x 10-9, p>0.9999; Figure 20A). The frequency of

each of the step patterns differed significantly within groups (F(5, 96) = 29.01, p<0.0001,
no interaction with genotype: F(5, 96) = 0.3908, p=0.8541; Figure 20A). The alternate b
(Ab) step pattern was the most common amongst both groups, with an average
frequency of 60.95% for WT mice and 54.25% for 5xFAD mice. There were no
significant differences in regularity index (t(16) = 1.247, p=0.2302; Figure 20B), forelimb
base of support (t(16) = 0.186, p=0.8548; Figure 21A), hindlimb base of support (t(16) =
0.1946, p=0.8482; Figure 21B), or weights between the groups (t(16) = 0.9989,
p=0.3327; Figure 21C).
The frequency of each of the support types differed significantly within groups (F (6, 112) =
135.9, p<0.0001, no interaction effect: F(6,

112)

= 2.132, p=0.0551; Figure 20C).

However, there was no significant difference between genotypes (F (1,

112)

= 0.00,

p>0.9999; Figure 20C). Diagonal limb support was most frequently used by WT
(62.57%) and 5xFAD mice (52.61%).
In summary, male 5xFAD mice do not demonstrate gait impairments when compared to
their WT controls at 10 months of age.
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Table 2. Static gait parameters in 10-month 5xFAD mice.
Static gait parameters were assessed in male 5xFAD mice (n=9) and their WT controls
(n=9). All values shown as mean  SEM (unpaired two-tailed t-test).
Parameter

Wild-Type

5xFAD

10.4 ± 0.86
12.98 ± 1.17

9.49 ± 0.92
9.70 ± 1.37

84.06 ± 1.06
97.32 ± 2.36

80.97± 1.31
91.67 ± 2.81

4.85 ± 0.21
5.54 ± 0.30

5.07 ± 0.28
4.71 ± 0.40

4.67± 0.16
5.54 ± 0.14

4.70 ± 0.20
5.18 ± 0.73

21.33 ± 4.27
13.37 ± 2.52

20.98 ± 5.18
25.16 ± 9.88

2

Paw Print Area (mm )
Forelimb
Hindlimb
Paw Print Intensity
(arbitrary units)
Forelimb
Hindlimb
Paw Print Width (mm)
Forelimb
Hindlimb
Paw Print Length (mm)
Forelimb
Hindlimb
Paw Angle (degrees)
Forelimb
Hindlimb

Table 3. Dynamic gait parameters in 10-month 5xFAD mice.
Dynamic gait parameters were assessed in male 5xFAD mice (n=9) and their WT
controls (n=9). All values shown as mean  SEM (unpaired two-tailed t-test).
Parameter
Stride Length (mm)
Forelimb
Hindlimb
Swing Speed (m/s)
Forelimb
Hindlimb
Stand (s)
Forelimb
Hindlimb
Swing (s)
Forelimb
Hindlimb
Stand Index
Forelimb
Hindlimb
Duty Cycle (s)
Forelimb
Hindlimb

Wild-Type

5xFAD

57.14 ± 2.62
56.60 ± 2.24

54.22 ± 2.36
53.10 ± 2.37

0.69 ± 0.05
0.82 ± 0.10

0.64 ± 0.05
0.82 ± 0.10

0.08 ± 0.01
0.10 ± 0.01

0.09 ± 0.01
0.10 ± 0.01

0.09 ± 0.00
0.07 ± 0.00

0.09 ± 0.00
0.08 ± 0.01

-12.27 ± 0.66
-12.66 ± 0.78

-12.53 ± 1.28
-10.78 ± 1.03

47.62 ± 1.64
57.28 ± 1.53

47.54 ± 1.32
55.5 ± 4.25
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Figure 20. Step pattern and limb support measures in 10-month old 5xFAD mice.
A) Mean  SEM percentage occurrence of each of the step patterns indicated in B, C)
regularity index (%) and D) percentage occurrence of each of the possible limb support
types in male 5xFAD (n=9) and their WT controls (n=9). Unpaired two-tailed t-test (C) or
repeated measures two-way ANOVA (A, D).
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Figure 21. Base of support and weights in 10-month old 5xFAD mice.
Mean  SEM A) forelimb base of support (mm), B) hindlimb base of support (mm) and
weights of male 5xFAD (n=9) mice and their WT controls (n=9). Unpaired two-tailed ttest.

3.5.2 Gait is impaired in 14-month 5xFAD mice
To evaluate whether gait becomes impaired in old male 5xFAD mice, we subjected 14month-old male 5xFAD mice to gait analyses.
Forelimb paw print length (t(37) = 2.497, p=0.0171) was reduced in 5xFAD mice when
compared to controls, as well as forelimb (t(37) = 2.485, p=0.0176) and hindlimb paw
print width (t(37) = 2.42, p=0.0205). Likewise, 5xFAD mice showed a significant decrease
in forelimb print area (t(37) = 3.654, p=0.0008). There was no change in hindlimb paw
print area (t(37) = 1.693, p=0.0988) or hindlimb paw print length (t(37) = 0.3455,
p=0.7317). Forelimb paw print intensity was significantly lower in 5xFAD mice (t (37) =
3.563, p=0.0010), while hindlimb paw print intensity was not affected (t (37) = 1.284,
p=0.2070). 5xFAD mice also exhibit an increase in forelimb (t(37) = 2.228, p=0.0321) and
hindlimb paw angle (t(37) = 2.661, p=0.0115). These static gait parameters are listed in
Table 4.
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5xFAD mice showed significantly shorter stride lengths (forelimb: t (37) = 6.66, p<0.0001;
hindlimb: t(37) = 6.335, p<0.0001) and slower swing speeds (forelimb: t(37) = 4.17,
p=0.0002; hindlimb: t(37) = 2.156, p<0.0001) than their WT controls. There were no
differences in stand/stance time duration (forelimb: t(37) = 2.01, p=0.0517; hindlimb: t(37)
= 0.0618, p=0.9511), swing (forelimb: t(37) = 0.9667, p=0.9667; hindlimb: t(37) = 0.7251,
p=0.4729), stand index (forelimb: t(37) = 1.578, p=0.1231; hindlimb: t(37) = 0.9501,
p=0.3482), or duty cycle (forelimb: t(37) = 1.643, p=0.1089; hindlimb: t(37) = 0.5578,
p=0.5669). These dynamic gait parameters are listed in Table 5.
The frequency of each of the step patterns differed significantly within the groups (F(5,
222)

= 84.03, p<0.0001; Figure 22A), but there was no difference between genotypes

(F(1, 222) = 2.115 x 10-8, p=0.9999, no interaction effect: F(5, 222) = 2.734, p=0.0203; Figure
22A). The Ab step pattern was the most common among both genotypes – with an
average of 64.13% for WT mice and 49.19% for 5xFAD mice. However, the regularity
index of the 5xFAD mice was significantly lower than that of the WT controls (t(37) =
3.054, p=0.0042; Figure 22B). The frequency of each of the support types differed
significantly within groups (F(6, 259) = 5.262, p<0.0001, interaction effect: F(6, 259) = 5.262,
p<0.0001; Figure 22C). However, there was no significant difference between
genotypes (F(1,

222)

= 3.264 x 10-9, p>0.9999; Figure 22C). Diagonal limb support was

most frequently used by WT mice (53.08%), while a three-limb support was most
frequently used by 5xFAD mice (39.06%). Diagonal limb support was used 36.32% of
the time by 5xFAD mice.
5xFAD mice demonstrate a decrease in forelimb base of support (t (37) = 2.919,
p=0.0059; Figure 23A) and an increase in hindlimb base of support when compared to
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their WT controls (t(37) = 5.609, p<0.0001; Figure 23B). There were no significant
differences in weight between the genotypes (t(37) = 1.463, p=0.1517; Figure 23C). A
total of 6 outliers were removed – 3 from each group according to the ROUT method
and a G of 1%.
In summary, male 5xFAD mice demonstrate significant impairments in gait at 14 months
of age.

Table 4. Static gait parameters in 14-month 5xFAD mice.
Static gait parameters were assessed in male 5xFAD mice (n=19) and their WT
littermates (n=21) at 14 months. All values shown as mean  SEM (unpaired two-tailed
t-test; *p<0.05, **p<0.005).
Parameter
Paw Print Area (mm2)
Forelimb
Hindlimb
Paw Print Intensity
(arbitrary units)
Forelimb
Hindlimb
Paw Print Width (mm)
Forelimb
Hindlimb
Paw Print Length (mm)
Forelimb
Hindlimb
Paw Angle (degrees)
Forelimb
Hindlimb

Wild-Type

5xFAD

21.22 ± 1.19
22.44 ± 1.42

13.94 ± 1.64**
18.06 ± 2.25

92.13 ± 1.21
101.1 ± 1.35

85.24 ± 1.55**
97.97 ± 2.07

6.93 ± 0.23
7.71 ± 0.33

5.92 ± 0.35*
6.48 ± 0.38*

6.00 ± 0.19
6.64 ± 0.22

5.18 ± 0.27*
6.69 ± 0.41

11.82 ± 1.51
9.82 ± 1.44

20.97 ± 4.08*
17.21 ± 2.49*
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Table 5. Dynamic gait parameters in 14-month 5xFAD mice.
Dynamic gait parameters were assessed in 5xFAD mice (n=19) and their WT littermates
(n=21) at 14 months of age. All values shown as mean  SEM (unpaired two-tailed ttest; *p<0.05, ***p<0.0005, ****p<0.0001).
Parameter
Stride Length (mm)
Forelimb
Hindlimb

Wild-Type

5xFAD

60.48 ± 1.14
60.13 ± 1.13

47.50 ± 1.64****
48.23 ± 1.54****

0.70 ± 0.03
0.88 ± 0.03

0.53 ± 0.02***
0.77 ± 0.04*

0.12 ± 0.00
0.13 ± 0.01

0.10 ± 0.01
0.13 ± 0.01

Swing Speed (m/s)
Forelimb
Hindlimb
Stand (s)
Forelimb
Hindlimb
Swing (s)
Forelimb
Hindlimb
Stand Index
Forelimb
Hindlimb

0.09 ± 0.00
0.07 ± 0.00

0.09 ± 0.00
0.07 ± 0.00

-9.98 ± 0.55
-9.37 ± 0.59

-11.95 ± 0.68
-10.15 ± 0.55

Duty Cycle (s)
Forelimb
Hindlimb

55.76 ± 0.94
62.15 ± 1.27

51.67 ± 2.47
63.61 ± 2.31
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Figure 22. Step pattern and limb support measures in 14-month 5xFAD mice.
A) Mean  SEM percentage occurrence of each of the step patterns, B) regularity index
(%) and C) percentage occurrence of each of the possible limb support types in male
5xFAD mice (n=18) and their WT controls (n=21). Two-way ANOVA (A, C) or unpaired
two-tailed t-test (B); **p<0.005.
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Figure 23. Base of support and weights in 14-month 5xFAD mice.
Mean  SEM A) forelimb base of support (mm), B) hindlimb base of support (mm) and
C) weights of male 5xFAD mice (n=18) and their WT controls (n=21). Unpaired twotailed t-test; **p<0.005, ****p<0.0005.
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3.5.3 The gait of 5xFAD mice at 14-months of age is mildly
improved by intraperitoneal injection of donepezil
To determine whether intraperitoneal injection of donepezil had an effect on the
previously observed gait impairments in 14-month male 5xFAD mice, the 5xFAD mice
received intraperitoneal injections (replicating the Romberg et al. (2013) study) of either
donepezil or saline + 10% DMSO. Gait was evaluated 30 min after the injection.
Forelimb print length (t(7) = 1.853, p=0.1063), hindlimb print length (t(7) = 0.7068,
p=0.5025) and forelimb print width (t(7) = 2.162, p=0.0674) were not significantly affected
by treatment with donepezil. However, there was a significant increase in hindlimb print
width (t(7) = 2.721, p=0.0297), leading to a significant increase in hindlimb print area (t(7)
= 2.457, p=0.0437). There was also a significant increase in forelimb print area (t(7) =
3.182, p=0.0155). Intensity (forelimb: t(7) = 0.304, p=0.7699, hindlimb: t(7) = 0.171,
p=0.8691) and paw angle (forelimb: t(7) = 0.4448, p=0.6699, hindlimb: t(7) = 1.100,
p=0.3078) were not significantly affected by treatment. The values of these static gait
parameters are listed in Table 6.
Stride length (forelimb: t(7) = 2.342, p=0.0517, hindlimb: t(7) = 2.007, p=0.0847) and
swing speed (forelimb: t(7) = 1.654, p=0.1422, hindlimb: t(7) = 1.188, p=0.2736) did not
differ significantly between the groups. The duration of swing phase (forelimb: t (7) =
0.4286, p=0.6811, hindlimb: t(7) = 1.768, p=0.1204) and stand/stance phase (forelimb:
t(7) = 1.414, p=0.2004, hindlimb: t(7) = 0.8443, p=0.4264) were not affected by donepezil.
The forelimb stand index (t(7) = 1.455, p=0.1890), hindlimb stand index (t(7) = 1.976,
p=0.0886) and forelimb duty cycle (t(7) = 2.138, p=0.0698) were not significantly
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different. However, there was a significant increase in hindlimb duty cycle (t(7) = 2.53,
p=0.0393) in the 5xFAD mice that were treated with donepezil. The values of these
dynamic gait parameters are listed in Table 7.
Intraperitoneal injection of donepezil had no effect on the frequency of step patterns in
5xFAD mice (F(1,

84)

= 0.00, p>0.9999; Figure 24A). The frequency of each of step

pattern differed significantly within groups (F(5, 84) = 11.76, p<0.0001, no interaction with
treatment: F(5, 84) = 0.2834, p=0.9210; Figure 24A). The Ab step pattern was the most
common amongst both groups – 42.43% among those who were treated with saline +
10% DMSO and 50.53% among those who were treated with donepezil. Treatment had
no effect on the regularity index (t(7) = 1.256, p=0.2493; Figure 24B), forelimb (t(7) =
1.107, p=0.3050; Figure 25A) or hindlimb base of support (t(7) = 2.328, p=0.0528; Figure
25B). There were no significant differences between the weights of the mice (t(7) =
0.7662, p=0.4686; Figure 25C).
Treatment did not significantly affect the frequency of each support type (F (1, 98) = 4.265
x 10-9, p>0.9999; Figure 24C), although the frequency differed significantly within
groups ((F(6,

98)

= 122.9, p<0.0001, no interaction with treatment: (F(6,

98)

= 3.093,

p=0.0081; Figure 24C). A diagonal support was most commonly used by 5xFAD mice
treated with saline + 10% DMSO (47.60%), while a three-limbed support was most
commonly used by 5xFAD mice treated with donepezil (49.35%).
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Table 6. Static gait parameters in 14-month 5xFAD mice following donepezil
treatment.
Static gait parameters were assessed male 5xFAD that have been given intraperitoneal
injections of donepezil (n=8) or saline + 10% DMSO (n=8). All values shown as mean 
SEM (paired two-tailed t-test; *p<0.05).
Parameter
Paw Print Area (mm2)
Forelimb
Hindlimb
Paw Print Intensity
(arbitrary units)
Forelimb
Hindlimb
Paw Print Width (mm)
Forelimb
Hindlimb
Paw Print Length (mm)
Forelimb
Hindlimb
Paw Angle (degrees)
Forelimb
Hindlimb

5xFAD Control

5xFAD Donepezil

13.79 ± 1.11
17.28 ± 2.51

18.47 ± 2.03*
29.09 ± 3.75*

86.95 ± 1.12
104.7 ± 4.61

86.50 ± 1.99
105.6± 1.52

6.41 ± 0.20
6.18 ± 0.40

7.04 ± 0.37
8.01 ± 0.51*

4.87 ± 0.14
7.40 ± 0.90

5.13 ± 0.20
8.52 ± 1.37

14.34 ± 4.09
6.84 ± 2.06

12.00 ± 2.54
9.99 ± 1.31

Table 7. Dynamic gait parameters in 14-month 5xFAD mice following donepezil
treatment.
Dynamic gait parameters were assessed in male 5xFAD that have been given
intraperitoneal injections of donepezil (n=8) or saline + 10% DMSO (n=8). All values
shown as mean  SEM (paired two-tailed t-test; *p<0.05).
Parameter
Stride Length (mm)
Forelimb
Hindlimb
Swing Speed (m/s)
Forelimb
Hindlimb
Stand (s)
Forelimb
Hindlimb
Swing (s)
Forelimb
Hindlimb
Stand Index
Forelimb
Hindlimb
Duty Cycle (s)
Forelimb
Hindlimb

5xFAD Control

5xFAD Donepezil

52.94 ± 2.67
52.8 ± 1.93

45.26 ± 2.06
47.32 ± 2.04

0.62 ± 0.02
0.70± 0.30

0.55 ± 0.03
1.05 ± 0.07

0.09 ± 0.00
0.34 ± 0.22

0.11 ± 0.01
0.15 ± 0.01

0.09 ± 0.00
0.06 ± 0.01

0.09 ± 0.00
0.05 ± 0.00

-13.24 ± 0.59
-10.37 ± 0.66

-11.35 ± 0.97
-8.51 ± 0.75

50.15 ± 1.22
64.96 ± 0.71

54.99 ± 1.52
73.91 ± 1.84*
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Figure 24. Step pattern and limb support measures in 14-month old 5xFAD mice
following donepezil treatment.
A) Mean  SEM percentage occurrence of each of the step patterns, B) regularity index
(%) and C) percentage occurrence of each of the possible limb support types in male
5xFAD mice given intraperitoneal injections of donepezil (n=8) or saline + 10% DMSO
(n=8) following the completion of the second 5-CSRTT probe trial (paired two-tailed ttest (B) or two-way ANOVA (A, C)).
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Figure 25. Base of support and weights in 14-month 5xFAD mice following
donepezil treatment.
Mean  SEM A) forelimb base of support (mm), B) hindlimb base of support (mm) and
weights of the male 5xFAD that have been given intraperitoneal injections of donepezil
(n=8) or saline + 10% DMSO (n=8). Paired two-tailed t-test.

3.5.4 Gait remains altered in 15-month male 5xFAD mice
To determine whether food-restriction during touchscreen evaluation affected the gait of
mice and may have contributed for the deficits observed in 5xFAD mice, we took the
cohort of mice from the 14-month experiment that did not receive donepezil, provided
food ad libitum for one month, and then assessed gait once again.
Paw print width was not significantly altered in 5xFAD mice (forelimb: t (16) = 1.076,
p=0.2981; hindlimb: t(16) = 0.5839, p=0.5675). There was also no significant difference in
forelimb paw print width (t(16) = 3.161, p=0.0060), however hindlimb print length was
significantly increased (t(16) = 0.5839, p=0.5675). This led to a significant increase in
hindlimb print area (t(16) = 2.234, p=0.0401). There was no change in forelimb paw print
area (t(16) = 1.297, p=0.2131). Forelimb (t(16) = 5.255, p<0.0001) and hindlimb paw print
intensity was significantly lower in 5xFAD mice (t(16) = 7.583, p<0.0001). There were
also no significant changes in forelimb (t(16) = 1.544, p<0.1420) and hindlimb paw angle
(t(16) = 1.544, p=0.1420). These static gait parameters are listed in Table 8.
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5xFAD mice have significantly shorter stride lengths (forelimb: t(16) = 2.756, p=0.0141;
hindlimb: t(16) = 3.339 p=0.0042) than their WT controls. Although there was no
difference in forelimb swing speed (t(16) = 1.253, p=0.2281), 5xFAD mice had a
significantly faster hindlimb swing speed than WT mice (t(16) = 2.454, p=0.0260). There
were no differences in stand/stance time duration (forelimb: t (16) = 0.2905, p=0.7752;
hindlimb: t(16) = 2.081, p=0.0539), and forelimb swing (t(16) = 0.02621, p=0.9794).
However, the length of the hindlimb swing phase was significantly lower in 5xFAD mice
(t(16) = 5.309, p<0.0001). Forelimb (t(16) = 1.459, p=1.640) and hindlimb stand index (t(16)
= 0.7853, p=0.4437) was not significantly different. Forelimb duty cycle was not affected
(t(16) = 0.4272, p=0.6749), while there was a significant increase in the hindlimb duty
cycle (t(16) = 5.650, p<0.0001). These dynamic gait parameters are listed in Table 9.
Once the 5xFAD mice were given food ad libitum, 5xFAD mice do not gain as much
weight as WT mice (t(16) = 2.983, p<0.0125; Figure 27C). The frequency of each of the
step patterns differed significantly within the groups (F(5,

96)

= 13.94, p<0.0001; Figure

26A), but there was no difference between genotypes (F(1, 96) = 8.082x 10-9, p>0.9999,
with an interaction effect: F(5,

96)

= 8.614, p>0.9999; Figure 26A). The Ab step pattern

was most frequently used (53.87%) by 5xFAD mice, while the alternate a (Aa) pattern
was most frequently used by WT mice (31.44%). This was followed closely by the
cruciate b (Cb) at 28.64%. The regularity index was not significantly different between
5xFAD mice and their WT controls (t(16) = 0.6824, p=0.5048; Figure 26B).
The frequency of each of the support types differed significantly within groups (F (6, 112) =
222.5, p<0.0001, interaction effect: F(6,

112)

= 12.18, p<0.0001; Figure 26C). However,

there was no significant difference between genotypes (F(1,

112)

= 1.843 x 10-7,
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p=0.9997; Figure 26C). Diagonal limb support was most frequently used by WT mice
(56.60%), while a three-limb support was most frequently used by 5xFAD mice
(44.39%). 5xFAD mice had a significantly lower forelimb base of support compared to
their WT controls (t(16) = 0.3.457, p=0.0032; Figure 27A), while their hindlimb base of
support was significantly higher (t(16) = 2.474, p=0.0279; Figure 27B).
A total of 2 outliers were removed – 1 from each group according to the ROUT method
and a G of 1%.
In summary, although the weights of 5xFAD mice are significantly lower than that of WT
mice following one month of free-food, gait remains altered.
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Table 8. Static gait parameters in 15-month 5xFAD mice.
Static gait parameters were assessed in male 5xFAD mice (n=7) and their WT
littermates (n=11) following one month of free-food. All values shown as mean  SEM
(unpaired two-tailed t-test; *p<0.05, **p<0.005, ****p<0.0001).
Parameter
Paw Print Area (mm2)
Forelimb
Hindlimb
Paw Print Intensity
(arbitrary units)
Forelimb
Hindlimb
Paw Print Width (mm)
Forelimb
Hindlimb
Paw Print Length (mm)
Forelimb
Hindlimb
Paw Angle (degrees)
Forelimb
Hindlimb

Wild-Type

5xFAD

27.19 ± 1.20
24.12 ± 0.95

24.54 ± 1.76
32.80 ± 4.71*

118.40 ± 2.12
126.60 ± 2.16

100.20 ± 2.78****
100.40± 2.12****

7.90 ± 0.15
8.16 ± 0.11

7.64 ± 0.20
8.41 ± 0.51

7.40 ± 0.31
6.940 ± 0.15

6.72 ± 0.60
11.16 ± 1.69**

7.14 ± 1.80
8.18 ± 1.68

14.64 ± 4.47
11.60 ± 3.40

Table 9. Dynamic gait parameters in 15-month 5xFAD mice.
Dynamic gait parameters were assessed in male 5xFAD mice (n=7) and their WT
littermates (n=11) one month of free food. All values shown as mean  SEM (unpaired
two-tailed t-test; *p<0.05, **p<0.005, ****p<0.0001).
Parameter
Stride Length (mm)
Forelimb
Hindlimb
Swing Speed (m/s)
Forelimb
Hindlimb
Stand (s)
Forelimb
Hindlimb
Swing (s)
Forelimb
Hindlimb
Stand Index
Forelimb
Hindlimb
Duty Cycle (s)
Forelimb
Hindlimb

Wild-Type

5xFAD

61.36 ± 0.95
60.58 ± 1.03

50.83 ± 4.62*
52.07 ± 2.79**

0.75 ± 0.05
0.92 ± 0.06

0.64 ± 0.07
1.164 ± 0.08*

0.12 ± 0.00
0.13 ± 0.01

0.12 ± 0.01
0.17 ± 0.02

0.09 ± 0.00
0.07 ± 0.00

0.09 ± 0.00
0.05 ± 0.00****

-8.65 ± 0.47
-8.74 ± 0.66

-10.08 ± 0.99
-7.95 ± 0.72

56.20 ± 0.70
63.71 ± 0.71

57.11 ± 2.45
73.31 ± 1.84****
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Figure 26. Step pattern and limb support measures in 15-month 5xFAD mice.
A) Mean  SEM percentage occurrence of each of the step patterns, B) regularity index
(%) and C) percentage occurrence of each of the possible limb support types in male
5xFAD mice (n=7) and their WT controls (n=11) following one month of free food (twoway ANOVA (A, C) or unpaired two-tailed t-test (B)).
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Figure 27. Base of support and weight in 15-month 5xFAD mice.
Mean  SEM A) forelimb base of support (mm) and B) hindlimb base of support (mm) of
male 5xFAD mice (n=7) and their WT controls (n=11) following one month of free food.
Weights of WT (n=5) and 5xFAD mice (n=7) prior to transcardial perfusion (unpaired
two-tailed t-test; *p<0.05, **p<0.005).

3.6 Neuromuscular Strength is not Affected in 5xFAD Mice at 14Months of Age
It is possible that the gait impairments observed in 5xFAD mice are a result of
perturbations in neuromuscular strength. And so, following gait assessments,
neuromuscular strength was assessed using a grip-strength meter. Forelimb grip force
was not significantly different between the 14-month-old male 5xFAD and WT mice (t(20)
= 1.208, p=0.2413; Figure 28).

Grip Force (N)

1.5

1.0

0.5

0.0

WT

5xFAD

Figure 28. Forelimb grip force in 14-month old 5xFAD mice.
Mean  SEM forelimb grip force of male 5xFAD mice (n=12) and their WT controls
(n=10) at 14-months of age (unpaired two-tailed t-test).
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3.7 Mild Food-Restriction Does Not Affect Amyloid Pathology in
Male and Female 5xFAD Mice
In order to encourage mice to perform in the touchscreen tasks, the mice are mildly food
restricted. Some studies have shown that caloric restriction (defined as a reduction of
average calorie intake to 50-70% of the calories consumed ad libitum) has the ability to
significantly reduce cognitive deficits in AD mouse models and humans (Halagappa et
al., 2007; Schroeder et al., 2010; Witte et al., 2009; Wu et al., 2008). Various mouse
models of AD also show a reduction in amyloid pathology following caloric restriction
(Halagappa et al., 2007; Patel et al., 2005; Schroeder et al., 2010; Wang et al., 2005).
Thus, we want to determine whether our food-restriction protocol would have any
significant effect on amyloid pathology in these mice.
Three months of mild food-restriction in 5xFAD mice to 85% of their adult weight did not
have a significant influence on amyloid pathology. Amyloid-beta immunoreactivity in the
hippocampi and corticies of food-restricted 5xFAD mice did not significantly differ from
that of free-feeding 5xFAD mice on a regular ad libitum diet. This was the case for both
male (hippocampus (t(6) = 0.7622, p=0.4748, cortex (t(6) = 0.9598, p=0.3742); Figure 29)
and female 5xFAD mice (hippocampus (t(6) = 0.9946, p=0.3583, cortex (t(6) = 1.237,
p=0.2624); Figure 30). In addition, Thioflavin-S staining did not differ significantly in the
hippocampi (t(6) = 0.2291, p=0.8264; Figure 31A, B) and cortex (t(6) = 1.168, p=0.2870;
Figure 31C, D) of food-restricted female 5xFAD mice when compared to free-feeding
female 5xFAD mice.
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Figure 29. The effect of mild caloric restriction on 6E10 amyloid pathology in male
5xFAD mice at 6 months of age.
A) Representative images of amyloid-beta 6E10 antibody and ToPro-3 (20x
magnification; scale bar = 100µm) and B) quantification (mean  SEM) of 6E10
immunoreactivity in the hippocampi (CA1b) of mildly food-restricted (n=4; 3-4
slices/mouse) and free food male 5xFAD mice (n=4; 3-4 slices/mouse) at 6 months of
age. C) Representative images of amyloid-beta 6E10 antibody and ToPro-3 (20x
magnification; scale bar = 100µm) and D) quantification (mean  SEM) of 6E10
immunoreactivity in the cortices of mildly food-restricted (n=4; 3-4 slices/mouse) and
free food male 5xFAD mice (n=4; 3-4 slices/mouse) at 6 months of age. Unpaired twotailed t-test.
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Figure 30. The effect of mild caloric restriction on 6E10 amyloid pathology in
female 5xFAD mice at 6 months of age.
A) Representative images of amyloid-beta 6E10 antibody and ToPro-3 (20x
magnification; scale bar = 100µm) and B) quantification (mean  SEM) of 6E10
immunoreactivity in the hippocampi (CA1) of mildly food-restricted (n=4; 3-4
slices/mouse) and free food female 5xFAD mice (n=4; 3-4 slices/mouse) at 6 months of
age. C) Representative images of amyloid-beta 6E10 antibody and ToPro-3 (20x
magnification; scale bar = 100µm) and D) quantification (mean  SEM) of 6E10
immunoreactivity in the cortices of mildly food-restricted (n=4; 3-4 slices/mouse) and
free food male 5xFAD mice (n=4; 3-4 slices/mouse) at 6 months of age. Unpaired twotailed t-test.
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Figure 31. The effect of mild caloric restriction on Thioflavin-S amyloid pathology
in female 5xFAD mice at 6 months of age.
A) Representative images of Thioflavin-S (Thio-S) and and ToPro-3 (20x magnification;
scale bar = 100µm) and B) quantification (mean  SEM) of Thio-S in the hippocampi
(CA1b) of mildly food-restricted (n=4; 3-4 slices/mouse) and free food male 5xFAD mice
(n=4; 3-4 slices/mouse) at 6 months of age. C) Representative images of Thioflavin-S
and ToPro-3 (20x magnification; scale bar = 100µm) and D) quantification (mean 
SEM) of Thio-S in the cortices of mildly food-restricted (n=4; 3-4 slices/mouse) and free
food male 5xFAD mice (n=4; 3-4 slices/mouse) at 6 months of age. Unpaired two-tailed
t-test.
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Chapter 4 - Discussion
4.1 5xFAD Mice Do Not Show Retinal Degeneration Due to the
Pdebrd1 allele
Although 5xFAD mice may carry the Pdebrd1 allele for retinal degeneration, the
presence of one Pdebrd1 allele does not affect vision (Giménez and Montoliu, 2001) or,
as we have observed, performance in the PVD task. In addition, young 5xFAD mice
have been able to perform on a variety of other vision-requiring tasks without
impairment. This includes the 5-CSRTT (Masood, 2015), the Y-maze (Oakley et al.,
2006), and the Morris Water Maze (Ohno, 2006; Schneider et al., 2014), where the
mouse is required to use spatial cues on the wall of a room to orient themselves in a
water pool and find a hidden platform. Thus, Pdebrd1 induced changes in retinal function
does not affect the ability of 5xFAD mice to perform touchscreen tasks.

4.2 Visual Discrimination and Cognitive Flexibility is not Impaired
in 5xFAD Mice
5xFAD mice did not show significant alterations in visual discrimination acquisition and
reversal when compared to control mice. The lack of impairments in visual
discrimination has also been observed in 21-month-old TASTPM (Harper et al., 2013),
18-month PDAPP (Harper et al., 2013) and APPSwDl/Nos2-/- (CVN) mice (Piiponniemi
et al., 2017). Harper et al., used an apparatus similar to the Bussey-Saksida
touchscreens, although their visual discrimination task used different images and did not
consist of a reversal stage. TASTPM mice express two of the five mutations carried by
5xFAD mice: the Swedish APP K670N/M671L mutation, and a mutation in the gene for
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presenilin 1 (M146V), resulting in cerebral A deposition beginning at 3-months (Howlett
et al., 2004). Meanwhile, PDAPP mice express the Indiana APP V717F mutation,
leading to some plaque deposition by 10-12 months of age (Games et al., 1995;
Hartman et al., 2005). CVN mice express a few mutations in human APP (Swedish
K670N/M671L, Dutch E693Q, and Iowa D694N) along with a homozygous deletion of
the gene for nitric oxide synthase from Nos2−/− (B6 129P2Nos2 tau1Lau/J) animals
(Piiponniemi et al., 2017). These mice present dense A deposits and extensive tau
pathology by 52 weeks of age (Wilcock et al., 2008). Meanwhile, deficits in visual
discrimination learning have been observed in the PVD task with 11-month old rTg4510
mice (Harper et al., 2013). These mice have tetracycline regulated expression of human
P301L mutant Microtubule Associated Protein Tau, resulting in age related tau
pathology (Harper et al., 2013). The rTg4510 mice performed with significantly less
accuracy during the acquisition/learning phase of the PVD task (Harper et al., 2013).
Meanwhile, 4-5 month old TgCRND8 mice were found to reverse the previously
acquired association faster than WT mice (Romberg et al., 2013). TgCRND8 mice
express the Swedish K670N/M671L and the Indiana V717F APP mutation, leading to
plaque formation by 3 months of age (Chishti et al., 2001).
Interestingly, at the 10-month time-point, 5xFAD mice take significantly longer than WT
mice to make a correct response and collect the reward in PVD. Significant delays in
reward collection and task response were also observed in 10-13.5 month-old 5xFAD
mice subject to the 5-CSRTT (Masood, 2015). Delays in reward collection have also
been observed in CVN mice, but without delays in task response, leading Piiponniemi et
al. (2017) to conclude that this was not likely due to gross motor impairments
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(Piiponniemi et al., 2017). However, in our case, it is possible that this deficit results
from a motor/gait impairment and/or a delay in cognitive processing – both of which
have been observed in patients with AD (Dudgeon, 2010; Li et al., 2014b; O’keeffe et
al., 1996; Sala et al., 2004).
Although we observed no significant differences in accuracy between the genotypes,
mice performed better at 7-months than at 4- or 10-months of age. Treviño et al. (2013)
demonstrated that the difficulty of visual discrimination depends on the degree of
structural similarity between the CS+ and CS- images, affecting learning rate and
maximum performance (Treviño et al., 2013). The three image sets used in our
longitudinal study were subsequently assessed for their difficulty in three separate
groups of WT mice at 4 months of age (Beraldo et al., unpublished). Image set 2 was
significantly easier to acquire than image set 1 (a reduction in the number of sessions to
criteria), likely leading to a significant increase in accuracy (% correct) compared to
image set 3 during the 10 sessions of reversal (Beraldo et al., unpublished). Therefore,
image sets could be manipulated to alter the difficulty of the PVD task, potentially
allowing for magnification of deficits in visual discrimination and/or cognitive flexibility.
Image sets could also be counterbalanced across time-points to avoid this issue.

4.3 The Sustained Attention of 5xFAD Mice is Affected by the
Injection of Donepezil
Attention is affected by damage to the prefrontal cortex and/or striatum, and
impairments in attention have been previously observed patients with AD (Perry and
Hodges, 1999). The accuracy of mice in the 5-CSRTT task is significantly reduced by
damage to the prefrontal cortex and/or striatum as well (Muir et al., 2012; Passetti et al.,
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2003; Rogers et al., 2001). Various mouse models of cholinergic dysfunction also
demonstrate deficits in attention, including M1 muscarinic receptor deficient mice
(Bartko, 2011), ChAT-ChR2-EYFP mice (Kolisnyk et al., 2013b) and VAChTSix3-Cre-flox/flox
mice (Kolisnyk et al., 2013a), suggesting that cholinergic transmission is vital for
attentional processes. Studies have also shown that the cholinergic system can be
leveraged in order to improve attention. Galantamine was able to improve the attention
of wild-type mice in the most demanding 0.6s stimulus length of the 5-CSRTT (Kolisnyk
et al., 2013a). Meanwhile, donepezil has been shown to improve executive function and
involuntary attention in human AD patients (Bohnen et al., 2005; Rokem et al., 2010)
and in the 3xTG mouse model (Romberg et al., 2011). 3xTG mice were assessed in the
5-CSRTT at 9-months of age and were found to demonstrate significant deficits in
response accuracy when compared to WT controls (Romberg et al., 2011). These
attentional deficits were ameliorated following daily intraperitoneal injection of donepezil
prior to the task (Romberg et al., 2011). Donepezil also improved the vigilance – the
ability to maintain a constant level of attention across time – of these mice (Romberg et
al., 2011). At high doses (4 mg/kg), the long-term administration of donepezil has also
been shown to reduce the levels of soluble A40 and A42, reduce plaque deposition
and prevent synapse loss in the Tg2576 mouse model of AD (Dong et al., 2009). This
mouse model carries the Swedish K670N/M671L APP mutation (Hsiao et al., 1996).
However, the administration of donepezil to 5xFAD mice – through implanted
subcutaneous osmotic mini-pumps for the purpose of maintaining drug concentrations
and increasing the efficacy of donepezil (Fara and Urquhart, 1984) – had little effect on
attention as measured by the 5-CSRTT. However, when donepezil was administered
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via intraperitoneal injection to replicate the study performed by Romberg et al. (2011),
there was a significant reduction in the omission percentage of 5xFAD mice at the 0.6s
stimulus length. This suggests that the injection of donepezil improved the ability of
5xFAD mice to attend to the stimulus display area throughout the duration of the task
(Romberg et al., 2011). Deficits in vigilance have also been observed in patients with
AD (Perry and Hodges, 1999).
Donepezil is normally recommended as a treatment for patients with mild to moderate
AD that can tolerate the adverse side effects of the drug (Bishara et al., 2015).
Continued treatment with donepezil in combination with memantine has also been
associated with cognitive benefits in more advanced cases of AD, suggesting that it can
be used for the treatment of severe AD as well (Howard et al., 2012). The administration
of donepezil and other cholinesterase inhibitors should begin early and remain
uninterrupted, as their benefits are rapidly lost and may not be fully regained upon readministration (Bishara et al., 2015; Doody et al., 2001). In our experiment, the infusion
of donepezil only lasted 28 days, after which the pump was removed and the drug was
washed out. There is a possibility that the previous – although not statistically significant
– benefits of donepezil on attention were lost during this time, and that the effects of
donepezil following re-administration were insufficient to improve the performance of
5xFAD mice in all aspects of the task. It is also possible that the administration of
donepezil began when cholinergic neuron death and dysfunction was already too
pronounced. The number of ChAT+ neurons in these 5xFAD mice would already have
been halved by 6 months of age (Devi and Ohno, 2010). As a result, enhancing
cholinergic transmission past this age may be insufficient to entirely compensate for the
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loss of acetylcholine-releasing neurons. So, if these experiments were to be repeated,
donepezil treatment should commence prior to significant ChAT+ neuron death and
dysfunction – or perhaps even earlier – as amyloid pathology begins to develop in
5xFAD mice at approximately 2 months of age (Oakley et al., 2006). In addition,
treatment should continue until all assessments involving donepezil are completed.

4.4 Open-Field Locomotion in 5xFAD mice
Literature regarding locomotion on an open-field in male 5xFAD mice has been limited
and inconsistent. One study showed that male 5xFAD mice have a significant reduction
in locomotion and rearing activity at 9 months of age compared to WT littermates
(Schneider et al., 2014). These mice also appear to be less anxious, spending
significantly more time in the center of the maze (Schneider et al., 2014). Another study
found that male 5xFAD mice only travel significantly less than their WT controls at 12
and 15 months of age and reared significantly less at 9, 12 and 15 months (O’Leary,
2013). However, they recorded no significant differences in center time (O’Leary, 2013).
The mice in these studies were not food-restricted (O’Leary, 2013; Schneider et al.,
2014). Another study claims that 5xFAD mice are hyperactive at 9 and 12 months of
age (Yang et al., 2014). We only observe significant changes at 14 months of age (with
no significant differences in locomotion), where food-restricted male 5xFAD mice spend
significantly less time rearing than their WT controls. Both O'Leary (2013) and
Schneider et al. (2014) suggest that a reduction in rearing activity with age could be due
to impairments in the motor coordination required by a mouse to stand on their
hindlimbs. Decreases in rearing have also been reported in other non-AD mouse
models that walk with an irregular gait and thus lack the ability to maintain balance upon
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rearing (Baik et al., 1995; Nelson and Young, 1998). The fourteen-month-old male
5xFAD mice in our study demonstrated changes in weight-bearing capacity, and
balance (Gensel et al., 2006). This also has been observed by O'Leary et al. in 10, 13
and 16 month-old male and female 5xFAD mice as well (O’Leary, 2013; O’Leary et al.,
2013). In addition, our 14-month-old male 5xFAD mice also had a significantly lower
regularity index, suggesting that these mice have an impairment in interlimb
coordination (Parvathy and Masocha, 2013). Overall, this suggests that the reduction in
rearing activity observed in our mice was likely was a result of gait impairments.

4.4.1 Donepezil reduces anxiety in 5xFAD mice
The anxiolytic effects of donepezil have been previously observed in patients with AD.
When compared to AD patients given the placebo, those given donepezil (5mg/day for
28 days) showed a significant reduction in anxiety (relative to baseline) as measured by
the 12-item Neuropsychiatric Inventory (Feldman et al., 2001; Gauthier et al., 2002).
Similar effects have also been observed in three mouse models of anxiety (Nakamura
and Kurasawa, 2001) and a valproic acid-induced model of autism (Kim et al., 2014).
There are not yet any studies evaluating the effects of donepezil on the anxiety-like
behavior of AD mouse models.
In addition to locomotor and rearing activity, open-field locomotion can also be used to
measure anxiety-like behavior. Small rodents tend to prefer to be in corners rather than
out in the open to avoid potential predators, and the time spent in the edges of an openfield can be used as a measure of anxiety-like behaviour. Less anxious animals will
spend significantly more time in the center of open-field and less time closer to the walls
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of the box (Carola, 2002; Kulesskaya and Voikar, 2014). Like Kim et al. (2014), we also
observe a significant increase in center time following treatment with donepezil,
suggesting that donepezil also had anxiolytic effects on 10-month male 5xFAD mice.
This also implies that the donepezil did indeed inhibit acetylcholinesterase in these
mice. An acetylcholinesterase activity assay could always be run in tissue, blood or
urine samples taken from mice given donepezil to confirm this.

4.4.2 The effect of food-restriction on locomotion and gait
In older mice, long-term caloric restriction has been shown to lead to hyperlocomotion in
an open-field (Halagappa et al., 2007), while short-term caloric-restriction in mice
appears to cause hypoactivity (Kuhla et al., 2013). In one study, male and female 3month-old 3xTG mice that were food-restricted for 7 or 14 months prior both
demonstrated a significant increase in open-field locomotion (Halagappa et al., 2007).
Meanwhile the 3xTG mice that were given food ad libitum exhibited reduced locomotion
and exploratory behaviour compared to WT controls (Halagappa et al., 2007). Kuhla et
al. found that after 4 weeks of food restriction, C57BL/6 mice travelled significantly less
distances in an open-field compared to controls. However, this was not observed after
20 or 74 weeks of food-restriction. In another study, caloric restriction in female
C3B10RF1 mice (a long-lived F1 hybrid strain) 11-15 or 31-35 months of age led to an
increase in locomotor activity in a runwheel cage but not in an open field (Ingram et al.,
1987). After being given food ad libitum for one month, both WT and 5xFAD mice
travelled less distances in the open-field than they did when they were still on foodrestriction one month prior, suggesting that the long-term food-restriction led to
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hyperlocomotion in these mice. However, because we used the same cohort of mice for
both of these experiments, it is also possible that these mice have already habituated to
the open-field boxes and their surroundings. Since this cohort of mice aged between the
two locomotor assessments, we also cannot rule out the gait impairments that come
with age as a contributor to the reduction in locomotion (O’Leary, 2013; O’Leary et al.,
2013). For these reasons, we also evaluated gait in 5xFAD before and after one month
of free food. Because the weights of the 5xFAD mice and their WT controls were
significantly different, we cannot compare the static gait parameters. However, the
dynamic gait parameters of 15-month-old 5xFAD mice after 1 month of free-food did not
significantly differ from what is described below, thus changes in gait are likely not
responsible for the reductions in locomotion.

4.5 Gait Impairments in 5xFAD Mice
Patients with AD also demonstrate impairments in gait – although the dominating type
of gait disorder depends on the severity of the disease (O’keeffe et al., 1996; Sala et al.,
2004). These gait impairments contribute to the increase in fall risk and immobility in AD
patients compared to age matched controls (Amboni et al., 2013; Muir et al., 2012; Nutt,
2013). Gait is also affected in various mouse models of AD. Six month old APP/PS1
knock-in mice also exhibit an abnormal gait, with a reduction in average stride length
but no apparent neurogenic muscular fiber atrophy (Wirths et al., 2008). These mice
express the Swedish K670N/M671L and London V717I APP mutation, in addition to two
presenilin 1 knock-in mutations PS1 M233T and PS1 L235P (Wirths et al., 2008).
Alterations in gait have also been observed in the TG2576 mouse model of AD at 6
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months – prior to expected plaque accumulation (Schroer et al., 2010). At 12 months of
age, female 5xFAD mice demonstrate impairments in gait, motor coordination and
balance – with no differences in motor strength (O’Leary et al., 2013). Similar to what
has been observed in other mouse models of AD, we also observed gait impairments in
male 5xFAD mice at 14 months of age in the absence of differences in neuromuscular
function and weight. Male 5xFAD mice demonstrate a significant increase in the
hindlimb base of support, accompanied by a decrease in the forelimb base of support.
The further apart the paws are placed during locomotion, the less likely the animal is to
fall – thus a large base of support can compensate for an instable gait (Liu et al.,
2013b). Changes in base of support have also been observed in patients with AD,
where they widen their base to increase stability (Nutt, 2013). However, the reduction in
forelimb base of support suggests that there may have been a shift in how the weight
was carried in the 5xFAD mice – which could also result in an increase in the hindlimb
base of support (Gensel et al., 2006). This is supported by the decrease in the paw print
area and paw intensity of forepaws, which is often affected in response to a reduction in
forelimb weight bearing (Gensel et al., 2006; Neumann et al., 2009). There is also a
slight decrease in the paw print area of the hindpaws, but the forepaws play a more
important role in supporting the body weight during walking (Neumann et al., 2009). The
decrease in maximum paw area during the stance phase is mostly attributed to the
significant decrease in print width. There were no significant differences between the
weights of the WT and 5xFAD mice, so the changes in these gait parameters cannot be
attributed to differences in weight. Forelimb and hindlimb paw angle was also
significantly increased in 5xFAD mice. This larger paw placement is an indication of
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dysfunctional ataxia (Hannigan and Riley, 1988). Lastly, 5xFAD mice have significantly
shorter stride lengths and slower swing speeds than their WT controls. Therefore,
5xFAD mice would take longer than their WT controls to travel the same distance.
The gait impairments we observed in 14-month-old 5xFAD mice could explain the
delays we observe on the touchscreens at the 10-month time-point (when mice were
between 10-13.5 months of age) and the reduction in rearing activity observed during
open-field locomotion. Remarkably, at least for the PVD task, the 5xFAD mice
performed as well as their controls, suggesting that touchscreen tasks can be used
effectively even in mice with changes in gait. However, the gait of 5xFAD mice must be
taken into consideration when subjecting them to other behavioural assessments.
Further studies need to be done to investigate the reasons behind the extensive gait
impairments observed in 5xFAD mice and other AD mouse models. Cholinergic neuron
death and dysfunction in brain structures associated with gait – such as the
pedunculopontine nucleus (Mesulam, 2013) – could be the cause of what we have
observed, as these areas are also perturbed in patients with AD (Mesulam, 2013).
Problems with gait and balance have been associated with impairments in cholinergic
function, and cholinergic augmentation via donepezil has been shown to improve gait
and balance while reducing fall frequency in patients with mild AD (Mancini et al., 2015;
Montero-Odasso et al., 2015; Segev-Jacubovski et al., 2011). Some improvements in
gait were sustained and continued to improve over a four month period (SegevJacubovski et al., 2011). The deletion of VAChT in the peduncolopontine and
laterodorsal tegmental nuclei cholinergic neurons in VAChTEn1-Cre-flox/flox mice impairs
motor learning/coordination, which continues to deteriorate with age (Janickova et al.,
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2017). In addition, at 2-5 months of age, these mice also demonstrate a significant
reduction in stride length and swing speed on the Catwalk (Janickova et al., 2017).
Deficits in balance on the Catwalk become more pronounced at 13-16 months of age
(Janickova et al., 2017). We also observed these impairments in 14-month male 5xFAD
mice, suggesting that the death of cholinergic neurons in theses mice could have led to
perturbations in gait as well. After all, 5xFAD mice do demonstrate a significant
reduction of ChAT, a marker of cholinergic neurons (Devi and Ohno, 2010; Francis et
al., 1999). At 6-months, 5xFAD mice have 50% less ChAT+ positive neurons than their
WT controls (Devi and Ohno, 2010). However, neither the infusion or intraperitoneal
injection of donepezil had significant effects on gait. There is a possibility that the
administration of donepezil began when cholinergic neuron death and dysfunction was
already too severe – such that inhibiting acetylcholinesterase would not be capable of
enitrely compensating for the loss and dysfunction of cholinergic neurons in these mice.
As previously discussed, it is also possible that, because donepezil administration did
not begin early in life and remain uninterrupted, the benefits of donepezil were rapidly
lost and not fully regained upon re-administration (Bishara et al., 2015; Doody et al.,
2001). This should be taken into consideration if these series of experiments were to be
repeated, ensuring that treatment begins early and continues until all donepezil-related
evaluations are complete. There are currently no published studies assessing the
effects of donepezil on gait in AD mouse models.
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4.6 Food-restriction had no effect on amyloid pathology in 5xFAD
mice
Caloric restriction has been shown to reduce cognitive impairments in both humans and
mouse models of AD (Halagappa et al., 2007; Schroeder et al., 2010; Witte et al., 2009;
Wu et al., 2008). In mice, food-restriction is associated with a reduction in pathology,
and could confound our behavioural experiments (Halagappa et al., 2007; Patel et al.,
2005). Male and female 3xTG mice that have been food-restricted for 14 months
showed significantly lower levels of A40, A42 and hyperphosphorylated tau than their
controls (Halagappa et al., 2007). A significant reduction in A-plaque accumulation and
astrocytic activation was also observed following 15 weeks of caloric-restriction in male
APP/PS1 mice (Patel et al., 2005). These mice carry the Swedish K670N/M671L
mutation of APP and the M146L mutation of presinilin 1 (Patel et al., 2005). Both Patel
et al. (2005) and Halagappa et al. (2007) defined caloric-restriction as 60% of the ad
libitum diet. Our food-restriction protocol is more mild, reducing food consumption to
maintain 85% of adult weight beginnning at 12 weeks of age. We did not obseve
signficant differences in amyloid pathology in male and female 5xFAD mice following 23 months of food resctriction. There are strong associations between pathology and
cognitive function, suggesting that cognition was likely unaffected by our food-restriction
protocol. However, there remains a possibility that food-restriction can affect cognition
through mechanisms that may not be related to A or tau pathologies – like insulin
sensitivity (Halagappa et al., 2007), but this will need to be explored further. This
experiment could be repeated with the same food-restriction protocol but beginning at 3
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months of age (when we begin to food restrict our mice) and with a longer duration to
evaluate the effects of long-term caloric-restriction on 5xFAD mice, as this would be
more respresntative of the 5xFAD mice used in our study.

4.7 Conclusions, Significance and Future Directions
In summary, male 5xFAD mice do not demonstrate deficits in visual discrimination and
cognitive flexibility in the PVD task at 4, 7 and 10-month time-points. The lack of
impairments in this task suggests that male 5xFAD mice are not a good model of visual
discrimination or cognitive flexibility in AD. It is also possible that this touchscreen task
is not sensitive enough to detect impairments in these particular cognitive domains in
5xFAD mice. However, the variety of parameters recoded by the touchscreen apparatus
still allowed us to detect latencies in task response and reward collection when these
mice were 10-13.5 months of age (at the 10-month time-point). This could have been
the result of delays in cognitive processing and/or locomotor impairments. Locomotor
activity assessments demonstrated that these mice were not significantly more or less
active than their WT controls. Meanwhile, gait analyses revealed that 14-month-old
male 5xFAD mice exhibit severe impairments in gait. Most notably, the stride lengths
are significantly shorter and the swing speeds are significantly slower in male 5xFAD
mice when compared to their controls. This suggests that it would take male 5xFAD
mice significantly longer than their WT controls to travel the same distances. Further
studies need to be done to evaluate the reasons behind these gait impairments in
5xFAD mice and pinpoint the brain regions involved, as there were no significant
differences in weight and neuromuscular function between male 5xFAD mice and their
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WT controls. Recent studies demonstrating the effects of cholinergic dysregulation on
gait suggests that the death and dysfunction of cholinergic neurons in 5xFAD mice may
play a role (Janickova et al., 2017). Gait and locomotor activity in male 5xFAD mice was
also not significantly affected by food-restriction. In conclusion, impairments in gait
could explain the delays observed in the PVD and other touchscreen tasks, although it
did not affect their accuracy on either of the tasks. This suggests that gait does not
significantly influence or confound the performance of mice in the PVD task. However,
gait must be taken into consideration when subjecting old 5xFAD mice to other
behavioural assessments. These findings also suggest that the 5xFAD mouse model
can be used as an animal model of non-cognitive function in AD. Drugs aimed at
improving motor function in AD patients could use 5xFAD mice as their pre-clinical
model. Gait is an important non-cognitive domain to treat in AD patients, as it
contributes to the increase in fall risk and immobility in AD patients compared to age
matched controls (Amboni et al., 2013; Muir et al., 2012; Nutt, 2013). Immobility is
associated with changes in social behaviour, personality and deteriorations in mental
health, along with poorer outcomes and more co-morbidities (McCarron et al., 2005).
Infusion of donepezil had minor effects on the performance of male 5xFAD mice in the
5-CSRTT when compared to the 5xFAD mice that received saline + 10% DMSO.
Meanwhile, the injection of donepezil reduced the omission percentage and therefore
improved the vigilance of in 5xFAD mice. Treatment with donepezil also had no
significant effect on gait in these mice. Donepezil had anxiolytic effects on the 5xFAD
mice, significantly increasing the amount of time spent in the center of the open-field.
This effect has also been observed in 7-month old 5xFAD mice that have been treated
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with galantamine, another cholinesterase inhibitor (Bhattacharya et al., 2014), AD
patients (Gauthier, 2012) and mouse models of anxiety (Nakamura and Kurasawa,
2001). This suggests that donepezil did indeed inhibit acetylcholinesterase as intended.
However, acetylcholinesterase activity assays can be performed to confirm this. For
reasons described previously, if this entire experiment were to be repeated, donepezil
should be administered early and remain uninterrupted for the entire duration of
donepezil related experiments to achieve maximum effects.
Lastly, none of the male 5xFAD mice were homozygous for Pdebrd1, and Pdebrd1
genotype did not affect performance in the PVD task. In addition, 2-3 months of mild
food-restriction in 5xFAD mice did not significantly affect amyloid pathology, suggesting
that our food-restriction protocol also did not alter amyloid pathology in 5xFAD mice and
that touchscreen food restriction protocols are compatible with the study in AD mice.

108

References
Akasofu, S., Kimura, M., Kosasa, T., Sawada, K., and Ogura, H. (2008). Study of
neuroprotection of donepezil, a therapy for Alzheimer’s disease. Chem. Biol. Interact.
175, 222–226.
Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R.,
Eikelenboom, P., Emmerling, M., Fiebich, B.L., et al. (2000). Inflammation and
Alzheimer’s disease. Neurobiol. Aging 21, 383–421.
Albert, M.S. (1996). Cognitive and neurobiologic markers of early Alzheimer disease.
Proc. Natl. Acad. Sci. U. S. A. 93, 13547–13551.
de-Almada, B.V.P., de-Almeida, L.D., Camporez, D., de-Moraes, M.V.D., Morelato,
R.L., Perrone, A.M.S., Belcavello, L., Louro, I.D., and de-Paula, F. (2011). Protective
effect of the APOE-e3 allele in Alzheimer’s disease. Braz. J. Med. Biol. Res. 45, 8–12.
Amboni, M., Barone, P., and Hausdorff, J.M. (2013). Cognitive Contributions to Gait and
Falls: Evidence and Implications. Mov. Disord. Off. J. Mov. Disord. Soc. 28, 1520–1533.
Arnold, H.M., Burk, J.A., Hodgson, E.M., Sarter, M., and Bruno, J.P. (2002). Differential
cortical acetylcholine release in rats performing a sustained attention task versus
behavioral control tasks that do not explicitly tax attention. Neuroscience 114, 451–460.
Baik, J.H., Picetti, R., Saiardi, A., Thiriet, G., Dierich, A., Depaulis, A., Le Meur, M., and
Borrelli, E. (1995). Parkinsonian-like locomotor impairment in mice lacking dopamine D2
receptors. Nature 377, 424–428.
Bari, A., Dalley, J.W., and Robbins, T.W. (2008). The application of the 5-choice serial
reaction time task for the assessment of visual attentional processes and impulse
control in rats. Nat. Protoc. 3, 759–767.
Bartko, S.J. (2011). Intact attentional processing but abnormal responding in M1
muscarinic receptor-deficient mice using an automated touchscreen method.
Neuropharmacology 61, 1366–1378.
Bartus, R.T., Dean, R.L., Beer, B., and Lippa, A.S. (1982). The cholinergic hypothesis of
geriatric memory dysfunction. Science 217, 408–414.
Beach, T.G., Monsell, S.E., Phillips, L.E., and Kukull, W. (2012). Accuracy of the Clinical
Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer’s Disease
Centers, 2005–2010. J. Neuropathol. Exp. Neurol. 71, 266–273.
Bekris, L.M., Yu, C.-E., Bird, T.D., and Tsuang, D.W. (2010). Genetics of Alzheimer
Disease. J. Geriatr. Psychiatry Neurol. 23, 213–227.

109

Bhattacharya, S., Haertel, C., Maelicke, A., and Montag, D. (2014). Galantamine Slows
Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of
Alzheimer’s Disease. PLoS ONE 9.
Birks, J.S. (2006). Cholinesterase inhibitors for Alzheimer’s disease. In Cochrane
Database of Systematic Reviews, (John Wiley & Sons, Ltd),.
Bishara, D., Sauer, J., and Taylor, D. (2015). The pharmacological management of
Alzheimer’s disease. Prog. Neurol. Psychiatry 19, 9–16.
Bohnen, N., Kaufer, D., Hendrickson, R., Ivanco, L., Lopresti, B., Koeppe, R., Meltzer,
C., Constantine, G., Davis, J., Mathis, C., et al. (2005). Degree of inhibition of cortical
acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s
disease. J. Neurol. Neurosurg. Psychiatry 76, 315–319.
Boncristiano, S., Calhoun, M.E., Kelly, P.H., Pfeifer, M., Bondolfi, L., Stalder, M.,
Phinney, A.L., Abramowski, D., Sturchler-Pierrat, C., Enz, A., et al. (2002). Cholinergic
changes in the APP23 transgenic mouse model of cerebral amyloidosis. J. Neurosci.
Off. J. Soc. Neurosci. 22, 3234–3243.
Braak, H., and Braak, E. (1991). Demonstration of amyloid deposits and neurofibrillary
changes in whole brain sections. Brain Pathol. Zurich Switz. 1, 213–216.
Brigman, J.L., and Rothblat, L.A. (2008). Stimulus specific deficit on visual reversal
learning after lesions of medial prefrontal cortex in the mouse. Behav. Brain Res. 187,
405–410.
Brigman, J.L., Bussey, T.J., Saksida, L.M., and Rothblat, L.A. (2005). Discrimination of
multidimensional visual stimuli by mice: intra- and extradimensional shifts. Behav.
Neurosci. 119, 839–842.
Brigman, J.L., Feyder, M., Saksida, L.M., Bussey, T.J., Mishina, M., and Holmes, A.
(2008). Impaired discrimination learning in mice lacking the NMDA receptor NR2A
subunit. Learn. Mem. Cold Spring Harb. N 15, 50–54.
Brigman, J.L., Daut, R.A., Wright, T., Gunduz-Cinar, O., Graybeal, C., Davis, M.I.,
Jiang, Z., Saksida, L.M., Jinde, S., Pease, M., et al. (2013). GluN2B in corticostriatal
circuits governs choice learning and choice shifting. Nat. Neurosci. 16, 1101–1110.
Brookmeyer, R., Johnson, E., Ziegler-Graham, K., and Arrighi, H.M. (2007). Forecasting
the global burden of Alzheimer’s disease. Alzheimers Dement. 3, 186–191.
Buée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A., and Hof, P.R. (2000). Tau
protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res.
Rev. 33, 95–130.

110

Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., Yates, J.,
Cotman, C., and Glabe, C. (1992). Assembly and aggregation properties of synthetic
Alzheimer’s A4/beta amyloid peptide analogs. J. Biol. Chem. 267, 546–554.
Burns, A., Gauthier, S., and Perdomo, C. (2007). Efficacy and safety of donepezil over 3
years: an open-label, multicentre study in patients with Alzheimer’s disease. Int. J.
Geriatr. Psychiatry 22, 806–812.
Bussey, T.J., Muir, J.L., Everitt, B.J., and Robbins, T.W. (1997). Triple dissociation of
anterior cingulate, posterior cingulate, and medial frontal cortices on visual
discrimination tasks using a touchscreen testing procedure for the rat. Behav. Neurosci.
111, 920–936.
Bussey, T.J., Saksida, L.M., and Rothblat, L.A. (2001). Discrimination of computergraphic stimuli by mice: a method for the behavioral characterization of transgenic and
gene-knockout models. Behav. Neurosci. 115, 957–960.
Bussey, T.J., Saksida, L.M., and Murray, E.A. (2003). Impairments in visual
discrimination after perirhinal cortex lesions: testing “declarative” vs. “perceptualmnemonic” views of perirhinal cortex function. Eur. J. Neurosci. 17, 649–660.
Bussey, T.J., Padain, T.L., Skillings, E.A., Winters, B.D., Morton, A.J., and Saksida,
L.M. (2008). The touchscreen cognitive testing method for rodents: how to get the best
out of your rat. Learn. Mem. Cold Spring Harb. N 15, 516–523.
Bussey, T.J., Holmes, A., Lyon, L., Mar, A.C., McAllister, K. a. L., Nithianantharajah, J.,
Oomen, C.A., and Saksida, L.M. (2012). New translational assays for preclinical
modelling of cognition in schizophrenia: the touchscreen testing method for mice and
rats. Neuropharmacology 62, 1191–1203.
Carli, M., Robbins, T.W., Evenden, J.L., and Everitt, B.J. (1983). Effects of lesions to
ascending noradrenergic neurones on performance of a 5-choice serial reaction task in
rats; implications for theories of dorsal noradrenergic bundle function based on selective
attention and arousal. Behav. Brain Res. 9, 361–380.
Carola, V. (2002). Evaluation of the elevated plus-maze and open-field tests for the
assessment of anxiety-related behaviour in inbred mice. Behav. Brain Res. 134, 49–57.
Chishti, M.A., Yang, D.S., Janus, C., Phinney, A.L., Horne, P., Pearson, J., Strome, R.,
Zuker, N., Loukides, J., French, J., et al. (2001). Early-onset amyloid deposition and
cognitive deficits in transgenic mice expressing a double mutant form of amyloid
precursor protein 695. J. Biol. Chem. 276, 21562–21570.
Chudasama, Y., and Robbins, T.W. (2003). Dissociable contributions of the orbitofrontal
and infralimbic cortex to pavlovian autoshaping and discrimination reversal learning:
further evidence for the functional heterogeneity of the rodent frontal cortex. J. Neurosci.
Off. J. Soc. Neurosci. 23, 8771–8780.

111

Clapcote, S.J., Lazar, N.L., Bechard, A.R., Wood, G.A., and Roder, J.C. (2005). NIH
Swiss and Black Swiss Mice Have Retinal Degeneration and Performance Deficits in
Cognitive Tests. Comp. Med. 55, 310–316.
Conejero-Goldberg, C., Gomar, J.J., Bobes-Bascaran, T., Hyde, T.M., Kleinman, J.E.,
Herman, M.M., Chen, S., Davies, P., and Goldberg, T.E. (2014). APOE2 enhances
neuroprotection against Alzheimer’s disease through multiple molecular mechanisms.
Mol. Psychiatry 19, 1243–1250.
Contestabile, A. (2011). The history of the cholinergic hypothesis. Behav. Brain Res.
221, 334–340.
Cummings, J.L., Morstorf, T., and Zhong, K. (2014). Alzheimer’s disease drugdevelopment pipeline: few candidates, frequent failures. Alzheimers Res. Ther. 6, 37.
Cutuli, D., De Bartolo, P., Caporali, P., Tartaglione, A.M., Oddi, D., D’Amato, F.R.,
Nobili, A., D’Amelio, M., and Petrosini, L. (2013). Neuroprotective effects of donepezil
against cholinergic depletion. Alzheimers Res. Ther. 5, 50.
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W.,
Von Figura, K., and Van Leuven, F. (1998). Deficiency of presenilin-1 inhibits the normal
cleavage of amyloid precursor protein. Nature 391, 387–390.
Devi, L., and Ohno, M. (2010). Phospho-eIF2α Level Is Important for Determining
Abilities of BACE1 Reduction to Rescue Cholinergic Neurodegeneration and Memory
Defects in 5XFAD Mice. PLoS ONE 5.
Dong, H., Yuede, C.M., Coughlan, C.A., Murphy, K.M., and Csernansky, J.G. (2009).
Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model
of Alzheimer’s disease. Brain Res. 1303, 169–178.
Doody, R.S., Geldmacher, D.S., Gordon, B., Perdomo, C.A., Pratt, R.D., and Donepezil
Study Group (2001). Open-label, multicenter, phase 3 extension study of the safety and
efficacy of donepezil in patients with Alzheimer disease. Arch. Neurol. 58, 427–433.
Downes, J.J., Roberts, A.C., Sahakian, B.J., Evenden, J.L., Morris, R.G., and Robbins,
T.W. (1989). Impaired extra-dimensional shift performance in medicated and
unmedicated Parkinson’s disease: evidence for a specific attentional dysfunction.
Neuropsychologia 27, 1329–1343.
Dudgeon, S. (2010). Rising tide: the impact of dementia on Canadian society : a study
(Alzheimer Society of Canada).
Efange, S.M.N., Garland, E.M., Staley, J.K., Khare, A.B., and Mash, D.C. (1997).
Vesicular Acetylcholine Transporter Density and Alzheimer’s Disease. Neurobiol. Aging
18, 407–413.

112

Fara, J., and Urquhart, J. (1984). The value of infusion and injection regimens in
assessing efficacy and toxicity of drugs. Trends Pharmacol. Sci. 5, 21–25.
Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P., Whalen, E., and
Donepezil MSAD Study Investigators Group (2001). A 24-week, randomized, doubleblind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 57, 613–
620.
Francis, P.T., Palmer, A.M., Snape, M., and Wilcock, G.K. (1999). The cholinergic
hypothesis of Alzheimer’s disease: a review of progress. J. Neurol. Neurosurg.
Psychiatry 66, 137–147.
Fukui, T., and Lee, E. (2009). Visuospatial Function is a Significant Contributor to
Functional Status in Patients With Alzheimer’s Disease. Am. J. Alzheimers Dis.
Dementias® 24, 313–321.
Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C.,
Carr, T., Clemens, J., Donaldson, T., and Gillespie, F. (1995). Alzheimer-type
neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor
protein. Nature 373, 523–527.
Gauthier, S. (2012). Pharmacological treatment of Alzheimer’s disease. Alzheimers
Dement. J. Alzheimers Assoc. 8, P2.
Gauthier, S., Feldman, H., Hecker, J., Vellas, B., Ames, D., Subbiah, P., Whalen, E.,
Emir, B., and Donepezil MSAD Study Investigators Group (2002). Efficacy of donepezil
on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int.
Psychogeriatr. 14, 389–404.
Gensel, J.C., Tovar, C.A., Hamers, F.P.T., Deibert, R.J., Beattie, M.S., and Bresnahan,
J.C. (2006). Behavioral and histological characterization of unilateral cervical spinal cord
contusion injury in rats. J. Neurotrauma 23, 36–54.
German, D.C., Yazdani, U., Speciale, S.G., Pasbakhsh, P., Games, D., and Liang, C.-L.
(2003). Cholinergic neuropathology in a mouse model of Alzheimer’s disease. J. Comp.
Neurol. 462, 371–381.
Gilmor, M.L., Erickson, J.D., Varoqui, H., Hersh, L.B., Bennett, D.A., Cochran, E.J.,
Mufson, E.J., and Levey, A.I. (1999). Preservation of nucleus basalis neurons
containing choline acetyltransferase and the vesicular acetylcholine transporter in the
elderly with mild cognitive impairment and early Alzheimer’s disease. J. Comp. Neurol.
411, 693–704.
Giménez, E., and Montoliu, L. (2001). A simple polymerase chain reaction assay for
genotyping the retinal degeneration mutation (Pdeb(rd1)) in FVB/N-derived transgenic
mice. Lab. Anim. 35, 153–156.

113

Goate, A., Chartier-Harlin, M.C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra,
L., Haynes, A., Irving, N., and James, L. (1991). Segregation of a missense mutation in
the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349, 704–
706.
Halagappa, V.K.M., Guo, Z., Pearson, M., Matsuoka, Y., Cutler, R.G., LaFerla, F.M.,
and Mattson, M.P. (2007). Intermittent fasting and caloric restriction ameliorate agerelated behavioral deficits in the triple-transgenic mouse model of Alzheimer’s disease.
Neurobiol. Dis. 26, 212–220.
Hannigan, J.H., and Riley, E.P. (1988). Prenatal ethanol alters gait in rats. Alcohol 5,
451–454.
Harper, A.J., Billa, S., Potts, S., Richardson, J.C., Murray, T.K., O’Neill, M.J., Hutton,
M., and Dix, S.L. (2013). Characterisation of three lines of transgenic mice expressing
pathology relevant to Alzheimer’s disease using touchscreens: Performance of PDAPP,
TASTPM and rTg4510 mice on the acquisition of spatial and visual discriminations.
618.05/G5.
Hartman, R.E., Izumi, Y., Bales, K.R., Paul, S.M., Wozniak, D.F., and Holtzman, D.M.
(2005). Treatment with an amyloid-beta antibody ameliorates plaque load, learning
deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer’s
disease. J. Neurosci. Off. J. Soc. Neurosci. 25, 6213–6220.
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A.,
Dening, T., Findlay, D., Holmes, C., et al. (2012). Donepezil and Memantine for
Moderate-to-Severe Alzheimer’s Disease. N. Engl. J. Med. 366, 893–903.
Howlett, D.R., Richardson, J.C., Austin, A., Parsons, A.A., Bate, S.T., Davies, D.C., and
Gonzalez, M.I. (2004). Cognitive correlates of Abeta deposition in male and female mice
bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 1017,
130–136.
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F.,
and Cole, G. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques
in transgenic mice. Science 274, 99–102.
Ingram, D.K., Weindruch, R., Spangler, E.L., Freeman, J.R., and Walford, R.L. (1987).
Dietary Restriction Benefits Learning and Motor Performance of Aged Mice. J. Gerontol.
42, 78–81.
Janickova, H., Rosborough, K., Al-Onaizi, M., Kljakic, O., Guzman, M.S., Gros, R.,
Prado, M.A.M., and Prado, V.F. (2017). Deletion of the vesicular acetylcholine
transporter from pedunculopontine/laterodorsal tegmental neurons modifies gait. J.
Neurochem. 140, 787–798.

114

Juottonen, K., Laakso, M.P., Insausti, R., Lehtovirta, M., Pitkänen, A., Partanen, K., and
Soininen, H. (1998). Volumes of the entorhinal and perirhinal cortices in Alzheimer’s
disease. Neurobiol. Aging 19, 15–22.
Karran, E., Mercken, M., and Strooper, B.D. (2011). The amyloid cascade hypothesis
for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat. Rev.
Drug Discov. 10, 698–712.
Kawas, C.H. (2003). Early Alzheimer’s Disease. N. Engl. J. Med. 349, 1056–1063.
Kaye, J.A. (1998). Diagnostic challenges in dementia. Neurology 51, S45–S52;
discussion S65–S67.
Kim, J.-W., Seung, H., Kwon, K.J., Ko, M.J., Lee, E.J., Oh, H.A., Choi, C.S., Kim, K.C.,
Gonzales, E.L., You, J.S., et al. (2014). Subchronic Treatment of Donepezil Rescues
Impaired Social, Hyperactive, and Stereotypic Behavior in Valproic Acid-Induced Animal
Model of Autism. PLoS ONE 9.
Klinkenberg, I., Sambeth, A., and Blokland, A. (2011). Acetylcholine and attention.
Behav. Brain Res. 221, 430–442.
Kolisnyk, B., Al-Onaizi, M.A., Hirata, P.H.F., Guzman, M.S., Nikolova, S., Barbash, S.,
Soreq, H., Bartha, R., Prado, M.A.M., and Prado, V.F. (2013a). Forebrain Deletion of
the Vesicular Acetylcholine Transporter Results in Deficits in Executive Function,
Metabolic, and RNA Splicing Abnormalities in the Prefrontal Cortex. J. Neurosci. 33,
14908–14920.
Kolisnyk, B., Guzman, M.S., Raulic, S., Fan, J., Magalhães, A.C., Feng, G., Gros, R.,
Prado, V.F., and Prado, M.A.M. (2013b). ChAT–ChR2–EYFP Mice Have Enhanced
Motor Endurance But Show Deficits in Attention and Several Additional Cognitive
Domains. J. Neurosci. 33, 10427–10438.
Kryger, G., Silman, I., and Sussman, J.L. (1999). Structure of acetylcholinesterase
complexed with E2020 (Aricept®): implications for the design of new anti-Alzheimer
drugs. Structure 7, 297–307.
Kuhla, A., Lange, S., Holzmann, C., Maass, F., Petersen, J., Vollmar, B., and Wree, A.
(2013). Lifelong Caloric Restriction Increases Working Memory in Mice. PLOS ONE 8,
e68778.
Kulesskaya, N., and Voikar, V. (2014). Assessment of mouse anxiety-like behavior in
the light-dark box and open-field arena: role of equipment and procedure. Physiol.
Behav. 133, 30–38.
Leonard, J.A. (1959). Five choice serial reaction apparatus. Med. Res. Counc. Appl.
Psychol. Unit Rep. 326, 59.

115

Li, X., Rastogi, P., Gibbons, J.A., and Chaudhury, S. (2014a). Visuo-cognitive skill
deficits in Alzheimer’s disease and Lewy body disease: A comparative analysis. Ann.
Indian Acad. Neurol. 17, 12.
Li, X.-L., Hu, N., Tan, M.-S., Yu, J.-T., and Tan, L. (2014b). Behavioral and
Psychological Symptoms in Alzheimer’s Disease. BioMed Res. Int. 2014, e927804.
Lindenberger, U., Marsiske, M., and Baltes, P.B. (2000). Memorizing while walking:
increase in dual-task costs from young adulthood to old age. Psychol. Aging 15, 417–
436.
Liu, C.-C., Kanekiyo, T., Xu, H., and Bu, G. (2013a). Apolipoprotein E and Alzheimer
disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106–118.
Liu, Y., Ao, L.J., Lu, G., Leong, E., Liu, Q., Wang, X.H., Zhu, X.L., Sun, T.F.D., Fei, Z.,
Jiu, T., et al. (2013b). Quantitative gait analysis of long-term locomotion deficits in
classical unilateral striatal intracerebral hemorrhage rat model. Behav. Brain Res. 257,
166–177.
Maarouf, C.L., Kokjohn, T.A., Whiteside, C.M., Macias, M.P., Kalback, W.M., Sabbagh,
M.N., Beach, T.G., Vassar, R., and Roher, A.E. (2013). Molecular Differences and
Similarities Between Alzheimer’s Disease and the 5XFAD Transgenic Mouse Model of
Amyloidosis. Biochem. Insights 6, 1–10.
Macdonald, I., DeBay, D., O’Leary, T., Reid, A., Cash, M., Jollymore, C., Mawko, G.,
Burrell, S., Martin, E., Bowen, C., et al. (2013). Cerebral glucose metabolism, pathology
and behaviour in the 5XFAD mouse model of Alzheimer’s disease. Alzheimers Dement.
J. Alzheimers Assoc. 9, P246–P246.
Mancini, M., Fling, B.W., Gendreau, A., Lapidus, J., Horak, F.B., Chung, K., and Nutt,
J.G. (2015). Effect of augmenting cholinergic function on gait and balance. BMC Neurol.
15.
Maragos, W.F., Chu, D.C., Young, A.B., D’Amato, C.J., and Penney, J.B. (1987). Loss
of hippocampal [3H]TCP binding in Alzheimer’s disease. Neurosci. Lett. 74, 371–376.
Masood, T. (2015). Determining Attention Deficits In Mouse Models Of Alzheimer’s
Disease Using Touchscreen Systems. Electron. Thesis Diss. Repos.
McCarron, M., Gill, M., McCallion, P., and Begley, C. (2005). Health co-morbidities in
ageing persons with Down syndrome and Alzheimer’s dementia. J. Intellect. Disabil.
Res. 49, 560–566.
McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack Jr., C.R., Kawas,
C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., et al. (2011). The
diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National
Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement. 7, 263–269.

116

Mesulam, M.-M. (2013). Cholinergic Circuitry of the Human Nucleus Basalis and Its
Fate in Alzheimer’s Disease. J. Comp. Neurol. 521, 4124–4144.
Montero-Odasso, M., Muir-Hunter, S.W., Oteng-Amoako, A., Gopaul, K., Islam, A.,
Borrie, M., Wells, J., and Speechley, M. (2015). Donepezil improves gait performance in
older adults with mild Alzheimer’s disease: a phase II clinical trial. J. Alzheimers Dis.
JAD 43, 193–199.
Motulsky, H.J., and Brown, R.E. (2006). Detecting outliers when fitting data with
nonlinear regression – a new method based on robust nonlinear regression and the
false discovery rate. BMC Bioinformatics 7, 123.
Muir, J.L., Everitt, B.J., and Robbins, T.W. (1996). The cerebral cortex of the rat and
visual attentional function: dissociable effects of mediofrontal, cingulate, anterior
dorsolateral, and parietal cortex lesions on a five-choice serial reaction time task.
Cereb. Cortex N. Y. N 1991 6, 470–481.
Muir, S.W., Speechley, M., Wells, J., Borrie, M., Gopaul, K., and Montero-Odasso, M.
(2012). Gait assessment in mild cognitive impairment and Alzheimer’s disease: The
effect of dual-task challenges across the cognitive spectrum. Gait Posture 35, 96–100.
Mullan, M. (1992). Familial Alzheimer’s disease: second gene locus located. BMJ 305,
1108–1109.
Nakamura, K., and Kurasawa, M. (2001). Anxiolytic effects of aniracetam in three
different mouse models of anxiety and the underlying mechanism. Eur. J. Pharmacol.
420, 33–43.
Nelson, R.J., and Young, K.A. (1998). Behavior in mice with targeted disruption of
single genes. Neurosci. Biobehav. Rev. 22, 453–462.
Neumann, M., Wang, Y., Kim, S., Hong, S.M., Bilgen, M., and Liu, J. (2009). Assessing
gait impairment following experimental traumatic brain injury in mice. J. Neurosci.
Methods 176, 34–44.
Newman, M., Musgrave, F.I., and Lardelli, M. (2007). Alzheimer disease:
Amyloidogenesis, the presenilins and animal models. Biochim. Biophys. Acta BBA Mol. Basis Dis. 1772, 285–297.
Nikolaev, A., McLaughlin, T., O’Leary, D.D.M., and Tessier-Lavigne, M. (2009). APP
binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457,
981–989.
Nutt, J.G. (2013). Higher‐level gait disorders: An open frontier. Mov. Disord. 28, 1560–
1565.
Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A.,
Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006). Intraneuronal beta-amyloid

117

aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial
Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J.
Neurosci. Off. J. Soc. Neurosci. 26, 10129–10140.
Ohno, M. (2006). Temporal memory deficits in Alzheimer’s mouse models: rescue by
genetic deletion of BACE1. Eur. J. Neurosci. 23, 251–260.
O’keeffe, S.T., Kazeem, H., Philpott, R.M., Playfer, J.R., Gosney, M., and Lye, M.
(1996). Gait Disturbance in Alzheimer’s Disease: A Clinical Study. Age Ageing 25, 313–
316.
O’Leary, T. (2013). CHARACTERIZATION OF AGE-RELATED CHANGES IN MOTOR
ABILITY AND LEARNING AND MEMORY IN THE 5XFAD MOUSE MODEL OF
ALZHEIMER’S DISEASE.
O’Leary, T., Robertson, A., Chipman, P., Rafuse, V., and Brown, R. (2013). Motor
dysfunction in the 12-month-old 5xFAD mouse model of Alzheimer’s disease.
Alzheimers Dement. J. Alzheimers Assoc. 9, P497.
Pal, A., Biswas, A., Pandit, A., Roy, A., Guin, D., Gangopadhyay, G., and Senapati, A.K.
(2016). Study of visuospatial skill in patients with dementia. Ann. Indian Acad. Neurol.
19, 83–88.
Parvathy, S.S., and Masocha, W. (2013). Gait analysis of C57BL/6 mice with complete
Freund’s adjuvant-induced arthritis using the CatWalk system. BMC Musculoskelet.
Disord. 14, 14.
Passetti, F., Levita, L., and Robbins, T.W. (2003). Sulpiride alleviates the attentional
impairments of rats with medial prefrontal cortex lesions. Behav. Brain Res. 138, 59–69.
Patel, N.V., Gordon, M.N., Connor, K.E., Good, R.A., Engelman, R.W., Mason, J.,
Morgan, D.G., Morgan, T.E., and Finch, C.E. (2005). Caloric restriction attenuates Aβdeposition in Alzheimer transgenic models. Neurobiol. Aging 26, 995–1000.
Perry, R.J., and Hodges, J.R. (1999). Attention and executive deficits in Alzheimer’s
disease. Brain 122, 383–404.
Piiponniemi, T.O., Bragge, T., Vauhkonen, E.E., Vartiainen, P., Puoliväli, J.T., Sweeney,
P.J., and Kopanitsa, M.V. (2017). Acquisition and reversal of visual discrimination
learning in APPSwDI/Nos2−/− (CVN) mice. Neurosci. Lett. 650, 126–133.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., and Ferri, C.P. (2013). The
global prevalence of dementia: a systematic review and metaanalysis. Alzheimers
Dement. J. Alzheimers Assoc. 9, 63–75.e2.
Proulx, É., Fraser, P., McLaurin, J., and Lambe, E.K. (2015). Impaired Cholinergic
Excitation of Prefrontal Attention Circuitry in the TgCRND8 Model of Alzheimer’s
Disease. J. Neurosci. Off. J. Soc. Neurosci. 35, 12779–12791.

118

Quental, N.B.M., Brucki, S.M.D., and Bueno, O.F.A. (2013). Visuospatial Function in
Early Alzheimer’s Disease—The Use of the Visual Object and Space Perception
(VOSP) Battery. PLOS ONE 8, e68398.
Robbins, T.W., James, M., Owen, A.M., Sahakian, B.J., McInnes, L., and Rabbitt, P.
(1994). Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor
analytic study of a large sample of normal elderly volunteers. Dement. Basel Switz. 5,
266–281.
Rogers, R.D., Baunez, C., Everitt, B.J., and Robbins, T.W. (2001). Lesions of the medial
and lateral striatum in the rat produce differential deficits in attentional performance.
Behav. Neurosci. 115, 799–811.
Rokem, A., Landau, A.N., Garg, D., Prinzmetal, W., and Silver, M.A. (2010). Cholinergic
Enhancement Increases the Effects of Voluntary Attention but Does Not Affect
Involuntary Attention. Neuropsychopharmacology 35, 2538–2544.
Romberg, C., Mattson, M.P., Mughal, M.R., Bussey, T.J., and Saksida, L.M. (2011).
Impaired Attention in the 3xTgAD Mouse Model of Alzheimer’s Disease: Rescue by
Donepezil (Aricept). J. Neurosci. 31, 3500–3507.
Romberg, C., Horner, A.E., Bussey, T.J., and Saksida, L.M. (2013). A touch screenautomated cognitive test battery reveals impaired attention, memory abnormalities, and
increased response inhibition in the TgCRND8 mouse model of Alzheimer’s disease.
34, 731–744.
Sahakian, B.J., and Coull, J.T. (1993). Tetrahydroaminoacridine (THA) in Alzheimer’s
disease: an assessment of attentional and mnemonic function using CANTAB. Acta
Neurol. Scand. Suppl. 149, 29–35.
Sahakian, B.J., Owen, A.M., Morant, N.J., Eagger, S.A., Boddington, S., Crayton, L.,
Crockford, H.A., Crooks, M., Hill, K., and Levy, R. (1993). Further analysis of the
cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer’s disease: assessment
of attentional and mnemonic function using CANTAB. Psychopharmacology (Berl.) 110,
395–401.
Sala, S.D., Spinnler, H., and Venneri, A. (2004). Walking difficulties in patients with
Alzheimer’s disease might originate from gait apraxia. J. Neurol. Neurosurg. Psychiatry
75, 196–201.
Sarter, M., Hasselmo, M.E., Bruno, J.P., and Givens, B. (2005). Unraveling the
attentional functions of cortical cholinergic inputs: interactions between signal-driven
and cognitive modulation of signal detection. Brain Res. Brain Res. Rev. 48, 98–111.
Schneider, F., Baldauf, K., Wetzel, W., and Reymann, K.G. (2014). Behavioral and EEG
changes in male 5xFAD mice. Physiol. Behav. 135, 25–33.

119

Schroeder, J.E., Richardson, J.C., and Virley, D.J. (2010). Dietary manipulation and
caloric restriction in the development of mouse models relevant to neurological
diseases. Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1802, 840–846.
Schroer, W., Wahl, K., Ehrenstrom, R., Butano, V., James, K.J., Timson, B.F., and
Zimmerman, S.D. (2010). Early gait alterations in the TG2576 mouse model of
Alzheimer’s disease: A preliminary analysis. Alzheimers Dement. J. Alzheimers Assoc.
6, S215–S216.
Segev-Jacubovski, O., Herman, T., Yogev-Seligmann, G., Mirelman, A., Giladi, N., and
Hausdorff, J.M. (2011). The interplay between gait, falls and cognition: can cognitive
therapy reduce fall risk? Expert Rev. Neurother. 11, 1057–1075.
Selkoe, D.J., and Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25
years. EMBO Mol. Med. 8, 595.
Spires, T.L., and Hyman, B.T. (2005). Transgenic Models of Alzheimer’s Disease:
Learning from Animals. NeuroRX 2, 423–437.
Sun, A., Nguyen, X.V., and Bing, G. (2002). Comparative analysis of an improved
thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary
tangle demonstration on the same sections. J. Histochem. Cytochem. Off. J. Histochem.
Soc. 50, 463–472.
Sze, C., Bi, H., Kleinschmidt-DeMasters, B.K., Filley, C.M., and Martin, L.J. (2001). NMethyl-D-aspartate receptor subunit proteins and their phosphorylation status are
altered selectively in Alzheimer’s disease. J. Neurol. Sci. 182, 151–159.
Treviño, M., Oviedo, T., Jendritza, P., Li, S.-B., Köhr, G., and Marco, R.J.D. (2013).
Controlled variations in stimulus similarity during learning determine visual
discrimination capacity in freely moving mice. Sci. Rep. 3, 1048.
Wang, J., Ho, L., Qin, W., Rocher, A.B., Seror, I., Humala, N., Maniar, K., Dolios, G.,
Wang, R., Hof, P.R., et al. (2005). Caloric restriction attenuates beta-amyloid
neuropathology in a mouse model of Alzheimer’s disease. FASEB J. Off. Publ. Fed.
Am. Soc. Exp. Biol. 19, 659–661.
Wilcock, D.M., Lewis, M.R., Van Nostrand, W.E., Davis, J., Previti, M.L.,
Gharkholonarehe, N., Vitek, M.P., and Colton, C.A. (2008). Progression of amyloid
pathology to Alzheimer’s disease pathology in an amyloid precursor protein transgenic
mouse model by removal of nitric oxide synthase 2. J. Neurosci. Off. J. Soc. Neurosci.
28, 1537–1545.
Winters, B.D., Bartko, S.J., Saksida, L.M., and Bussey, T.J. (2010). Muscimol, AP5, or
scopolamine infused into perirhinal cortex impairs two-choice visual discrimination
learning in rats. Neurobiol. Learn. Mem. 93, 221–228.

120

Wirths, O., Breyhan, H., Schafer, S., Roth, C., and Bayer, T.A. (2008). Deficits in
working memory and motor performance in the APP/PS1ki mouse model for
Alzheimer’s disease. Neurobiol. Aging 29, 891–901.
Witte, A.V., Fobker, M., Gellner, R., Knecht, S., and Flöel, A. (2009). Caloric restriction
improves memory in elderly humans. Proc. Natl. Acad. Sci. 106, 1255–1260.
Wu, L., and Zhao, L. (2016). ApoE2 and Alzheimer’s disease: time to take a closer look.
Neural Regen. Res. 11, 412–413.
Wu, P., Shen, Q., Dong, S., Xu, Z., Tsien, J.Z., and Hu, Y. (2008). Calorie restriction
ameliorates neurodegenerative phenotypes in forebrain-specific presenilin-1 and
presenilin-2 double knockout mice. Neurobiol. Aging 29, 1502–1511.
Yang, C., Feng, R., Yang, L., Jiang, S., Liu, N., Yan, L., Liu, Y., Yang, C., and Wang, K.
(2014). Phenotyping age-sependent changes in the 5xFAD Alzheimer’s Disease Model
mice (LB556). FASEB J. 28, LB556.
Yue, W., Li, Y., Zhang, T., Jiang, M., Qian, Y., Zhang, M., Sheng, N., Feng, S., Tang,
K., Yu, X., et al. (2015). ESC-Derived Basal Forebrain Cholinergic Neurons Ameliorate
the Cognitive Symptoms Associated with Alzheimer’s Disease in Mouse Models. Stem
Cell Rep. 5, 776–790.
Zhang, Y., Thompson, R., Zhang, H., and Xu, H. (2011). APP processing in Alzheimer’s
disease. Mol. Brain 4, 3.
Zheng, H., and Koo, E.H. (2006). The amyloid precursor protein: beyond amyloid. Mol.
Neurodegener. 1, 5.

121

Appendices
APPENDIX 1
TITLE:

Food restriction for adult mice (12 weeks or older)

PREPARED BY:

Matthew Cowan

1.0

PURPOSE
1.1

2.0

SCOPE
2.1

3.0

4.2
4.3

4.4

6.0

Individuals who have been trained, and are competent in performing the
procedures described herein must follow this procedure.

NOTES
4.1

5.0

This SOP applies to all research personnel that are employing food restriction of
mice for use in the Bussey-Saksida touch screen chambers.

RESPONSIBILITIES
3.1

4.0

Standardized body weight at 85% of adult baseline weight is required to
motivate mice to perform tasks designed to assess attention or cognitive
ability, where successful completion results in the presentation of a food
reward.

The validity of results obtained from behavioral phenotyping is largely dependent
on methods of animal husbandry. It is of vital importance that individuals
following this procedure are experienced and aware of the animal’s welfare, and
are familiar with the animal being tested, in order to reduce the anxiety levels of
the animal prior to testing.
The majority of the mouse behavior studies are age/sex/strain dependent. It is
important to keep these parameters comparable throughout a single experiment.
Environmental factors may contribute to the levels of mouse anxiety.
Temperature, humidity, ventilation, noise intensity and light intensity must be
maintained at levels appropriate for mice. It is essential that the mice be kept in a
uniform environment before and after testing to avoid anomalous results being
obtained.
It is recommended that all phenotyping experimentation is conducted at
approximately the same time of day (day time difference should not be more than
90 min) because physiological and biochemical parameters change throughout
the day.

EQUIPMENT
5.1

Electronic balance accurate to 0.01g (Ex: Scout Pro, Ohaus)

5.2

Rodent fur dye (Ex: fine tip marker from Ketchum, tattoo machine)

PROCEDURE
6.1

Acclimation and identification:
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6.1.1

Record the weight of each mouse when it arrives in the behavior facility.
Mice should be allowed to acclimatize to the environment for 5 days
(minimum) with ad libitum food and water. Do not conduct any
experimental procedure during this acclimatization period.

6.1.2

During acclimatization a unique visual identification number should be
applied to the back (or tail) of each mouse using for instance, a semipermanent fur dye, or a tattoo machine. It is important to ensure that

each animal can be reliably and easily identified.
6.2

Determining individual food consumption:

6.2.1 To determine the amount of food each mouse is consuming per
day it is important to keep only 2 or 3 mice per cage (obs: Ideally 2
mice should be kept per cage. To avoid having single housed
cages it might be necessary to keep 3 mice per cage).
6.2.2 Weigh out the food that is going to be provided to the mice making sure
that an amount of food in excess of what could possibly be consumed in
a day is going to be supplied (6g per mouse per day should be enough).
Food should be provided in a Petri dish (or similar container) on the
cage floor. The next day, weigh the food that remains and estimate the
amount of food consumed per mouse Mice should not be found without
food at this stage. Repeat the procedure the next two days. Use the
average of the three days for individual food consumption.
6.3

Food restriction to 85% of baseline adult (12 weeks or older) body weight:
6.3.1

We have determined the body weight baseline for male and female mice
in a C57BL/6 background from ages ranging from 4-24 weeks (see below
Fig1: Male weight curve and Fig2: Female weight curve). We observed
that the average weight of an adult male ranging from 13 to 22 weeks is
around 30g (13 weeks: 28.5g±0.6; 22 weeks: 31.2g±0.9) while the
average weight of an adult female ranging from 12-24 weeks is around
22g (12 weeks: 20.0g±0.51; 24 weeks: 23.6g±0.67). Thus, to reach 85%
of the average adult body weight adult male mice weight should be
reduced to ±25.5g and adult female mouse weight should be
reduced to ±18.7g.

6.3.2

Weigh each mouse daily, 7 days a week. For males, provide 2.0 – 3.0 g
of food per 25-35 g of mouse per day. For females, provide 1.5-2.0 g of
food per 20-23g of mice. Proceed until body weight is reduced to 85% of
baseline.

6.3.3

Cages of mice on food restriction must be flagged with orange labels so
that animal care staff is aware of them. Mice should be monitored for
changes in appearance or signs of aggression. The weight decrease is
intended to be gradual and may take 7-15 days.

6.3.4

In the C57Bl/6 background it is common to find obese mice (males >30g,
females>22g). Obese mice are less motivated to complete food rewarded
tasks therefore, it is essential that all subjects within an experimental
group weight approximately the same prior to the experiment (adult male
mice weight should be reduced to ±25.5g and adult female mouse
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weight should be reduced to ±18.7g). Thus, obese mice must be food
restricted longer until they get to the appropriate weight.
6.4

7.0

Maintenance at 85% of baseline adult body weight:
6.4.1

When 85% of baseline is reached, male mice can be safely maintained
through the testing period by providing 2.5g of food per mouse per day,
as they are going to receive the strawberry shake during the tests. In
case of females provide 2.0g of food per mouse per day. Caution –2.5 g
per male mouse or 2.0 g per female mouse is an average of food to
keep mice at 85% of their weigh. This amount must be carefully
monitored and properly adjusted.

6.4.2

Each mouse must be weighed every second day. No individual’s weight
can be allowed to fall below 80% of its pre-established adult baseline.
Mice between 80-85% of baseline weight should receive up to 3.0g of
food per mouse per day on the cage floor until they are stable at 85%
again.

6.4.3

Mice should be weighed and fed after completion of the day’s experiment
to ensure the experimental food reward is motivating and that rationed
food is consumed in advance of the next days schedule.

6.4.4

Group housed mice may compete for rationed food. Break the food
pellets into several pieces so that each mouse can manipulate and eat
their own. Watch for changes in body condition and aggressive behavior
immediately after the addition of food to the cage. If the weights of cage
mates begin to diverge the heavier mouse should be separated.

HEALTH & SAFETY
7.1

General laboratory procedures should be followed, which include: no eating or
drinking. Laboratory coats and gloves must be worn at all times in the work area,
unless the protocol specifically describes the appropriate attire for the procedure.
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8.0

REFERENCES / ASSOCIATED MATERIALS

JAX mice strain C57BL/6J mean weight by age and sex.
http://jaxmice.jax.org/support/weight/000664.html
http://www.nature.com/nprot/journal/v8/n10/full/nprot.2013.122.html
http://www.nature.com/nprot/journal/v8/n10/full/nprot.2013.123.html
http://www.nature.com/nprot/journal/v8/n10/full/nprot.2013.124.html

Figure 1: Male weight curve.

Figure 2: Female weight curve.
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APPENDIX 2
TITLE:

2-Choice Pairwise Visual Discrimination Task
Standard Operating Procedure

PREPARED BY:

Matthew Cowan

1.0 INTRODUCTION
The PD task has been designed to measure effects of drugs and other manipulations
(ex: genetic) on attentional performance. The test is performed in a specially designed
touchscreen-based automated chamber with 2 response locations (left and right
windows) using food reinforcers to maintain performance. The PD task requires the
subject to learn to associate a food reward with a nose-poke response to one image (S+
stimulus) when it appears in one of the windows and ignore a second visually distinct
image (S- stimulus) appearing simultaneously in the other location. After the task is
learned reversal learning is attempted where the food reward becomes linked to the
former S- stimulus and responses to the former S+ stimulus go unrewarded. Reversal
learning of the PD task is useful for measuring effects of different manipulations on the
functioning of the prefrontal cortex.
2.0 EQUIPMENT
- Mouse Touch Screen Systems and ABET II
- 89540CAM Pairwise (Visual) Discrimination (PD) Task with Cambridge
Amendment
3.0 PROCEDURE
3.1 Testing the hardware:
A quick test of the hardware should be done prior to every days training or
testing. To do the hardware testing, follow procedures indicted below:
a. From the main menu the Execution Manager, select the boxes you wish to test.
b. Click the ‘Open/Load Schedule’ icon and select ‘2-Touch MouseTestLines’ and click
‘Open’.
c. Click the play icon. The boxes are now ready to test.
See Table 1 for Inputs to activate a response and output response expected.

126

Table 1: Action necessary and output response expected.
Schedule
Inputs to activate (use
Output response
your fingers)
2-Touch Mouse
Test Lines

Enter feeder tray

House light on during tray beam break,
audio tone plays, pump activates
Tray light stays on when finger
removed.

Touch right window

Solid white square appears on screen

Enter feeder tray

Square removed from screen, tray light
goes off.

Repeat first 3 actions, this
time touching left
window

See above output responses

Block Front IR activity
beams

Count goes up by 1 for each beam
blockage. House light turns on, stays
on until feeder tray is re-entered

Block Back IR activity
beams

Count goes up by 1 for each beam
blockage

3.2 Testing the feeder and mask
- A quick test of the feeder should be done prior to every days training or
testing. Manually switch on the feeder pump and make sure the food is
delivered.
- If clogged, the tubing can be cleared by using a 5ml syringe with 21 gauge
needle to force water through.
- Build up does occur in the tubing and gradually reduce the flow rate even if it
does not clog completely so replace the tubing in each chamber every 2
months.
- Make sure the PD Mask is inserted (2 windows).
- Reward provided is Neilson Strawberry milkshake (SM) (Saputo Inc. Montreal
Quebec. H1P1X8). This milkshake can be found in most grocery stores
(including Wall Mart and Superstore).

-

3.3 Pre-training
Animals may require food restriction before task training and it will be required
throughout the experiment (see relevant SOPs: “Food restriction in young mice”
or “Food restriction in adult mice”).
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-

-

Divide each group of subjects (Ex: 5xFAD colony females or APP colony males,
etc.) into 2 counter-balanced sub groups containing both wt and transgenic mice
to control for the time of day the experiment is performed and the particular
cabinet being used in case of an equipment failure.
Pre-select a pair of images to be used in the discrimination/reversal task for each
age point required. Preselecting 5 pairs allows for 5 potential data sets over the
life of each cohort and prevents those images from being displayed during the
training and maintenance phases. All training schedules should be checked for
which images they will display.
3.4 Training Procedures
3.4.1 Basic training schedule

IMPORTANT: for both training and probe trials, each mouse is submitted to one
session per day.
Stage 1: Habituation1: 1 session. Load the PD_habituation_1_v2 schedule from the
PD v3 subdirectory in the ABETII software. The session duration is set to 600s (10
minutes), and the number of trials is left to unlimited. Mouse is left in the chamber for 10
min. All lights are turned off. No stimulus or reward is presented. It is critical that the
mouse is removed from the cabinet as soon as the habituation is complete.
Stage 2: Habituation2a: 2 sessions. Load the PD_habituation_2_v2 schedule from the
PD v3 subdirectory in the ABETII software. The session duration is set to 1200s (20
minutes), and the number of trials is left to unlimited. The mouse is left in the chamber
for 20 min sessions. The tray light is going to be initially turned on. A tone is played and
the food-tray/magazine is primed with strawberry milkshake (SM) delivered for 6000ms
(150μl). The program waits for the mouse to enter the food tray. When the mouse
leaves the reward tray, the reward tray light is turned off. There is a 10s delay before
the tray light is turned on, a tone is played and SM is then delivered for 280ms (7 μl). If
the mouse is in the reward tray at the end of the 10s delay, an extra 1s is added to the
delay. The procedure is repeated until the session ends. It is critical that the mouse is
removed from the cabinet as soon as the habituation is complete.
Stage 3: Habituation2b: 1 session. Load the habituation2 schedule from the PD v3
subdirectory in the ABETII software. The session duration is set to 2400s (40 minutes),
and the number of trials is left to unlimited. The mouse is left in the chamber for 40 min.
Reward presentation is the same as described in stage 2. It is critical that the mouse is
removed from the cabinet as soon as the habituation is complete.
Stage 4:
“Initial touch”: (usually 1 session). Load the schedule
‘PD_Initial_Touch_Training_v3’ from the PD v3 subdirectory. Set the Session:
Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No. Trials to 30. Make sure
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that “Image Time” is 30s; ‘Feed Pulse Time” is 280ms; “tone duration” is 1000 ms, and
ITI period is 20s. The stimulus (any image not designated for use in
discrimination/reversal trials) is displayed in either the left or right window. The other
window is blank. The position is chosen pseudo randomly, such that the stimulus will
not be displayed in the same position more than 3 times in a row. After a delay (Image
Time – 30s) the image is removed and food is delivered (‘Feed Pulse Time –280ms).
Food delivery is accompanied by illumination of the tray light and a tone. The tone
frequency is 3 KHz. The tone duration is (1000 ms). Entry to collect the food turns off
the tray light and starts the ITI. After the ITI period (20s) another image is displayed. If
the mouse touches the screen while the image is displayed (where the image is
displayed), the image is removed, a tone will be played and 3 x food is delivered
immediately. Collection of this reward again starts the ITI and then progresses to the
next image. Touch training is performed with the house light off.
Criterion: Completion of 30 trials within 60 min. Repeat sessions until criterion is
achieved.
Stage 5: “Must touch”: Number of session varies for individual mouse. Run the
schedule ‘PD_Must_Touch_Training_v3’ from the PD v3 subdirectory. Set the Session:
Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No Trials to 30. Make sure
tone duration is set to 1000 ms (from the ‘Tone Duration’ variable) and ITI period is
set to 20s.
The stimulus, an image selected pseudo randomly (no image shown twice in a row)
from a list which must not include any of the images to be used in
discrimination/reversal trials. The stimulus is presented in only one window at a time.
The other window is blank. The position is chosen pseudo randomly, such that the
stimulus will not be displayed in the same position more than 3 times in a row. The
mouse must touch the stimulus to elicit tone/food response. There is no response if
mouse touches blank part of the screen. Food delivery is accompanied by illumination
of the tray light and a tone. The tone frequency default is 3 KHz. Entry to collect the
food turns off the tray light and starts the ITI. After the ITI period (20s) another image is
displayed.
Criterion: Completion of 30 trials within 60 min. Repeat sessions until criterion is
achieved.
IMPORTANT: If after 7 sessions a mouse does not reach criterion for “must touch”, take
it back one step; that is, retrain the mouse on “PD_Initial_touch_RETRAIN_v3” until it
reaches criterion and repeat the “PD_Must_touch_Training_v3” training. If after 7
sessions of the second attempt of “must touch” the mouse does not reach criterion,
remove it from the study.
Stage 6: “Must initiate”: Number of session varies for individual mouse. Run the
schedule ‘PD_Must_Initiate_Training_v3’ from the PD v3 subdirectory. Set the Session:
Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No. Trials to 30. Make sure
tone duration is set to 1000 ms (from the ‘Tone Duration’ variable) and ITI period is
set to 20s.
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A free delivery of food is made and the tray light is turned on. The mouse must nose
poke and exit the reward tray before a stimulus is displayed randomly on the screen.
The stimulus, an image selected pseudo randomly (no image shown twice in a row)
from a list which must not include any of the images to be used in
discrimination/reversal trials. The stimulus is presented in only one window at a time.
The other window is blank. The position is chosen pseudo randomly, such that the
stimulus will not be displayed in the same position more than 3 times in a row. The
mouse must touch the stimulus to elicit tone/food response. There is no response if
mouse touches blank part of the screen. Food delivery is accompanied by illumination
of the tray light and a tone. The tone frequency default is 3 KHz. Entry to collect the
food turns off the tray light and starts the ITI. After the ITI period the tray light is again
illuminated. The mouse must nose poke and exit the reward tray before the next image
is displayed.
Criterion: Completion of 30 trials within 60 min. Repeat sessions until criterion is
achieved.
IMPORTANT: If after 5 sessions a mouse does not reach criterion for “must initiate”,
take it back one step; that is, retrain the mouse on “PD_must_touch_RETRAIN_v3” until
it reaches criterion and repeat the “PD_Must_Initiate_Training_v3”. If after 5 sessions of
the second attempt of “must initiate” the mouse does not reach criterion, remove it from
the study.
Stage 7: “Punish incorrect”. Number of session varies for individual mouse. Run the
schedule ‘PD_Punish_Incorrect_Training_v3’ from the PD v3 subdirectory. Set the
Session: Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No. Trials to 30.
Make sure tone duration is set to 1000 ms and ITI period is set to 20s.
This schedule trains the mouse to both initiate after an ITI and not to touch an incorrect
location. As for previous training described above, except if a mouse touches an
incorrect (blank) location the house light will be turned ON for 5s and no reward is
given. Once the time out period finishes the house light is turned OFF again and the ITI
period begins (20s). There is no time limit on the display of the image (no omissions
score) and no correction trials.
Criterion: Completion of 24/30 trials or better within 60 min for 2 consecutive sessions
IMPORTANT: If after 30 sessions (30 days) the mouse does not reach criterion for
“Punish incorrect”, remove it from study.
3.4.2 PD task acquisition, baseline and reversal learning , 1 st time
point
Stage 8: PD task acquisition, 1st time point. Number of session varies for individual
mouse. Run the ‘PD_Acquisition_1_v3’ from the PD v3 subdirectory schedule. Set the
Session: Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No. Trials to 30.
Make sure tone duration is set to 1000 ms, ITI period is set to 20s, Food/CM pulse time
[280ms (7 μl SM), time out (TO, 5s, paired with overhead light).
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The session begins with a priming delivery of reinforcer [280ms (7 μl SM)] and on
exiting the food magazine the first trial begins. Following tray exit a S+ image and a Simage are presented in either of the 2 windows. The left/right ordering of the S+ and Simages is pseudo random with no ordering repeated more than 3 times. A correct
response, touching at the location in which the S+ stimulus was presented, will trigger
the presentation of reinforce [280ms (7 μl SM)] into the food magazine. Food delivery is
accompanied by illumination of the tray light and a tone. The tone duration is (1000 ms
tone). The subject collects the food by making an entry at the food magazine. On
exiting the food tray the ITI (20s) will begin. After the ITI period, the tray light comes on
again and the mouse must enter and exit the food tray to start the next trial. An incorrect
response, i.e. touching the S- image will cause a time out (TO, 5s) and the house light
to be turned ON. After the TO, the house light will be turned OFF and the “ITI” will
begin (20s). After the ITI the tray light will come on and the subject must enter and exit
the food tray to start the correction trial. In a correction trial the left/right ordering of the
S+/S- images is repeated from the previous trial and repeated each subsequent trial
until a correct choice is made. The results of correction trials do not count toward criteria
for completion of the session.
Criterion: 24/30 trials correct within 60 min, for 2 consecutive days.
Stage 9: PD baseline, 1st time point. Run for 2 sessions immediately after reaching
PD acquisition criteria. Load the ‘PD_Baseline_1_v3’ schedule from the PD v3
subdirectory. Set the Session: Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the
Max No. Trials to 30. Make sure tone duration is set to 1000 ms, ITI period is set to 20s,
Food/CM pulse time [280ms (7 μl SM), time out (TO, 5s).
The session begins with a priming delivery of reinforce [280ms (7 μl SM)] and on
exiting the food magazine the first trial begins. Following tray exit a S+ image and a Simage are presented in either of the 2 windows. The left/right ordering of the S+ and Simages is pseudo random with no ordering repeated more than 3 times. A correct
response, touching at the location in which the S+ stimulus was presented, will trigger
the presentation of reinforce [280ms (7 μl SM)] into the food magazine. Food delivery is
accompanied by illumination of the tray light and a tone. The tone duration is (1000 ms
tone). The subject collects the food by making an entry at the food magazine. On
exiting the food tray the ITI (20s) will begin. After the ITI period, the tray light comes on
again and the mouse must enter and exit the food tray to start the next trial. An incorrect
response, i.e. touching the S- image will cause a time out (TO, 5s) and the house light
to be turned ON. After the TO, the house light will be turned OFF and the “ITI” will
begin (20s). After the ITI the tray light will come on and the subject must enter and exit
the food tray to start the correction trial. In a correction trial the left/right ordering of the
S+/S- images is repeated from the previous trial and repeated each subsequent trial
until a correct choice is made. The results of correction trials do not count toward criteria
for completion of the session.
Criterion: There is no score required to pass, the session ends after 30 trials have
been completed or 60 min has elapsed.
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Stage 10: PD task reversal, 1st time point. Run for 10 sessions immediately after
completing PD baseline criteria. Load the ‘PD_Reversal_1_v3’ schedule from the PD v3
subdirectory. Set the Session: Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the
Max No. Trials to 30. Make sure tone duration is set to 1000 ms, ITI period is set to 20s,
Food/CM pulse time [280ms (7 μl SM), time out (TO, 5s). The session begins with a
priming delivery of reinforce [280ms (7 μl SM)] and on exiting the food magazine the
first trial begins. Following tray exit a S+ image and a S- image are presented in either
of the 2 windows. The left/right ordering of the S+ and S- images is pseudo random with
no ordering repeated more than 3 times. A correct response is now defined as
touching at the location in which the S- stimulus was presented and will trigger the
presentation of reward [280ms (7 μl SM)] into the food magazine. Food delivery is
accompanied by illumination of the tray light and a tone. The tone duration is (1000 ms
tone). The subject collects the food by making an entry at the food magazine. On
exiting the food tray the ITI (20s) will begin. After the ITI period, the tray light comes on
again and the mouse must enter and exit the food tray to start the next trial. An incorrect
response, i.e. touching the S+ image will cause a time out (TO, 5s) and the house light
to be turned ON. After the TO, the house light will be turned OFF and the ITI will begin
(20s). After the ITI the tray light will come on and the subject must enter and exit the
food tray to start the correction trial. In a correction trial the left/right ordering of the
S+/S- images is repeated from the previous trial and repeated each subsequent trial
until a correct choice is made. The results of correction trials do not count toward criteria
for completion of the session.
Criterion: There is no score required to pass, the session ends after 30 trials have
been completed or 60 min has elapsed.
Stage 11: PD Maintenance. Run the schedule ‘PD_Maintenance_1_v3’ from the PD v3
subdirectory. This schedule is identical to ‘PD_Punish_Incorrect_Training_v3’. Run this
schedule once per week until the subjects are old enough to begin PD task
acquisition, 2nd time point.
Criterion: There is no score required to pass, the session ends after 30 trials have
been completed or 60 min has elapsed.
Subsequent time points: 2nd, 3rd, 4th, etc. time points are performed identically to the
1st time point using the appropriately named schedules which contain unique S+ and Simages. However as subjects age it is possible that acquiring the PD task will take
longer or fail to occur. This may require adjusting subsequent time points or dropping
subjects from the study according to previously stated criteria.
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APPENDIX 3
TITLE:

5-Choice Serial Reaction Time Task (5-CSRTT)
Standard Operating Procedure

PREPARED BY:

Matthew Cowan

1.0 INTRODUCTION
The 5-CSRT task has been designed to measure effects of drugs and other
manipulations (ex: genetic) on attentional performance (and stimulus control). The test
is performed in a specially designed touchscreen-based automated chamber with
multiple response locations (’five-screens”) using food reinforcers to maintain
performance. The 5CSRTT is useful for measuring effects of different manipulations on
various aspects of attentional control, including sustained, selective and divided
attention – and is relevant to the definition of neural systems of attention and has
applications to human disorders such as attention deficit/hyperactivity disorder (ADHD)
and Alzheimer’s disease.
4.0 EQUIPMENT
- Mouse Touch Screen Systems and ABET II
- 89543CAM 5-Choice Serial Reaction Time Task with Cambridge Amendment
5.0 PROCEDURE
5.1 Testing the hardware:
A quick test of the hardware should be done prior to every days training or
testing. To do the hardware testing, follow procedures indicted below:
a. From the main menu the Execution Manager, select the boxes you wish to test.
b. Click the ‘Open/Load Schedule’ icon and select ‘Touch MouseTestLines’ and click
‘Open’.
c. Click the play icon. The boxes are now ready to test.
See Table 1 for Inputs to activate a response and output response expected.
Table 1: Action necessary and output response expected.
Schedule
Inputs to activate (use
Output response
your fingers)
Touch Mouse
Test Lines

Touch Grid 1

Image in all grid spaces, Grid 1 has
30%
of full white, grids 2 to 4 have full white
image.

133

Activate the Tray to clear all images
and proceed with test.
Touch Grid 2

Image in all grid spaces, Grid 2 has
40%
of full white, all other grids have full
white image.
Activate the Tray to clear all images
and proceed with test.

Touch Grid 3

Image in all grid spaces, Grid 3 has
50%
of full white, all other grids have full
white image.
Activate the Tray to clear all images
and proceed with test.

Touch Grid 4

Image in all grid spaces, Grid 4 has
70%
of full white, all other grids have full
white image.
Activate the Tray to clear all images
and proceed with test.

Touch Grid 5

Full white (bright) image in all grid
spaces. Pulses Sound_On 500ms
Activate the Tray to clear all images
and proceed with test.

Enter the feed-tray

House-light and tray-light illuminate
and feeder - 800ms

Exit the feed-tray

Houselight and tray light extinguish
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Block Front IR activity
beams

House-light illuminates

Block Back IR activity
beams

Tray-light illuminates

5.2 Testing the feeder and mask
- A quick test of the feeder should be done prior to every days training or
testing. That is, turn on manually the switch on the feeder pump and make
sure the food is delivered.
- Make sure the 5CSRT Mask is inserted (5 windows).
- Reward provided is Neilson Strawberry milkshake (SM) (Saputo Inc. Montreal
Quebec. H1P1X8). This milkshake can be found in most grocery stores
(including Wall Mart and Superstore).

-

-

5.3 Pre-training
Animals need to be food restricted before task training and throughout
experiment (see relevant SOPs: “Food restriction in young mice” or Food
restriction in adult mice”).
Divide the subjects of each group to be tested (Ex: Group 1: 5xFAD females,
Group 2: APP males) into 4 sub-groups (A, B, C, D). Groups must be counterbalanced for genotype (wt x mutant). Each subgroup is going to follow specific
testing schedules during probe trial (see Table 2).
5.4 Training Procedures
5.4.1 Basic training schedule

IMPORTANT: for both training and probe trials, each mouse is submitted to one
session per day.
Stage 1: Habituation1: 1 session. Load the habituation1 schedule from the CAM5choice subdirectory in the ABETII software. The session duration is set to 600s (10
minutes), and the number of trials is left to unlimited. Mouse is left in the chamber for 10
min. All lights are turned off. No stimulus or reward is presented. It is critical that the
mouse is removed from the cabinet as soon as the habituation is complete.
Stage 2: Habituation2a: 2 sessions. Load the habituation2 schedule from the CAM5choice subdirectory in the ABETII software. The session duration is set to 1200s (20
minutes), and the number of trials is left to unlimited. The mouse is left in the chamber
for 20 min sessions. The tray light is going to be initially turned on. A tone is played and
the food-tray/magazine is primed with strawberry milkshake (SM) delivered for 6000ms
(150μl). The program waits for the mouse to enter the food tray. When the mouse
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leaves the reward tray, the reward tray light is turned off. There is a 10s delay before
the tray light is turned on, a tone is played and SM is then delivered for 280ms (7 μl). If
the mouse is in the reward tray at the end of the 10s delay, an extra 1s is added to the
delay. The procedure is repeated until the session ends.
Stage 3: Habituation2b: 1 session. Load the habituation2 schedule from the CAM5choice subdirectory in the ABETII software. The session duration is set to 2400s (40
minutes), and the number of trials is left to unlimited. The mouse is left in the chamber
for 40 min. Reward presentation is the same as described in stage 2. It is critical that
the mouse is removed from the cabinet as soon as the habituation is complete.
Stage 4: “Initial touch”: (usually 1 session). Load the schedule ‘5-choice Mouse Initial
Touch Training’ from the CAM-5choice subdirectory. Set the Session:
Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No. Trials to 30. Make sure
that “Image Time” is 30s; ‘Feed Pulse Time” is 280ms; “tone duration” is 1000 ms, and
ITI period is 5s. The stimulus (a white square) is displayed randomly in one of the 5
windows. The stimulus is presented in only one window at a time. The other windows
are left blank. The position is chosen pseudo randomly, such that the stimulus will not
be displayed in the same position more than 3 times in a row. After a delay (Image
Time – 30s) the image is removed and food is delivered (‘Feed Pulse Time –280ms).
Food delivery is accompanied by illumination of the tray light and a tone. The tone
frequency is 3 KHz. The tone duration is (1000 ms). Entry to collect the food turns off
the tray light and starts the ITI. After the ITI period (5s) another image is displayed. If
the mouse touches the screen whilst the image is displayed (where the image is
displayed), the image is removed, a tone will be played and 3 x food is delivered
immediately. Collection of this reward again starts the ITI and then progresses to the
next image. Touch training is performed with the house light off.
Criterion: Completion of 30 trials within 60 min. Repeat sessions until criterion is
achieved.
Stage 5: “Must touch”: Number of session varies for individual mouse. It can go from
~1-7 days (median: 2 days). Run the schedule ‘5-choice Mouse Must Touch Training’
from the CAM-5choice subdirectory. Set the Session: Max_Schedule_Time to 60
minutes, i.e. 60:00. Set the Max No Trials to 30. Make sure tone duration is set to
1000 ms (from the ‘Tone Duration’ variable) and ITI period is set to 5s.
The stimulus (a white square) is displayed randomly in one of the 5 windows. The
stimulus is presented in only one window at a time. The other windows are left blank.
The position is chosen pseudo randomly, such that the stimulus will not be displayed in
the same position more than 3 times in a row. The mouse must touch the stimulus to
elicit tone/food response. There is no response if mouse touches blank part of the
screen. Food delivery is accompanied by illumination of the tray light and a tone. The
tone frequency default is 3 KHz. Entry to collect the food turns off the tray light and
starts the ITI. After the ITI period (5s) another image is displayed.
Criterion: Completion of 30 trials within 60 min. Repeat sessions until criterion is
achieved.
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IMPORTANT: If after 7 sessions a mouse does not reach criterion for “must touch”, take
it back one step; that is, retrain the mouse on “Initial touch” until it reaches criterion and
repeat the “Must touch” training. If after 7 sessions of the second attempt of “must
touch” the mouse does not reach criterion, remove it from the study.
Stage 6: “Must initiate”: Number of session varies for individual mouse. It usually
takes ~1-2 sessions (i.e. 1 or days). Run the schedule ‘5-Choice Must Initiate Training’
from the CAM-5choice subdirectory. Set the Session: Max_Schedule_Time to 60
minutes, i.e. 60:00. Set the Max No. Trials to 30. Make sure tone duration is set to
1000 ms (from the ‘Tone Duration’ variable) and ITI period is set to 5s.
A free delivery of food is made and the tray light is turned on. The mouse must nose
poke and exit the reward tray before a stimulus is displayed randomly on the screen.
The stimulus (a white square) is displayed randomly in one of the 5 windows. The
stimulus is presented in only one window at a time. The other windows are left blank.
The position is chosen pseudo randomly, such that the stimulus will not be displayed in
the same position more than 3 times in a row.) The mouse must touch the stimulus to
elicit tone/food response. There is no response if mouse touches the blank parts of the
screen. Food delivery is accompanied by illumination of the tray light and a tone. Entry
to collect the food turns off the tray light and starts the ITI. After the ITI period the tray
light is again illuminated. The mouse must nose poke and exit the reward tray before
the next image is displayed.
Criterion: Completion of 30 trials within 60 min. Repeat sessions until criterion is
achieved.
IMPORTANT: If after 5 sessions a mouse does not reach criterion for “must initiate”,
take it back one step; that is, retrain the mouse on “must touch” until it reaches criterion
and repeat the “Must Initiate” training. If after 5 sessions of the second attempt of “must
initiate” the mouse does not reach criterion, remove it from the study.
Stage 7: “Punish incorrect”. Number of session varies for individual mouse. It can go
from ~2-30 days (median: 9 days). Run the schedule ‘5-Choice Mouse Punish Incorrect
Training’ from the CAM-5choice subdirectory. Set the Session: Max_Schedule_Time to
60 minutes, i.e. 60:00. Set the Max No. Trials to 30. Make sure tone duration is set to
1000 ms and ITI period is set to 5s.
This schedule trains the mouse to both initiate after an ITI and not to touch an incorrect
location. As for previous training described above, except if a mouse touches an
incorrect (non-illuminated) location the house light will be turned ON for 5s and no
reward is given. Once the time out period finishes the house light is turned OFF again
and the ITI period begins (5s). The mouse must then complete a correction trial: the
image and position from the previous trial are kept the same and the mouse must
repeat the same trial until a correct response to the image is made, at which point it will
receive a tone and reward.
Criterion: Completion of 23/30 trials or better within 60 min for 2 consecutive sessions
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IMPORTANT: If after 30 sessions (30 days) the mouse does not reach criterion for
“Punish incorrect”, remove it from study.
5.4.2 5-CSRT Training to baseline
Stage 8: 5-CSRT training to baseline- 4s stimulus. Number of session varies for
individual mouse. It can go from ~4-30 days (median: 11 days). Run the
‘5CSRTT_2s_Var1’ from the CAM-5choice subdirectory schedule. Set the Session:
Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the Max No. Trials to 50. Make sure
tone duration is set to 1000 ms, ITI period is set to 5s, Food/CM pulse time [280ms (7 μl
SM), Delay interval (5s), time out (TO, 5s) and ITI Incorr (5s).
The session begins with a priming delivery of reinforce [280ms (7 μl SM)] and on
exiting the food magazine the first trial begins. Following tray exit, a “Delay interval”
(5s) begins at the end of which a stimuli is presented in one of the 5 stimuli grid spaces
on the LCD touch screen. The sequence of presentations of the stimuli is a
pseudorandom schedule such that there are 4 presentations at each spatial location
within a block of 20 trials. The subject must respond within a time period defined
(limited hold period 5s). A correct response, touching at the location in which the
stimulus was presented, will trigger the presentation of reinforce [280ms (7 μl SM)] into
the food magazine. Food delivery is accompanied by illumination of the tray light and a
tone. The tone duration is (1000 ms tone). The subject collects the food by making an
entry at the food magazine. On exiting the food tray the ITI (5s) will begin. After the ITI
period, the tray light comes on again and the mouse must enter and exit the food tray to
start the next trial and start the Delay’ interval. An incorrect response, i.e. touching a
location other than where the stimulus was presented, or making no response at all (an
omission) within the limited hold period, will cause a time out (TO, 5s) as identified
house light turned ON. After the TO, the house light will be turned OFF and the “ITI
Incorr” will begin (5s). After the ITI incorr period the tray light will come on and the
subject must enter and exit the food tray to start the next trial and start the Delay’
interval. A premature response is recorded when a touch is made in one of the
response grid areas during the Delay and also results in a TO.
> 80% accuracy = [number of Correct trials / Total number of trials responded to
(correct and incorrect)]
< 20% omissions = [number of trials missed / number of trials presented]
Criterion: 80% accuracy or better, 20% omission or less, 3 consecutive days,
minimum 30 trials completed per session.
Stage 9: 5-CSRT training to baseline- 2s stimulus. Number of session varies for
individual mouse. Number of session varies for individual mouse. It can go from ~5-30
days (median: 12 days). Run the ‘5CSRTT_2s_Var1 schedule from the CAM-5choice
subdirectory. Set the Session: Max_Schedule_Time to 60 minutes, i.e. 60:00. Set the
Max No. Trials to 50. . Make sure tone duration is set to 1000 ms, ITI period is set to 5s,
Food/CM pulse time [280ms (7 μl SM), Delay interval (5s), time out (TO, 5s) and ITI
Incorr (5s).
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The session begins with a priming delivery of reinforce [280ms (7 μl SM)] and on
exiting the food magazine the first trial begins. Following tray exit, a “Delay interval”
(5s) begins at the end of which a stimuli is presented in one of the 5 stimuli grid spaces
on the LCD touch screen. The sequence of presentations of the stimuli is a
pseudorandom schedule such that there are 4 presentations at each spatial location
within a block of 20 trials. The subject must respond within a time period defined
(limited hold period 5s). A correct response, touching at the location in which the
stimulus was presented, will trigger the presentation of reinforce [280ms (7 μl SM)] into
the food magazine. Food delivery is accompanied by illumination of the tray light and a
tone. The tone duration is (1000 ms tone). The subject collects the food by making an
entry at the food magazine. On exiting the food tray the ITI (5s) will begin. After the ITI
period, the tray light comes on again and the mouse must enter and exit the food tray to
start the next trial and start the Delay’ interval. An incorrect response, i.e. touching a
location other than where the stimulus was presented, or making no response at all (an
omission) within the limited hold period, will cause a time out (TO, 5s) as identified
house light turned ON. After the TO, the house light will be turned OFF and the ‘ITI
Incorr’ will begin (5s). After the ITI incorr period the tray light will come on and the
subject must enter and exit the food tray to start the next trial and start the Delay’
interval. A premature response is recorded when a touch is made in one of the
response grid areas during the Delay and also results in a TO.
Criterion: 80% accuracy or better, 20% omission or less, 3 consecutive days, 50 trials
must be completed per session.

5.4.3 Testing schedules
Stage 10: First probe trial evaluation. Subjects will not progress through the training
at exactly the same rate. The first set of probe trials for a group begins once the last
mouse in that group has passed the 2s stimulus performance criteria (Stage 9).
Subjects that have completed the Stage 9 before the slowest subject are maintained on
food restriction and repeat Stage 9 before performing their probe trial. There is no
minimum performance criterion for subjects to advance through the probe trials. The
order of performance of probe trials for each counter-balanced group varies according
to Table 2.
-

-

-

For the 2s stimulus run the ‘5CSRTT_2s_Var1schedule from the CAM-5choice
subdirectory. Set the Session: Max_Schedule_Time to 60 minutes, i.e. 60:00. Set
the Max No. Trials to 50.
For the 1.5s stimulus run the ‘5CSRTT_1.5s_Var1schedule from the CAM-5choice
subdirectory. Set the Session: Max_Schedule_Time to 60 minutes, i.e. 60:00. Set
the Max No. Trials to 50.
For the 1s stimulus run the ‘5CSRTT_1s_Var1schedule from the CAM-5choice
subdirectory. Set the Session: Max_Schedule_Time to 60 minutes, i.e. 60:00. Set
the Max No. Trials to 50.
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-

-

For the 0.8s stimulus run the ‘5CSRTT_0.8s_Var1schedule from the CAM-5choice
subdirectory. Set the Session: Max_Schedule_Time to 60 minutes, i.e. 60:00. Set
the Max No. Trials to 50.
For the 0.6s stimulus run the ‘5CSRTT_0.6s_Var1schedule from the CAM-5choice
subdirectory. Set the Session: Max_Schedule_Time to 60 minutes, i.e. 60:00. Set
the Max No. Trials to 50.

Table 2: Order of stimulus duration for individual groups (1st probe trial
evaluation)
# of
consecutive
sessions

Stimulus
duration
throughout
sessions for

Stimulus
duration
throughout
sessions for

Stimulus
duration
throughout
sessions for

Stimulus
duration
throughout
sessions for

Sub-group A

Sub-group B

Sub-group C

Sub-group D

2

0.6s

0.8s

1.0s

1.5s

2

2.0s

2.0s

2.0s

2.0s

2

1.5s

0.6s

0.8s

1.0s

2

2.0s

2.0s

2.0s

2.0s

2

1.0s

1.5s

0.6s

0.8s

2

2.0s

2.0s

2.0s

2.0s

2

0.8s

1.0s

1.5s

0.6s

140

Table 3: Setting adjustment for additional variables in probe trials
Variable
Value
Session Length

60 min

Food/CM pulse time

280 ms

DELAY

5s

Time out

5s

Limited Hold Value

5s

Stage 11: Reusing same mouse cohort for a new probe trial
- All subjects are maintained on food restriction for 1 month.
- Subjects perform one 2s stimulus trial per week during the interval between probe
trials.

Stage 12: Second probe trial (and all subsequent probe trials) evaluation

-

Mice should be re-baselined at 2s for 5 consecutive days before beginning
the next probe trial (Stage 9: >80% Accuracy, <20% omissions). Depending
on how long it’s been since the previous probe trial it might be necessary to
rebaseline them at 4s first (Stage 8). If they are not re-baselined the second
probe trial will not be accurate.

-

A second probe trial should be performed according to the order shown in
Table 4.
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Table 4: Order of stimulus duration for individual groups (2nd probe trial
evaluation)
# of
Stimulus
Stimulus
Stimulus
Stimulus
consecutive
duration
duration
duration
duration
sessions
throughout
throughout
throughout
throughout
sessions for
sessions for
sessions for
sessions for
Sub-group A

Sub-group B

Sub-group C

Sub-group D

2

1.5s

0.6s

0.8s

1.0s

2

2.0s

2.0s

2.0s

2.0s

2

1.0s

1.5s

0.6s

0.8s

2

2.0s

2.0s

2.0s

2.0s

2

0.8s

1.0s

1.5s

0.6s

2

2.0s

2.0s

2.0s

2.0s

2

0.6s

0.8s

1.0s

1.5s
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